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SUMMARY
The pathogenesis of Hodgkin’s disease (HD) still poses many questions and 
this disease is the subject of intense and varied research. There is now 
little doubt tha t Epstein-Barr virus (EBV) plays a role in the development of 
a num ber of cases, over one third of all HD. The role played by the virus in 
these cases, however, is as yet not fully understood.
The immunopathology of HD is complex. There is a large reactive infiltrate 
of immune cells, including lymphocytes, histiocytes and eosinophils, with 
the tum our cells comprising only around 1% of the total tum our mass. 
However, despite these infiltrating lymphocytes, among them CD8+ CTLs, 
the Reed-Stemberg (RS) cells are not eliminated, persisting in the lymph 
nodes and eventually increasing in number if the patient is left untreated.
In 1992, a t the start of the work of this thesis, little was known about the 
m echanism s by which RS cells evade immune detection. This phenomenon 
is of particular interest in EBV-associated HD, where the RS cells are 
known to harbour latent virus and express several viral latent antigens 
including EBNA-1 and the latent membrane proteins (LMPs). The LMPs are 
known to be targets for EBV-specific CTLs, therefore why do such CTLs not 
recognise or eliminate RS cells expressing these proteins?
The answer to this question may fall into one of two broad categories. First, 
there may be a defect in EBV-specific CTL function in people who develop 
EBV-associated HD; secondly, there may be a defect in foreign antigen 
presentation by RS cells that allows these cells to persist and proliferate. 
The first possibility is investigated in the work presented in chapter 3 of this 
thesis. EBV-specific CTL responses in the peripheral blood of HD patients 
were assayed using an in vitro technique. EBV-associated HD cases were 
compared to other HD cases and to healthy subjects. Although the study 
was small, the findings suggest that there may be a diminished CTL 
response in EBV-associated HD which is not seen in the other cases and 
controls.
The second possibility is addressed in chapter 4 of this thesis. It was 
postulated that people possessing HLA class I antigens known to present 
epitopes of the LMPs would not develop EBV-associated HD. HLA-A2 was 
the focus of this study as an epitope of LMP-2 is restricted through this 
HLA antigen. The results refuted this hypothesis.
XI
The possibility that EBV itself may be the cause of the recognition defect 
rather than  the existence of a presentation defect was also investigated. 
The sequence of a target LMP-2 epitope presented by HLA-A2 was 
investigated in selected cases and analysed for the presence of m utations 
which would abolish recognition of the epitope by CTLs. This hypothesis 
was also refuted by these studies. In conclusion, there m ust be other 
m echanism s by which the RS cells evade immune detection.
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Chapter 1 
Introduction
1
1.1 Introduction to  study
Viruses have been shown to play a direct role in the aetiology of malignant 
disease in a wide range of animal species. In hum ans it is estimated that 
around 20% of all cancers are associated with infection by a specific viral 
agent (Waterhouse et aL, 1982; Parkin et a l , 1992). In some cases there is 
strong evidence that the virus plays a causative role in the development of 
disease. One example of this is the involvement of hum an T-cell leukaemia 
virus type-1 (HTLV-1) in adult T-cell leukaemia, for which a large body of 
scientific evidence exists (Hinuma et aL, 1981). For other associations it 
has been harder to establish that the virus implicated plays a causal role in 
the development of malignancy.
Epidemiological data suggest that Hodgkin’s disease (HD) is likely to have 
an  infectious aetiology. In the last decade an association has been made 
between certain cases of HD and the lymphotropic herpesvirus Epstein- 
Barr virus (EBV). EBV has been shown to be present in the tum our cells of 
HD in a proportion of cases and current evidence suggests that the virus 
may play a direct role in the pathogenesis of these cases.
EBV is a ubiquitous virus which is carried throughout life by the infected 
host. The studies described in this thesis aimed to investigate the host- 
virus equilibrium in HD, particularly in EBV-associated HD. It was 
postulated that an  impaired immune response to EBV could predispose to 
the development of HD.
In order to investigate this hypothesis the cellular immune response to EBV 
was m easured in HD patients using an in vitro system. The study also 
aimed to determine whether a sub-group of the population may be 
predisposed to the disease, either by possession of a specific HLA type, or 
by harbouring a viral strain carrying a mutation.
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1,2 Hodgkin's D isease
HD is a lymphoma which was first described by Thomas Hodgkin in 1832 
(Hodgkin, 1832). At the turn  of the century, Reed and Sternberg separately 
described the large bi- or multi-nucleated cells, which are the main 
histological feature of the disease (Sternberg, 1898; Reed, 1902); these cells 
are now referred to as Reed-Stemberg cells (Fig. 1.1a). The progressive 
nature of untreated HD, with spreading lymphadenopathy followed by 
frequent involvement of the spleen, liver and bone marrow, leading 
ultimately to the death of the patient, led to the belief tha t the disease was 
malignant. By the 1980s this was a well established school of thought 
(Kaplan, 1980; 1981; Rosenberg, 1989). The demonstration of clonality and 
frequent aneuploidy in the RS cell population using molecular-based 
m ethods supported the theory that HD was indeed a malignancy (Haber et 
a l, 1992; Trumper et a l, 1993; Kuppers et a l , 1994). A recent report, 
although controversial, has cast doubt on this subject with the finding that 
50% of HD cases studied had polyclonal RS cell populations (Hummel et a l ,
1995). Further investigation is required to resolve this issue which has 
im portant implications for the pathogenesis of HD.
1.2.1 H istopathology o f Hodgkin’s disease
HD has a distinct histological appearance characterised by the presence of 
RS cells, the putative malignant cells (Fig. 1.1a). These are large bi- or 
multi-nucleate cells with prominent nucleoli. Cells with a similar 
morphology are seen in other lymphomas and in infectious mononucleosis 
(Strum et a l , 1970; Tindle et a l , 1972; Khan et a l , 1993b); in order to 
make the diagnosis of HD the RS cells m ust be present in an  appropriate 
cellular background (Lukes, 1971). This background consists of T-cells, B- 
cells, plasma cells, eosinophils and histiocytes. Fig. 1.1 shows (a) 
histological appearance of classical HD with multinucleate RS cells and (b) 
lymphocyte predominance HD showing ’’popcorn” cells. The disease is 
unusual among malignancies in that the RS cells usually make up  less 
than  1% of the total tumour mass, the remainder being the large reactive 
cellular component.
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Fig. 1.1 Histological appearance of HD 
a. "classical" HD
b. HDLP
• •  • % * '  • * •
•i / 1% *'*
V  * #
-  ^  _  *  * *
(high power)
Reprinted with kind permission of David Mason
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Table I.i Rye classification for Hodgkin's disease
subtype % o f cases criteria fo r definition
HDMC 20-40% obvious RS cells
infiltrate mainly small lymphocytes, plasma 
cells, granulocytes
HDNS 50-70% RS variant "lacunar" cells and RS cells 
nodule formation due to subdivision of lymph 
node by collagen bands
HDLD <5% cellular depletion and disordered fibrosis 
numerous obvious RS cells
HDLP 5-10% few classical RS cells 
"popcorn" RS cell variants 
wide range of other features
HD is divided into four histological subtypes based on the histology - mixed 
cellularity (HDMC), nodular sclerosis (HDNS), lymphocyte depleted (HDLD) 
and lymphocyte predominant (HDLP) (Lukes et a l, 1966). This 
nomenclature is known as the Rye classification system and is a simplified 
version of the original histopathological definition made by Lukes and 
Butler (1966). Although this classification has remained essentially 
unchanged for 30 years it is still regarded as clinically and pathologically 
relevant (Bennett e ta l ,  1991). The Rye classification is outlined in Table I.i.
Recent data suggest that HDLP is a discrete condition which should be 
classed separately from other forms of HD (Nicholas et a t, 1990; Mason et 
a l, 1994). The malignant cells of HDLP are thought to be of B-cell origin 
and express B-lineage surface markers (Mason et a l, 1994). In the recently 
proposed REAL system for the classification of lymphomas, HD is now 
divided into two main entities, classical HD and HDLP (Harris et a l, 1994).
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1.2 .2  Nature o f the Reed-Stemberg cell
The lineage of the RS cell has been under debate since its first description 
in the literature in 1898 (Sternberg, 1898). There are currently three 
candidate lineages; macrophage/monocyte and their myeloid precursors 
(Hsu et a l , 1985), interdigitating or follicular dendritic cells (Delsol et a l , 
1993; Soderstrom et a l, 1994), and lymphoid cells (Stein e t a l , 1985; 
Hummel et a l , 1995). Characterisation of the RS cell has proved difficult 
due to the small num ber of these cells within the total tum our mass. The 
question of the lineage of the RS cell has been addressed using 
immunophenotyping and more recently genotyping; results of 
immunophenotyping studies of frozen biopsy tissue and paraffin-embedded 
m aterial have been reviewed by Drexler (Drexler, 1992).
RS cells do not consistently express any lineage markers. In a proportion of 
cases they have been shown to express B-cell m arkers including CD 19, 
CD20, CD22 and CD79 (Schmid e t a l , 1991; Knapp et a l, 1994). This has 
led certain groups to suggest tha t the RS cell is of B-cell origin. However 
there are also reports of the presence of T-cell markers such as  CD2, CD3 
and CD4 being expressed (Agnarsson & Kadin, 1989). The m arkers most 
consistently expressed by classical RS cells are activation antigens; the 
m ost reliable marker is generally accepted to be CD30 (Durkop et a l,  1992), 
an  activation marker which is also expressed by lymphoblastoid cell lines 
(Andreesen et a l, 1984) and activated T-cells (Stein et a l,  1985). In 
addition they generally express CD 15 (Paietta, 1992), CD25, the
interleukin-2 receptor, CD71, the transferrin receptor (Hugh & Poppema, 
1992), CD40 (O’Grady et a l, 1994) and HLA class II. Adhesion molecules 
including ICAM-1 (CD54) and LFA-3 (CD58) are also frequently expressed. 
In contrast to this expression pattern, the characteristic ’'popcorn" cells of 
HDLP usually express CD20 and CD45 but are seldom CD 15 or CD30 
positive (Stein et a l, 1991). These cells also express epithelial membrane 
antigen (EMA) whereas classical RS cells do not.
HD biopsy material, and more recently micromanipulated single RS cells, 
have been investigated for the presence of immunoglobulin (Ig) and T-cell 
receptor (TCR) gene rearrangements. Ig gene rearrangem ents have been 
detected in DNA extracted from biopsy material in most series investigated; 
in non-selected series rearrangements have been detected in up  to 25% of 
cases, with more rearrangements demonstrable following enrichm ent of RS 
cells or selection of cases with higher RS cell num bers (Weiss et a l, 1986;
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Brinker etaL , 1987; Sundeen e t a l , 1987; Kuppers e t a l , 1994). Results of 
TCR rearrangem ent studies have been more variable, with only two studies 
reporting rearrangem ents in a significant num ber of cases (Griesser et a l , 
1987; Herbst et a l, 1989). Using micromanipulation and single cell PCR, Ig 
gene rearrangem ents have been detected in putative RS cells (Kuppers et 
a l , 1994). As mentioned above, such studies have led to controversy about 
the clonal nature of the RS cell.
Overall, these data suggest that RS cells are almost certainly of 
haematopoietic origin and current opinion favours the lymphoid lineage.
1.2 .3  Epidem iology o f Hodgkin's disease
HD is not a particularly common cancer overall bu t one which 
predominantly affects young adults, being the second most common cancer 
in this age group. The incidence is 3 .0 /105 person years in the UK 
(McKinney et a l, 1989) and 2 .4 /105 person years in the USA (Glaser, 
1987).
The age-incidence for HD has a bimodal distribution (Fig. 1.2). In developed 
countries (Fig. 1.2a) there is low incidence in early childhood rising to a 
prominent peak in the young adult (15-34 years) age group, and  a second, 
less pronounced peak in older age (over 50 years). In developing countries 
the first peak occurs in childhood with low incidence in the young adult age 
group and a second peak in older adults (Fig. 1.2b). An intermediate 
distribution has been described in countries undergoing socio-economic 
development and in rural areas of developed countries (MacMahon, 1966; 
MacFarlane et a l , 1995). These differences in the age-incidence curves for 
different geographical locales led to the suggestion that HD has several 
epidemiological patterns (Correa 8s O’Conor, 1971).
The risk factors for the development of HD in different age groups are 
distinct. There is consistent evidence suggesting that high socio-economic 
s ta tu s is a risk factor in the development of young adult HD (Gutensohn 8s 
Cole, 1981; Glaser, 1987; Alexander et a l, 1991a). In contrast, the older 
adult peak and the childhood peak seen in developing countries are 
associated with lower standards of living (Gutensohn, 1982; Alexander et 
a l,  1991b).
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Fig. 1.2 Age incidence of HD
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The different histological subtypes of HD have different age distributions 
(McKinney et a l, 1989; Glaser & Swartz, 1990; Alexander et aL, 1991b). 
HDNS has a unimodal age-incidence curve and these cases account for the 
young adult peak seen in developed countries. The other subtypes show a 
gradual increase in incidence with increasing age and largely account for 
the second peak (Fig. 1.3). There is a male predominance which is most 
striking in childhood cases and older adults; in the young adult peak the 
male:female ratio is decreasing (McKinney et a l, 1989; Glaser & Swartz, 
1990). A recent study investigating international tim e-trends has shown an 
increase in young adult and a decrease in older adult HD cases (Hartge et 
a l , 1994).
1.2.3.1 H ypotheses for the aetiology o f Hodgkin's disease
In 1966 MacMahon put forward the hypothesis tha t HD was a 
heterogeneous condition encompassing at least three disease entities with 
distinct aetiologies. This was based on the epidemiological features of the 
three age groups, the histological subtypes and also on prognosis/survival 
(MacMahon, 1966). He defined three age groups, 0-14 years, 15-34 years 
and 50+ years and proposed that the aetiologies in these three groups were 
different. He suggested that HD in the 15-34 year age group involves an 
infectious agent. Since then a body of data has accum ulated suggesting 
tha t the risk factors for the young adult and older age group are indeed 
different. The older age group cases are more similar to non-Hodgkin's 
lymphoma in this respect. These findings have given rise to the widely 
accepted "two disease" hypothesis (Gutensohn, 1982; Alexander et a l, 
1991a).
A second, though not mutually exclusive, hypothesis suggests that HD 
occurs as a result of delayed exposure to a common infectious agent which 
would normally be encountered in early childhood (Gutensohn & Cole, 
1977). The hypothesis is based on data which found an  increased risk of 
developing young adult HD in persons with high socio-economic sta tus 
(section 1.2.3). It is thought that such persons lacked early social contact 
and thus were not exposed to certain childhood pathogens until later in life. 
A study performed by PafFenbarger et a l  (1977) showed that college 
students who developed HD had suffered fewer common childhood illnesses
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relative to controls. The hypothesis is referred to as the delayed exposure 
hypothesis or late host response model. An extension of this theory draws 
a comparison between the aetiologies of HD and paralytic poliomyelitis in 
the pre-vaccine era (Gutensohn & Cole, 1981). This was suggested 
following the finding that there is an  inverse relationship between childhood 
incidence in developing countries and young adult incidence in developed 
countries (Correa & O’Conor, 1971). This is known as the polio model and 
is outlined below.
In the pre-vaccine era, living conditions determined the age of infection with 
polio virus. Infection in childhood was usually associated with mild 
symptoms and paralysis was rare; infection in adolescence and beyond was 
m uch more likely to result in more severe symptoms including paralysis. In 
developing countries living conditions were poor and thus infection in 
childhood was usual and paralytic cases were observed in this age group. 
In developed countries the standard of living was higher and infection was 
delayed until early adulthood; the result was a peak of paralytic cases in 
this age group. The similarity was therefore drawn between paralytic polio 
and HD, and it was hypothesised that the childhood peak seen in 
developing countries and the young adult peak present in developed 
countries involved the same infectious agent.
In 1995 MacFarlane performed a new analysis of world HD data sets, 
including the same data as that analysed by Correa & O'Conor in 1971, and 
failed to find the same inverse association between incidence rates of HD in 
childhood and young adults in developed and developing countries. This 
was largely the evidence on which the polio model was based, therefore the 
findings in the recent analysis provide further support for the distinct 
aetiologies hypothesis (MacFarlane e t a l , 1995).
With regard to the putative infectious aetiology of HD, cluster analysis was 
carried out in the 1970s and early 1980s, but with inconclusive results 
(Kiyscio et a l, 1973; Greenberg et a l, 1983), possibly confounded by the 
long latent period from initial infection to onset of disease. Data from more 
recent studies suggest weak clustering of HD cases which is consistent with 
an  infectious aetiology involving a virus with a long latent phase, or delayed 
exposure to a common pathogen (Alexander, 1995).
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1.2.4 Aetiology o f Hodgkin's disease
Isolation of RS cells from sample material is thwarted by the small 
proportion of these cells within the overall tum our mass. Attempts a t in 
vitro propagation of these cells, to enable further investigation, have been 
largely unsuccessful; only 15 continuous HD cell lines have been recorded 
to date (Kapp et a l, 1995; Kanzler et a l , 1996; Wolf et a l , 1996). There is 
no suitable animal model available for the study of this disease. The severe 
combined immunodeficiency mouse model has been investigated recently, 
however tum ours developing in the mice appear to be EBV-driven 
lymphoproliferations and not true HD lesions (Kapp et a l , 1993; Krajewski 
et a l , 1995). Recent studies using single RS cells micromanipulated from 
cell suspensions have provided information about gene expression in these 
cells (Trumper et a l, 1993), and should prove to be a useful future strategy 
in the investigation of HD.
Several well characterised oncogenes and tum our suppressor genes, 
including bcl-2 and p53, have been investigated with regard to HD and 
tum our development. Most of the studies investigating oncogene 
expression have been performed using HD-derived cell lines and these have 
an  uncertain relationship to RS cells. The results are variable; expression 
of p53 has been found in a large proportion of HD cases, up to 90% 
(Neidobitek et a l, 1993; Dousis et a l, 1993). It has been suggested that 
p53 expression is inversely related to EBV LMP-1 protein expression 
(section 1.4.5.5). Chromosomal translocations involving bcl-2 in HD have 
been studied extensively in recent years with contradictory results. Some 
studies reported detection of bcl-2 translocations in a high proportion of HD 
cases and proposed that the translocation was im portant for tumorigenesis 
(Weiss et a l, 1987a; Stetler-Stevenson et a l, 1990; Bhagat et a l, 1993). 
Other studies, including unpublished findings from our group, did not find 
translocations which could be unequivocally demonstrated in the RS cells. 
The consensus at present is that bcl-2 does not play a central role in the 
development of HD; it is probable that the majority of bcl-2 translocations 
detected in biopsy material were present in the reactive tum our infiltrate 
and not the actual tum our cells.
The involvement of viruses in the aetiology of HD has been the focus of 
m uch investigation. A significant advance in the study of HD was the 
detection of EBV genomes in the RS cells in a significant proportion of cases 
(section 1.5.1). The potential role of other viruses e.g. HHV-6 has also been 
studied (section 1.5.2).
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1,3 The Family Herpesviridae
The Herpesviridae are a family of double-stranded DNA enveloped viruses, 
members of which infect a diverse range of hosts, both hum an and animal 
(reviewed by Roizman & Sears, 1996). The genomes of these viruses are 
large, ranging from 125-229kb, with a coding capacity for over 100 genes. 
They are characterised by their ability to establish persistent infection by 
adopting a latent state.
1.3.1 Classification of herpesviruses
Herpesviridae are subdivided into three classes according to their biological 
properties; these are the alpha, beta and gammaherpesvirinae (Roizman, 
1982; Roizman et a l , 1992). There are other classification systems in use, 
based on genome size and structure.
Alphaherpesvirinae are characterised by a short replicative cycle, 
productive infection of epithelial cells, and latency in sensory ganglia. 
Members of this group include herpes simplex viruses (HSV) types 1 & 2, 
Varicella Zoster virus (VZV) and equine herpesvirus (EHV) type 1. 
Betaherpesvirinae have slow replicative cycles and infected cells display 
cytomegaly. Secretory glands, kidney and lymphoreticular cells are among 
the tissues and cell types which can support latency in vitro (Britt & Alford,
1996). Members of this group include hum an cytomegalovirus (HCMV) and 
hum an herpesviruses (HHV) 6 & 7. Gammaherpesvirinae have lymphoid 
tropism and the site of latency is also in lymphoid tissue. This group 
includes Epstein-Barr virus (EBV) and herpesvirus Saimiri among its 
members.
Until recently, there were seven hum an herpesviruses which had been 
isolated and partially characterised (Table I.ii). In 1994 an  eighth hum an 
herpesvirus was described (Chang et a l , 1994) and has been termed 
Kaposi’s sarcoma associated herpesvirus (KSHV) or HHV-8. It has since 
been partially sequenced and characterised (Moore et a l, 1996), and viral 
particles have now been visualised (Said et aL, 1996).
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1.3.2 Diseases associated with herpesvirus infections
Infection with a herpesvirus can result in a wide variety of different 
outcomes ranging from subclinical infection to extensive and sometimes 
fatal viraemia. Members of the herpesvirus family achieve lifelong infection 
of the natural host by establishing latency. Reactivation into productive 
infection from the latent state occurs in response to certain stimuli, e.g. 
psychological or physiological stress, exposure to UV light. Little is known 
about the mechanism of reactivation or the genes involved for different 
herpesviruses. The consequences of such reactivation are usually less 
severe than  those of primary infection, with the exception of VZV (reviewed 
by Arvin, 1996), and are generally quickly and effectively controlled by the 
immune response of the host (Table I.ii).
Herpesviruses are of clinical importance as they can cause widespread 
viraemia in the immunocompromised host. HCMV can cause diffuse 
pneum onitis when reactivated in immunosuppressed patients such as HIV- 
infected individuals (Jacobson & Mills, 1988). It is also a major factor in 
the destruction and rejection of renal allografts and other transplanted 
organs, both during primary infection and on reactivation (Ho, 1982; Ruben 
et a t,  1985; Pollard, 1988). Perinatal infection with HSV-2 can produce 
fatal viraemia in the neonate where immunocompetence has not yet been 
fully established (reviewed by Whitley, 1996). EBV causes lympho- 
proliferative disorders and extensive lesions of the oral mucosa on 
reactivation in immunosuppressed patients (section 1.4.7).
The association of EBV with Burkitt’s lymphoma (BL) (section 1.4.7.2) was 
the first instance that a virus had been implicated in the pathogenesis of a 
hum an cancer. The isolation of KSHV sequences from tissues of Kaposi's 
sarcoma, which is a neoplasm affecting AIDS sufferers (Chang et a t,  1994), 
could prove to be a firm link between this newest member of the 
herpesvirus family and a tumorigenic process.
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Table I.ii Diseases associated with herpesvirus infection
virus main diseases caused
immunocompetent host immunosuppressed host
HSV-1 cold sores, eye infections 
encephalitis
HSV-2 genital herpes
VZV chicken pox, shingles
EBV infectious mononucleosis; 
association with BL, 
nasopharyngeal carcinoma
lymphoproliferation
HCMV congenital defects pneumonitis, graft rejection
HHV-6 exanthem subitum pneumonitis, encephalitis
HHV-7 exanthem subitum
HHV-8/KSHV *Kaposi's sarcoma
?body cavity-based lymphoma
?multicentric Castieman's disease
* These diseases are more often seen in the context of HIV/AIDS-related immuno­
suppression but can occur in the immunocompetent host.
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1.3.3 Replicative cycle of a herpesvirus
Herpesviruses have two distinct phases which are characteristic of their life 
cycle. These comprise a lytic and a latent phase. The lytic phase 
represents typical productive infection of permissive cell types and results 
in generation of progeny virions. The latent phase, occurring in non- 
permissive cells, enables the virus to persist undetected within the cell and 
express only a restricted number of viral genes.
1.3.3.1 Lytic infection
In order to gain entry into the cell the virus attaches to receptors on the 
target cell surface; expression of viral receptors by different cell types 
therefore has a major influence on the cellular tropism of individual 
herpesviruses. The virus penetrates the cell via interaction of spike 
glycoproteins in the viral envelope with cell surface molecules in the plasma 
membrane, causing fusion of the two membranes to occur (Roizman & 
Sears, 1996).
Once inside the cell the virus uncoats and the capsid is transported to the 
nucleus. Here the viral DNA is released and circularises. Transcription of 
the viral genome occurs, followed by translation of viral mRNA species into 
protein. At this stage, all host cell transcription and protein synthesis are 
sh u t down (Roizman & Roane, 1964). Translation of viral messages occurs 
in a temporal cascade with initial translation of viral transcription factors, 
followed by DNA modifying enzymes and finally the structural components 
of the virions. Viral DNA is replicated and packaged into capsids and as 
these exit the nucleus they acquire the viral envelope. The progeny virions 
are released from the cell in vacuoles and this process invariably results in 
the destruction of that cell (reviewed by Roizman & Sears, 1996).
1.3.3.2 Latent infection
Latent infection represents persistence of the herpesvirus within the host in 
a non-infectious state. Latency usually occurs in a cell type distinct from 
tha t in which lytic replication takes place. The viral genome exists as a 
closed episome, and only a restricted subset of viral genes are expressed 
(Roizman, 1996). This enables the virus to remain for years, avoiding 
detection by the host immune system.
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1,4 Epstein-Barr virus
EBV was first isolated in 1964 by Epstein and co-workers from a culture of 
African BL cells (Epstein et a l , 1964). EBV is a gammaherpesvirus with a 
172kb genome containing over 100 open reading frames (ORF). The 
prototype virus is B95-8 and the entire nucleotide sequence of th is isolate 
has been determined (Baer et a l, 1984).
1.4.1 Infection with EBV
EBV is a ubiquitous virus with 90% of the adult population becoming 
seropositive in the first decade of life (reviewed by Evans & Niederman,
1989). Primary infection is almost always subclinical. Delayed infection, 
occurring a t adolescence or later, gives rise to the clinical syndrome 
infectious mononucleosis (IM) in approximately 50% of cases (Henle et a l , 
1968).
Transmission of the virus is by exchange of bodily fluids, principally saliva. 
Transmission by blood transfusion and bone marrow transplantation, and 
isolation of virus from vaginal secretions and cervical epithelial cells have 
all been reported (Henle & Henle, 1985; Gratama et a l , 1994; Sixbey et a l, 
1986).
EBV gains entrance to B-lymphoid cells via attachm ent of the viral envelope 
glycoprotein gp340/220 to the CD21 (CR2) antigen on the cell surface 
(Nemerow et a l , 1985; 1987; reviewed by Nemerow et a l , 1990). Entrance 
to epithelial cells can occur by this method also (Young et a l , 1986; Sixbey 
et a l, 1987; Birkenbach et a l, 1992) or by IgA-mediated endocytosis in the 
case of otherwise resistant epithelial cells (Sixbey & Yao, 1992). 
Attachment is followed by fusion of the viral envelope with the plasma 
membrane. Infection of T-cells can also occur (Kikuta et a l , 1988). It has 
been suggested that this occurs via expression of the IFN-a receptor on 
these cells, as this receptor shares a common sequence motif with CD21 
and is a member of the same family of receptors (Delcayre et a l,  1991; 
Watry et a l, 1991). IFN-a has been shown to prevent EBV from attaching 
to CD21 by binding to CD21 itself (Delcayre et a l, 1993).
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1.4.2 Subtypes o f EBV
EBV-1 and EBV-2, originally called subtypes A and B, are biologically 
distinct strains of the virus which can be distinguished on the basis of 
differences in several genes and their respective proteins (Sample et a l,
1990). Serology and virus isolation studies have shown tha t the serotypes 
have different distributions in nature, with EBV-1 being prevalent in 
developed countries such as Britain and North America, and EBV-2 being 
relatively more common in developing countries such as Africa and Papua 
New Guinea (Zimber et a l , 1986; Young et a l, 1987). It has been suggested 
th a t this distribution may display a bias due to the methods of detection 
used, and PCR based subtyping studies have since detected a more 
widespread distribution of type 2 virus in the West (Sixbey et a l , 1989).
1.4.3 Persistence o f EBV in the infected host
Following primary infection with EBV, lifelong persistence of the virus 
results (Klein & Klein, 1985) and can be dem onstrated in the following 
ways. First, continuous EBV-transformed B-cell lines can be grown in 
culture from the peripheral blood of infected donors (Rickinson et a l , 1984). 
Secondly, infectious virus can be recovered from throat washings of healthy 
seropositive individuals years after primary infection (Yao et a l , 1985a).
In the 1980s the site of initial viral replication following primary infection 
was believed to be the mucosa of the buccal cavity and oropharynx, e.g. 
salivary gland and pharyngeal epithelium. These cells are permissive for 
the virus and replication at these sites is productive; infectious virus is 
shed in the saliva (Yao et a l, 1985a). B-cells circulating through the 
oropharynx were thought to become infected by the virus produced by 
epithelial cells a t these sites. Recent opinion is that B-lymphoid tissue, 
such as the tonsils, is the site of primary EBV infection and tha t infection of 
proximal epithelial cells is a secondary event (Neidobitek et a l, 1992; 
Neidobitek & Young, 1994).
There has been much discussion regarding the true sites of latency and 
productive infection; the current consensus favours the idea tha t lymphoid 
tissue, rather than  epithelium, is the site of latency for three main reasons. 
First, treatm ent with antiviral compounds, such as acyclovir, results in a 
reduction in the am ount of virus shed in the saliva, but has no effect on the
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num ber of circulating lymphocytes which are EBV-positive (Yao et a l, 
1989b). This implies that lytic cycle replication, the target for acyclovir, 
occurs in the oropharyngeal mucosa. Secondly, oral hairy leukoplakia 
(OHL) (section 1.4.7.1), which occurs in the epithelium of the tongue in 
im m unosuppressed people, is characterised by lytic phase EBV replication 
with no detectable latent phase (Greenspan et aL, 1985), suggesting that 
epithelial cells are permissive for viral replication and cannot support the 
latent phase. Thirdly, in bone marrow transplant recipients whose own 
marrow has been irradiated, eradication of EBV infection has been recorded 
(Gratama et a l , 1988). This would suggest tha t cells of a haemopoietic 
derivation are the site of true viral latency.
The proposed site of viral persistence in the infected host is therefore 
lymphoid tissue. The role of nasopharyngeal epithelium as the main site for 
production of infectious virus has recently been challenged by the results of 
a study of IM patients (Anagnostopoulos et a l, 1995). Both latent and 
productive infection were demonstrated in lymphoid cells of the tonsillar 
crypts and epithelium, whereas no productive replication was detected in 
the epithelial cells. A second study of EBV seropositive people in southern 
China, without EBV-related disease, showed productive infection occurring 
in mucosal lymphocytes but no such infection of the nasopharyngeal 
epithelial cells (Tao et a l , 1995). This would suggest tha t lymphoid tissue 
could be the site of productive replication in addition to being the principle 
reservoir of latent viral genomes in the infected host, with infected 
epithelium acting as a secondary site of viral shedding.
The study of the association between nasopharyngeal carcinoma (NPC) and 
EBV provides evidence for EBV adopting a latent, rather than  purely lytic, 
state in epithelial cells. These tum ours are of epithelial origin and the virus 
is clearly present in the latent state with expression of several viral antigens 
(Brooks et a l, 1992). This may, however, still be reconcilable with a  B-cell 
site for true latency. EBV may initially productively infect the 
nasopharyngeal epithelium, which fits with the model for latent and lytic 
sites described above. This would correlate with the increased serum  titres 
to lytic cycle antigens which precede the onset of NPC tum ours (section 
1.4.7.3). A subset of epithelial cells may then aberrantly enter the latent 
phase, thus achieving a proliferative advantage and increasing the 
probability of progression to NPC.
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1.4.4 EBV infection in vitro
EBV is unique in its ability to efficiently immortalise infected B-lymphocytes 
in culture. In a cell culture situation, 10-100% of B-cells successfully 
infected with EBV will go on to yield progeny that can proliferate 
indefinitely, maintaining EBV within the cells in the latent state (Sugden, 
1989). Infection of peripheral blood mononuclear cells (PBMCs) with EBV is 
the standard means of establishing a continuous hum an cell line from a 
specific donor.
Latent EBV can be stimulated to productive replication using 12,0- 
tetradecanoyl phorbol- 13-acetate (TPA) (Table Il.ii). In a continuous EBV- 
driven culture, one in 102-106 cells will undergo spontaneous reactivation 
a t any one time (Sugden et a l , 1979). This occurs through triggered 
expression of the BZLF-1 gene, possibly involving EBNA-1, which activates 
the lytic gene expression cascade (reviewed by Miller, 1990).
1.4.5 EBV latent proteins
Latent infection in vitro results in immortalisation and activation of the host 
B-cell. The resulting immortalised cell line is known as a B-lymphoblastoid 
cell line or LCL (Pope et a l , 1968), and gene expression in these cells is 
restricted to a small subset of viral genes known collectively as the latent 
genes. Much study has gone into this phenomenon, unique among the 
herpesviruses, with emphasis on the functions of the individual gene 
products (Kieff & Leibowitz, 1990; Ring, 1994).
In an  LCL in vitro, the virus expresses a num ber of latent genes. These 
include the Epstein-Barr viral nuclear antigens (EBNAs) 1, 2, 3a, 3b, 3c, 
leader protein (EBNA-LP); the latent membrane proteins LMP-1 and LMP-2a 
and -2b and the Epstein-Barr encoded RNAs (EBERs) (reviewed by Sugden,
1994). These genes are expressed in various combinations during latency, 
except in the case of EBNA-1, the expression of which is obligatory. There 
is also expression of BamHI A fragment RNA transcripts during latency but 
little is known about their function (section 1.4.6). The location and 
orientation of the latent genes as they are expressed from the EBV episome 
is illustrated in Fig. 1.4.
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Fig 1.4 Transcripts are shown in the correct orientation relative to one 
another. Promoters are marked by pennants and splicing patterns are 
indicated. Exons for non-coding RNAs are shown in grey and for mRNAs in 
black. The actual genomic positions of these exons are given (top) on a 
linear map of the EBV genome. Note that the genome is circularised in 
latency due to fusion of the terminal repeats (TR); the LMP-2 transcripts 
are spliced across this region.
Fig. 1.4 O rientation and expression of EBV la ten t genes
Reproduced from “Virology” (1996) B.N.Fields et al. (eds)
21
1.4.5.1 EBNA-1
Expression of EBNA-1 during latency ensures that the viral genome is 
replicated and maintained as an  episome within the infected cell (Yates et 
a l y 1984; 1985). The EBNA-1 ORF encodes a relatively small protein of 641 
amino acids (aa) which has three distinct domains. The carboxy terminal 
domain has DNA binding activity, there is a central domain containing 
glycine-alanine repeat sequences and the amino terminal third is highly 
hydrophilic (Hennessy & Kieff, 1983; Ambinder et a l, 1991). The DNA 
binding domain transactivates OriP, the plasmid origin of replication 
(Ambinder et aL, 1990). EBNA-1 also regulates its own expression 
(Reisman & Sugden, 1986). It has been shown to associate with chromatin 
and the nucleoplasm in latently infected cells. Oncogenic properties have 
recently been attributed to this gene following studies using EBNA-1 
transgenic mice (Wilson & Levine, 1992; Wilson etaL f 1996).
1.4.5.2 EBNA-2
EBNA-2 is a transactivator of both cellular genes and viral latent genes, 
including its own gene and that of LMP-1 (Wang et a l, 1990). EBNA-2 is 
one of the first viral genes to be expressed in newly infected B-cells in vitro. 
The gene is thought to be essential for the in vitro immortalisation function 
of EBV (Hammerschmidt & Sugden, 1989; Cohen et a l , 1989; 1992). A 
m utan t strain of EBV, P3HR-1, which has a deletion of EBNA-2 and 
partially EBNA-LP, is transformation incompetent (Bomkamm et a l, 1982). 
Reconstitution of an  intact EBNA-2 gene restores this function. EBNA-2 
transfected into Rat-1 cells cannot transform the cells but does cause 
reduced serum  dependence (Dambaugh et a l , 1986). EBNA-2 also induces 
high levels of expression of the CD23 activation marker (Wang et a l, 1987) 
and causes BL cells to grow in tight clumps as opposed to single cells.
As outlined above, there are two subtypes of EBV, type-1 and type-2 
(section 1.4.2). The subtypes differ in the EBNA-2 gene among others 
(Aldlinger et a t, 1985), and also differ in their growth transformation 
properties. EBV-1 transforms B-cells in culture more efficiently than  EBV- 
2 (Rickinson e t a l t 1987).
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1.4.5.3 The EBNA-3 family
The EBNA-3 genes a, b and c have a common origin and are tandemly 
located along the EBV genome. Of these genes, EBNA-3a and -3c are 
essential for viral transformation of B-cells (Tomkinson & Kieff, 1992; 
Tomkinson et a l , 1993); EBNA-3c may ensure high levels of LMP-1 are 
m aintained in proliferating EBV-infected B-cells (Allday & Farrell, 1994). 
There are noticeable similarities between these proteins even though the 
amino acid sequences are not closely conserved. The proteins are 
distributed similarly throughout the nuclei of latently infected cells, being 
associated with the nuclear matrix but not strongly associated with 
chromatin (Petti et a l , 1990). The genes coding for the EBNA-3 proteins 
differ between the two subtypes of EBV (Sample et a l, 1990).
1.4.5.4 EBNA-LP
Leader protein (EBNA-LP) is so called because it is encoded by the leaders 
of the other EBNA mRNAs and translated when these messages are spliced. 
The protein is one of the first to be detected in the newly infected cell, 
alongside EBNA-2, but is not essential for immortalisation (Hammerschmidt 
& Sugden, 1989). It is believed, however, to fulfil an  im portant auxiliary 
role because deletion m utants are greatly impaired in their transformation 
efficiency (Hammerschmidt & Sugden, 1989; Mannick e ta l ,  1991). Recent 
studies have discovered colocalisation of EBNA-LP with the retinoblastoma 
protein (Rb) within the nucleus. This is comparable to the distribution of 
SV40 large T antigen and Rb (Jiang et a l, 1991), with complex formation 
resulting in inactivation of Rb. The EBNA-LP protein structure shows some 
similarity to E l A of adenovirus 5, another transforming protein shown to 
complex with Rb. These findings support the theory tha t EBNA-LP plays an 
im portant, albeit not essential, role in cellular growth transformation by 
EBV. In addition, it is thought that EBNA-LP could play a role in the 
complex mechanisms involved in EBV RNA processing and splicing due to 
its distinct nuclear distribution into discrete, sub-nuclear particles (Wang et 
a l, 1987; Petti e ta l ,  1990).
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1.4.5.5 The latent membrane proteins
The LMP-1 gene has a potentially oncogenic function in the latently infected 
cell. This viral gene behaves as a classical oncogene in tissue culture 
assays, transforming Rat-1 cells in vitro (Dambaugh et a l , 1986; Moorthy & 
Thorley-Lawson, 1993). This results in altered morphology and decreased 
serum  requirement of the cells (Dambaugh et a l , 1986). Loss of contact 
inhibition and reduced anchorage-dependent growth are observed in LMP-1 
transfectants (Wang e ta l ,  1985; Baichwal & Sugden, 1988). LMP-1 plays a 
role in immortalisation of B-cells in culture; genetically modified m utants 
lacking full length LMP-1 are transformation deficient (Kaye et a t ,  1993;
1995). Expression of LMP-1 in vitro induces increased expression of cellular 
activation markers LFA-1 and LFA-3 and the cellular adhesion molecule 
ICAM-1. It has also been shown to increase levels of bcl-2 and suppress 
apoptosis (Henderson e t a l , 1991; Rowe e t a l , 1994).
The molecule has a similar structure to the G-protein-coupled receptor 
family and forms discrete patches in the cell membrane (Liebowitz et a l , 
1986). The predicted topology of LMP-1 is shown in Fig. 1.5. The protein is 
thought to modify signal transduction pathways and has been shown to act 
in the TNF-a signal cascade (Arvanitakis et a l, 1995; Mosialos et a l , 1995), 
specifically inducing expression of the epidermal growth factor receptor 
(Miller et a l , 1995). It has also been shown to activate the NF-xB 
transcription factor (Herrero e t a l , 1995; Huen e t a l , 1995).
LMP-1 sequence variants, which may have altered biological properties, 
have been found in certain populations. Common variations include loss of 
an  Xhol restriction site a t the N-terminal end and deletions in the C- 
terminal region of the protein (Fig. 1.5); these have been found in Southern 
Chinese and Alaskan Inuit populations (Lung et a l , 1990; Hu et a l, 1991; 
W. Miller et a l , 1994). These mutations are found in EBV isolates from NPC 
cases, and similar deleted forms of LMP-1 have been isolated from BL 
tum ours (Chen e t a l , 1996). These links between LMP-1 deletion m utants 
and malignancy have led to the suggestion that they may represent more 
oncogenic forms of the protein. Some variants have been shown to have 
greater transforming properties in vitro (Chen et a l, 1992), have decreased 
sites for phosphorylation (W.Miller et a l, 1994), and be less immunogenic 
in some systems (Trivedi et a l, 1994). The latter observation raises the 
possibility of non-immunogenic LMP-1 escape m utants arising under 
immunoselection pressure (section 1.7.3). Deleted LMP-1 species are also 
found in EBV isolates from HD lesions, and these are identical to those 
found in NPC (Knecht et a l, 1993; 1995).
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Fig. 1.5 Schematic representation of LMP-1 and LMP-2a. The triangle 
indicates the deletion common to many LMP-1 variants. Functional 
domains affecting NF-xB activation and transformation are shown in 
yellow. LMP-2A is shown on the right, with the start codon of LMP-2b 
indicated by the arrow. The yellow domain represents a potential ATP- 
binding motif (Longnecker e t a l , 1991).
Fig. 1.5 Predicted topology of the LMPs
Reprinted with kind permission of Joanna Wilson
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The LMP-2s are two similar proteins which are transcribed across the 
terminal repeat sequences following circularisation of the viral genome 
(Laux et aL, 1988; reviewed by Longnecker, 1994). Transcription of the 
LMP-2 genes occurs in the opposite direction to transcription of LMP-1. 
LMP-2b is an  N-terminally truncated form of LMP-2a; the proteins are 40kD 
and 54kD respectively and both colocalise to the plasma membrane 
alongside LMP-1 (Longnecker & Kieff, 1990). The predicted structure of 
LMP-2 is shown in Fig. 1.5. The LMP-2s may modulate the activation effects 
of LMP-1 and be important for stabilising the latent state (C.Miller et a l , 
1994). Both LMP-2s are dispensable for B-cell transformation per se  
(Longnecker et aL, 1992; 1993a; 1993b) but are thought to contribute to 
the infected cell phenotype as indicated by their expression in several 
malignancies such as HD and NPC.
1.4.5.6 EBERs
EBER-1 and EBER-2 are small nonpolyadenylated, untranslated RNA 
transcripts which are present in very high copy num bers, approximately 
105-107 per cell, within the nucleus of the latently infected cell (reviewed by 
Clemens, 1994). Their function is as yet unknown but appears non- 
essential for the transformation process (Swaminathan et a l , 1991). 
Currently, the main interest in the EBERs is as a target for probes used in 
in situ  hybridisation.
1.4.6 Patterns of EBV latent gene expression
Three distinct patterns of EBV latent gene expression have been described 
for infected B-cells in vitro. These are designated latency (Lat) I, II and III 
(Rowe et a l , 1992) and are outlined in Table I.iii. Lat I is seen in the 
tum our cells of fresh EBV-positive BL biopsies and some BL-derived cell 
lines (Rowe et a l , 1987). Lat II expression is characteristic of RS cells of 
EBV-associated HD (Pallesen et a l, 1991; Deacon et a l , 1993; Grasser et 
a l , 1994) and tum our cells of undifferentiated NPC (Young et a l, 1988; 
Brooks et a l , 1992). The Lat III pattern, with unrestricted expression of all 
the latent gene products, is seen in cultured LCLs in vitro and some long­
term cultured, EBV-positive, BL-derived cell lines. In all known forms of 
latency there is expression of the EBERs and also latency-associated RNA 
transcripts expressed from the BamHI A fragment (Gilligan et a l , 1991; 
Brooks e t a l , 1993).
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Table I.iii Patterns of EBV latent gene expression
latency viral/cellular gene expression cells expressing this type o f latency
Lat I EBNA-1 only 
CD 10, CD77
1° BL cells
group I BL-derived cell lines
Lat II EBNA-1, LMP-1, LMP-2 
(CD 10, CD77)
(CD21, CD23, CD30)
RS cells of HD, NPC tum our cells 
group II BL-derived cell lines
Lat III all EBV latent genes 
CD21, CD23, CD30 
LFA-3, ICAM-1
LCLs, EBV-driven LPD in 
im m unosuppressed people 
group III BL-derived cell lines
■"Antigens given in brackets are not expressed in all cases of Lat II, e.g. they are not 
present on RS cells of HD.
In addition to expression of EBV latent genes, the Lats are characterised by 
differences in expression of cell-surface markers such as cellular activation 
antigens and adhesion molecules. Lat I is associated with expression of 
CD77 (BL-associated antigen) and CD10 only (Rooney et a l , 1986; Gregory 
et a l , 1988). In Lat II, additional expression of one or more activation 
markers, e.g. CD21, CD23 and CD30, is seen (Rowe et a l, 1992). Lat III is 
characterised by expression of all the activation m arkers plus cell adhesion 
molecules such as LFA-3 and ICAM-1, with loss of expression of CD 10 and 
CD77 (Rowe e t a l , 1992).
In the in vivo situation in healthy EBV-positive individuals, the pattern of 
latent gene expression in infected cells is distinct from the expression 
patterns described above. It is characterised by expression of EBNA-1 and 
LMP-2 only, as determined by analysis of mRNA from infected cell 
populations (Qu & Rowe, 1992; Tierney e ta l ,  1994; Chen et a l, 1995). The 
infected cells may also be phenotypically distinct (Gregory et a l, 1987; 
Miyashita e ta l ,  1995).
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1.4.7 Disease associations
EBV has been implicated in the aetiology of many lymphoid and epithelial 
conditions, including several malignancies. It is difficult experimentally to 
establish a firm relationship between a virus and a hum an malignancy. 
Association with a virus can be proposed on the basis of epidemiological 
and molecular findings. In the case of EBV, which is carried for life by 90% 
of the world’s population, association m ust be clearly demonstrated.
It is thought tha t the proliferative potential of EBV-infected cells, coupled 
with lifetime exposure through viral persistence, are major predisposing 
factors in the development of EBV-related neoplastic disease.
1.4.7.1 Benign diseases associated with EBV
IM is characterised by a polyclonal B-cell proliferation. T-cell responses to 
this proliferation are largely responsible for the clinical manifestations of 
this syndrome and for the atypical lymphocytosis. It is a self-limiting 
disease which usually resolves in time, however it can give rise to a chronic 
disease.
OHL occurs in immunocompromised individuals, most notably in HIV- 
infected people (Greenspan et a l , 1984) and less commonly in post­
transplant patients (Macleod et a l , 1990). OHL presents as a raised, 
’’hairy” white lesion occurring on the lateral borders an d /o r ventral surfaces 
of the tongue (Schiodt et a l, 1987). It is associated with chronic productive 
EBV infection of the upper epithelial cells of the tongue (Niedobitek et a l, 
1991). Lytic phase EBV has been detected in tissue sections using 
immunohistochemistry and in situ hybridisation, and more recently PCR 
(Mabruk e ta l ,  1994).
1.4.7.2 Burkitt's lymphoma
BL is a malignancy of B-cell origin. There are two forms of the disease, 
endemic and sporadic. The endemic type shows high incidence in parts of 
equatorial Africa and Papua New Guinea, and the sporadic form of the 
disease has 100-fold lower incidence worldwide (Magrath, 1990). The two 
forms of BL are histologically very similar but display different clinical 
presentation and aetiology.
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Endemic BL, which occurs primarily in children, is associated with EBV in 
virtually 100% of cases, with viral genomes being present in all the tum our 
cells and these genomes being clonal (Epstein & Achong, 1979). The 
pathogenesis of endemic BL is thought to involve a num ber of events which 
include virus-induced B-cell proliferation. The fully m alignant BL 
phenotype requires the presence of a chromosomal translocation which 
brings about dysregulation of the c-myc gene by juxtaposing th is gene to an 
immunoglobulin gene locus (Dalla-Favera et a l, 1982; Klein & Klein, 1985). 
There are three possible translocations which can achieve this result; 8:14 
(IgH locus), 8:22 [X light chain) or 2:8 (x light chain). Sporadic BL tum ours 
also possess the c-myc translocation but are associated with EBV in only 
10-20% of cases. The occurrence of holoendemic malaria is thought to 
facilitate tumorigenesis in EBV-associated endemic BL, although the exact 
mechanism by which this exerts its effect is unknown. High titres to EBV 
antigens precede the onset of the tum our by several months.
1.4.7.3 Nasopharyngeal carcinoma
NPC is endemic in Southern China where it is the most common cancer of 
men and second most common cancer of women (Zur Hausen et a l,  1970). 
The undifferentiated form of the disease does not occur in EBV seronegative 
individuals and displays complete correlation with presence of the viral 
genome in the tum our cells (Raab-Traub et a l, 1987); indeed this 
malignancy shows the most consistent world-wide association with EBV of 
all malignancies associated with this virus. The tum our cells of NPC 
contain multiple EBV genomes and express viral antigens (Fahraeus et a l, 
1988; Young et a l, 1988). This strongly suggests a causal role for the virus 
in tumourigenesis, although the restricted geographical and ethnic 
incidence of the disease (de The, 1982) would indicate tha t EBV infection, 
although necessary, is not sufficient for tum our development. Studies have 
been carried out to investigate the existence of genetic and environmental 
co-factors. Dietary factors such as foods which are high in nitrosamines 
and phorbol esters have been implicated (Zou et a l, 1994).
Serologically, high antibody titres to EBV VCA and EA occur in NPC 
patients. Of particular interest is the finding tha t elevated IgA titres to 
these viral antigens precede the onset of clinical disease by several years; 
the elevation of antibody titres also has prognostic significance, with higher 
titres indicating high tum our load and poor prognosis (Henle & Henle, 
1976; Yip e ta l ,  1996).
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1.4.7.4 Hodgkin's disease
HD has been associated with EBV in approximately 40% of cases. A more 
detailed account of this association is given in section 1.5.1.
1.4.7.5 B-lymphoproliferative disease
EBV-induced B-lymphoproliferative disease (LPD) is observed among 
im m unosuppressed individuals, both in the case of congenital and acquired 
imm unosuppression (Sullivan & Woda, 1989). Groups of individuals where 
there are well documented reports of LPD include post transplant patients 
(Shapiro et a l , 1988) and HIV-positive people suffering from AIDS 
(Hamilton-Dutoit et a l, 1991). Cases of HD arising in these people also 
tend to be EBV-positive (Hamilton-Dutoit et a l, 1991). LPD is thought to 
arise from B-cells expressing all the EBV latent proteins; such a  cell would 
normally be expected to be lysed by the host cellular immune response, but 
in the immunosuppressed person is allowed to persist. Where this occurs, 
viral antigens normally only transiently expressed in the immunocompetent 
host are constitutively expressed in the infected cell. Several of these 
proteins have been shown to play a role in growth transformation, and it is 
thought that the action of these viral gene products leads to increased 
proliferation and survival of the infected cells. This is believed to be the 
initiating step in the development of malignant lymphoma, bu t the exact 
mechanism of this progression is not understood. In cases where LPD has 
progressed to a clonal cell population, restoration of immune function can 
still result in complete regression of the lesion (Starzl et a l, 1984). This is 
possibly the only example of a virally associated tum our where the virus is 
solely responsible for the initiation and maintenance of the neoplastic state.
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1.5 Viral Involvement in HD
The epidemiological features of HD discussed in section 1.2.3 suggest an 
infectious aetiology with the strongest evidence relating to the young adult 
age group. Attempts have been made to correlate the incidence of HD with 
infection with several known viruses, particularly those associated with 
common childhood infections.
1.5.1 EBV
Serological studies have investigated potential associations between HD and 
antibody titres to a num ber of viruses, mainly herpesviruses. The most 
consistent correlation was found for EBV. Studies in the 1970s reported 
raised antibody titres to EBV in HD patients. This suggested an  association 
between the virus and the disease (Levine e t a l y 1971; Henle & Henle, 1973; 
Langenhuysen et a l , 1974; Hesse et a l, 1977; Evans et a l,  1978). It was 
later found tha t individuals with a past history of IM, a condition associated 
with delayed primary infection with EBV, were three times more likely to 
develop HD than  those with no such history (Munoz et a l , 1978; 
Gutensohn & Cole, 1980). An investigation was carried out by Mueller et 
a l  in 1989 to determine whether the raised antibody titres to EBV preceded 
diagnosis. A group of 43 HD patients, whose serum had been stored prior 
to diagnosis of the disease, were studied alongside 96 controls (Mueller et 
a t, 1989). The data indicated a significantly increased relative risk of 
developing HD in individuals with raised antibody titres. These results 
suggest that the elevation of antibody titres to EBV seen in HD patients is 
not simply due to viral reactivation induced by therapy or advanced disease 
state. The findings, together with the data on IM and HD, strengthened the 
evidence that EBV is involved in the pathogenesis of this disease.
Early molecular studies were undertaken to determine whether EBV had a 
causal role in the disease, and as no detectable viral genomes were found in 
the disease lesions it was believed that this was not the case (Pagano et a l , 
1973; Lindahl e t a l , 1974). These studies included only small num bers of 
cases and the sensitivity of the techniques used in the analyses, which 
utilised either radiolabelled virus or cRNA as a probe, was poor by present 
day standards. It was not until much later that it was dem onstrated by 
Weiss et a l  (1987b) that EBV genomes were detectable by Southern blot
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analysis in 4 of 21 HD cases (Weiss et a l, 1987b). This study utilised the 
BamHI W fragment as a probe (Arrand et a l, 1981) and this proved more 
sensitive as this is a repeat element. Since that time studies using this 
technique and others have shown EBV genomes to be present in HD 
samples from 17-50% of cases (Anagnostopoulos et a l, 1989; Ja rre tt et a l, 
1991; Weiss e ta l ,  1991; P.G.Murray e ta l ,  1992; Herbst e ta l ,  1992; Khan 
et a l, 1993a; Poppema & Visser, 1994a; Belkaid et a l, 1995). The results 
of these studies are summarised in Table I.iv.
By examining the terminal repeat sequences of the viral genomes present in 
any given infected cell population it is possible to assess the clonality of the 
virus (Raab-Traub & Flynn, 1986). In the above studies the EBV genomes 
found in HD samples were shown to be of a clonal nature. Ja rre tt et a l  
(1991) examined tum our material from 27 cases of HD which were positive 
by Southern blot analysis and found that in all cases the EBV was clonal 
(Jarrett e ta l ,  1991; Armstrong e ta l ,  1993).
The central question to be addressed was whether the EBV genomes could 
be localised to the tum our cell population as opposed to the bystander 
lymphocytes in the tum our mass. EBV was detected in cells with RS-like 
morphology using DNA in situ  hybridisation to the BamHI W region (Weiss 
et a l,  1989). Immunohistochemical assays for LMP-1 showed EBV gene 
expression which localised to RS cells (Pallesen et a l, 1991; Armstrong et 
a l, 1992; P.G.Murray et a l, 1992). The EBERs, two small 
nonpolyadenylated RNA transcripts, are also expressed. In situ 
hybridisation to the EBERs is a very sensitive indicator of EBV infection 
due to the high copy number of EBER transcripts present in the nuclei of 
latently infected cells. EBER in situ hybridisation localised to the RS cells 
in 30-50% of cases and was found to be much better for detecting EBV in 
RS cells than  any other method. With regard to the methods described 
above, EBER in situ  hybridisation is widely recognised as the m ost useful 
for defining EBV sta tus in HD (Weiss et a l, 1991; Armstrong et a l, 1992; 
1994; Herbst et a l, 1992). Studies determining cellular localisation also 
dem onstrated that RS cells express a pattern of latent genes that includes 
EBNA-1, LMP-1 and LMP-2 (Pallesen et a l, 1991; Deacon et a l, 1993; 
Grasser e ta l ,  1994).
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Table I.iv Results o f studies detecting EBV in HD cases
investigators year country detection method 
used
proportion o f 
EBV+ cases
Anagnostopolous et a l 1989 Germany S.blot BamHI W 
in situ BamHI W
17%
Jarre tt et a l 1991 UK S. blot BamHI W 36%
Weiss et a l 1991 USA PCR EBNA-1 
in situ EBER
48%
Murray et a l 1992 UK APAAP LMP-1 48%
Herbst et a l 1992 Germany APAAP LMP-1 
in situ EBER
50%
Khan et a l 1993 UK in situ EBER 32%
Poppema & Visser 1994 Canada in situ EBER 
APAAP LMP-1
26%
Belkaid et a l 1995 France APAAP LMP-1 
in situ BamHI W 
in situ EBER 
PCR BamHI W
38%
S.blot BamHI W 
in situ BamHI W 
APAAP LMP-1
in situ EBER 
PCR BamHI W 
PCR EBNA-1
Southern blot using probes to BamHI W repeat region of EBV
in situ hybridisation using probes to BamHI W repeat region of EBV
Alkaline phosphatase anti-alkaline phosphatase
immunohistochemical staining using antibodies to EBV LMP-1
in situ hybridisation using probes to EBV EBERs
PCR using primers specific for BamHI W internal repeats
PCR using primers specific for 80bp of EBNA-1 gene
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The heterogeneous nature of HD has led to the investigation of EBV- 
association within different subgroups of HD. Several studies have 
addressed the association of EBV with the histological subtypes of HD 
(section 1.2.1). The results of these studies find a significant association 
between EBV and HDMC; 50-90% of cases are EBV-associated. There is a 
m uch weaker association between EBV and HDNS, with only 10-50% of 
cases being EBV-associated (Pallesen e ta l ,  1991; Weiss e t a l , 1991; Delsol 
et a l, 1992; Khan et a l, 1993a). HDLP cases are generally EBV-negative 
and it is likely that HDLP, as recently defined, is an  EBV-negative disease. 
HDLD cases are usually EBV-associated, though the num ber of cases that 
have been studied is small.
Association of EBV with different age groups of cases has also been 
investigated. Paediatric HD cases (0-9 years) and older adult age group 
cases (over 50 years) were more often EBV-associated, with a dearth  of such 
cases in the young adult (15-24 years) age group (Armstrong et a l , 1993; 
Ja rre tt et a t, 1996) A comparison of the proportion of EBV-associated 
cases in children in developing countries with young adults in developed 
countries does not support the polio model as described in section 1.2.3.1 
(Armstrong et a l, 1993). At present the multiple aetiology hypothesis is 
more likely to relate to HD.
It is now almost certain that EBV plays a direct role in the development of a 
subgroup of cases of HD, although the mechanism of action of the virus 
rem ains unclear. In non-EBV-associated cases there may be another virus 
involved which acts in a similar m anner within the cell and therefore 
results in the same clinical manifestations. This is in keeping with the 
widely acknowledged heterogeneous nature of HD.
1.5.2 HHV-6
The virus was first isolated in 1986 from patients with lymphoproliferative 
and immunosuppressive conditions (Salahuddin et a l , 1986). It is now 
known to be a ubiquitous virus with seroconversion occurring in early life 
and a  persistent infection being established (Jarrett et a l, 1990). A num ber 
of studies have been undertaken to investigate HHV-6 antibody sta tus in 
HD (Ablashi et a l , 1988; Biberfeld et a l , 1988; Clark et a l , 1990; Torelli et 
a l , 1991), one of these being a large case controlled study covering various 
lymphoid malignancies (Clark et a l , 1990). All found elevated antibody
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titres to HHV-6 in HD. Raised titres were most marked in the young, as 
compared to older adult cases (Clark et a l, 1990). EBV serology carried out 
on the same serum  samples indicated that the antibody profiles of the two 
viruses are largely independent of each other (D. Clark, unpublished 
results). The raised titres suggested the possibility of involvement of HHV-6 
in HD. However, no viral genomes were detectable by Southern blot 
analysis in any of over 50 cases studied by our group and th is would 
indicate tha t HHV-6 is unlikely to play a direct role in pathogenesis 
(Gledhill e ta l ,  1991; R.Jarrett, personal communication).
Since the latter analyses there have been reports of detection of HHV-6 DNA 
in HD cases by PCR and Southern blot analysis (Torelli et aL, 1991). 
However these studies found HHV-6 in only 3 of 65 cases (Torelli et a l,
1991) and the virus has not been localised to the tum our cells (Khan et a l, 
1993a). Despite the results from these molecular analyses, the serological 
data do indicate tha t this virus could be associated with the young adult 
cases (Clark et a l, 1990). Further studies, such as more sensitive in situ  
hybridisation or single cell PCR, need to be undertaken to determine the 
role, if any, played by HHV-6 in these cases.
1.5.3 Other viruses in Hodgkin's disease
The epidemiological features of HD (section 1.2.3) suggest tha t the young 
adult cases, in particular young adult HDNS cases, are most likely to be 
linked with an infectious agent. To date, no one infectious agent has been 
identified which could account for the young adult peak of incidence. EBV 
is associated with a significant proportion of cases in other age groups, but 
there is a marked lack of EBV-associated cases in the young adult peak. 
HHV-6 has intriguing seroepidemiology, but no evidence exists for a direct 
role for this virus in the development of the disease.
There is much interest at present in the possible isolation of another 
infectious agent in these cases, especially a common virus which 
establishes persistent infection following primary exposure. Various 
molecular techniques are currently being employed to search for both 
known and novel viral sequences in the tissues of HD patients. Studies 
were carried out by our group to look for adenovirus serotypes 5 and 12, 
lymphotropic papovavirus and HHV-7 and -8. The results of these studies 
have so far been negative (A.Armstrong, personal communication).
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1.6 Immunity and the MHC
The major histocompatibility complex (MHC), also referred to in hum ans as 
the hum an leukocyte antigen (HLA) region, has been intensively studied 
over the past two decades especially in relation to the disease associations 
of specific HLA types (Lechler, 1994). The MHC region is m ost extensively 
characterised in man and mouse and is a highly conserved genetic locus 
encoding approximately 200 genes. The locus is present on chromosome 6 
in hum ans and includes the genes which code for the MHC class I and 
class II molecules (Fig. 1.6). The MHC genes are the most polymorphic set of 
mammalian genes identified to date.
1.6.1 MHC class I
Most nucleated cell types express MHC class I molecules. The class I 
antigen presentation system allows any protein species present within a cell 
to be processed and represented at the cell surface in conjunction with 
MHC class I molecules as part of a random sampling of the cell cytoplasm. 
In this way the cell presents peptides which are representative of its 
internal environment to the CD8+ cytotoxic T-lymphocyte (CTL) 
com partment of the immune system. Thus, MHC class I molecules present 
endogenous peptides. There are three groups of MHC class I molecules and 
these are encoded by the HLA-A, -B and -C genes.
1.6.1.1 Structure o f MHC class I molecules
In 1987 the crystal structure of the class I molecule was resolved (Bjorkman 
et a l, 1987a; 1987b). The molecule exists as a heterodimer comprising a 
heavy chain, or a-chain, and a light chain known as fomicroglobulin (fom). 
The a-chain has three domains (Fig. 1.7a); a\ and a 2 form two a-helices 
either side of a [3-pleated sheet and this represents the peptide binding 
groove as illustrated in Fig. 1.7b (section 1.6.1.2). The a 3 domain and fcm 
form anti-parallel (3-pleated sheets and make up the part of the molecule 
more proximal to the plasma membrane.
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Fig. 1.6 The MHC locus
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Fig. 1.7 Schem atic represen tation  of a MHC class I molecule 
a) positions of heavy chain and fom dom ains
b) s tru c tu re  of the  peptide binding groove
Reproduced from “HLA and disease” (1994) R.Lechler (ed)
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1.6.1.2 Antigen processing and assembly of MHC class I m olecules
The formation of class I heterodimers takes place in the endoplasmic 
reticulum (ER) soon after the translation of the a-chain and the fom 
molecules.
Endogenous proteins are degraded by a unique proteolytic cytoplasmic 
protein complex to yield random 8 -, 9- and 10-mer peptides. These 
peptides are then transported into the ER by the transporter-associated for 
antigen presentation, or TAP, proteins (DeMars et a l , 1985; Salter & 
Cresswell, 1986; Trowsdale et a l , 1990; Spies et a l, 1992). Peptides from 
proteins which contain ER-specific targeting signals enter the ER in a TAP- 
independent manner, although these are a minority (Henderson et a l, 
1992). Peptides from within the ER bind into the groove of the MHC a- 
chain and this facilitates complex formation with fem  (Townsend et a l, 
1989). The assembly process is energy dependent, requiring ATP, and it is 
thought tha t there are other as yet unidentified proteins involved a t this 
stage (Levy et a l, 1991). Only a t this point can the assembled molecules be 
transported to the cell surface via the golgi apparatus (Yewdell et a l,  1988; 
Nuchtem  et a l, 1989; Yewdell & Bennink, 1989). The complexes are 
anchored into the plasma membrane by a hydrophobic tail and persist at 
the cell surface until they are degraded.
1.6.1.3 Functional significance o f MHC class I
Presentation of endogenous peptide to the CD8 + CTL component of the 
imm une response protects against intracellular pathogens which are 
unreachable by neutralising antibody. The MHC class I molecule, when 
complexed with peptide, can be recognised by the TCR. In the case of class 
I interactions, the binding of TCR to the MHC complex is stabilised by the 
CD8  molecule (Salter e ta l ,  1990).
The MHC class I molecule, which is present a t the cell surface complexed 
with antigen, is exposed to a constant CTL surveillance. MHC class I alleles 
express different MHC molecules which possess peptide binding grooves 
with distinct architectures. Because of this, not all viral peptides bind into 
the groove of every MHC class I molecule and this leads to selective 
presentation of certain viral peptides by specific subclasses of MHC class I.
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1.6 .2  MHC class II
MHC class II molecules, encoded in hum ans by the HLA-DP, -DQ and -DR 
genes, are expressed by only a restricted set of cell types including B- 
lymphocytes, macrophages and monocytes, and other antigen presenting 
cells (APC) such as those of the reticuloendothelial system. Class II 
molecules present exogenous antigen to the CD4+ T-cell compartment. In 
th is way the extracellular environment is continually sampled and offered 
for T-cell surveillance.
The class n  molecules have a similar structure to their class I counterparts 
as  defined by X-ray crystallography (Brown et a l, 1988). The Class II 
molecule is a dimer consisting of a- and [3-chains which both have two 
domains. The antigen binding site is also similar to class I, being formed 
from the a \ and |3j domains of the two chains. The binding site itself is 
open ended and therefore can bind much larger peptides than  the closed 
site of class I molecules.
The antigen processing pathway for MHC class II is quite distinct from that 
of class I. Exogenous antigen, either native or complexed with neutralising 
antibody, is taken into the APC via the endosomal pathway (Cresswell, 
1985) and nested sets of peptides 13-25 amino acids in length are 
generated by cellular enzymes. The MHC class II molecules are synthesised 
in the ER and targeted to a distinct endosomal compartment (Guagliardi et 
a l , 1990). Irreversible complex formation occurs here between peptide and 
MHC molecule. The complexes are transported to the cell surface where 
they have a half life of 36 hours. Recognition of antigen presented on MHC 
II requires interaction with the TCR and CD4.
1.6.3 Immune response to  a viral agent
The normal immune response to a virus consists of the production of 
antibodies and cytokines, and the induction of natural killer cells and T- 
cells. In most cases, CTLs play a critical part in the antiviral defense 
mechanism, identifying and eliminating virus-infected cells (Nowak & 
Bangham, 1996). Thus, the main protective immune response to a viral 
agent is generated against intracellular viral peptides presented to CTLs on 
MHC class I molecules a t the surface of the infected cell (Townsend et a l , 
1986; Townsend & Bodmer, 1989). The existence of memory T-cells, which 
are less well understood, is also critically important in the immune 
response to a persistent viral infection.
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1.6.4 Immune evasion by viruses
For a virus to establish a persistent infection of any kind it m ust be able to 
achieve a balanced host-virus relationship. Immune evasion is the most 
common way to do this, and can be achieved in a variety of ways. Some of 
these are described below.
Antigenic variation is a feature of viruses such as influenza and HIV and 
results in the host immune response being constantly avoided (reviewed by 
Koup, 1994). In the case of HIV, viral antigens which are key targets for the 
host immune response are constantly mutating, and selection occurs in 
favour of those mutations which render the viral protein undetectable, 
however briefly, by the host immune system (Phillips et a l, 1991; Couillin 
et a l,  1994). In the case of influenza virus there is gross antigenic 
switching of the haemaglutinin and /o r neuraminidase proteins between 
viral strains during coinfection, resulting in an  entirely novel protein to 
which there is no primary or memory response in the hum an population 
(Webster e ta l ,  1982; reviewed by Kilboume, 1987).
Persistent infection of what is termed a privileged site is another 
mechanism of evasion of the host immune system. Certain sites within the 
body are not subjected to immune surveillance, thus a virus may remain 
undetected in any such site indefinitely (Barker & Billingham, 1977). An 
example of such a site is the central nervous system, which is protected 
from lymphocyte infiltration by the blood/brain barrier and does not 
express MHC class I or class II molecules (Joly e ta l ,  1991). These features 
make it an  excellent site for viral persistence; HSV-1 and VZV (section 
1.3.1-1.3.2) both persist in a latent state in sensory ganglia.
Viruses which can adopt a latent state, in which the expression of antigenic 
viral proteins can be minimised or eliminated, are more likely to be able to 
persist in the host, undetected by CTL surveillance. HSV-1 and EBV utilise 
this mechanism (Stevens, 1994).
Immune modulation is another example of a mechanism by which viruses 
persist in the infected host. Viruses such as HCMV and adenovirus types 2 
and 12 cause a decrease in cell surface MHC antigen expression (Bernards 
etaL , 1983; Anderson e ta l ,  1987; Browne e ta l ,  1990).
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1.7 Im m unity to  EBV
Proliferation of B-cells harbouring latent virus is controlled by the cellular 
component of the immune response, consisting of non-HLA-restricted 
natural killer cells and HLA-restricted CTLs (Misko et a l, 1980; reviewed by 
Moss et a l, 1992). Neutralising antibody limits the spread of virus from the 
oropharynx and controls further spread of infectious virus following 
reactivation events (reviewed by Lee, 1994).
Following primary infection there is a constant level of immunity to EBV 
which is maintained throughout life (Rocchi et a l , 1973). EBV establishes 
lifelong infection by adopting a latent state in lymphocytes and in th is way 
it escapes immune surveillance by expressing only a restricted subset of 
viral genes. The only genes expressed in the immunocompetent host in B- 
cells harbouring latent virus are EBNA-1 and LMP-2 as discussed in section 
1.4.6 (Qu & Rowe, 1992; Tierney et a l , 1994; Chen et a t, 1995). None of 
the lytic genes to which antibodies are made during the initial stages of 
infection are expressed.
1.7.1 Humoral immune response to EBV
The hum oral response to EBV peaks following primary infection when the 
host seroconverts. The first wave of antibodies is directed against lytic cycle 
antigens, mainly viral capsid antigen (VCA) and early antigen (EA) (Rosen et 
a l, 1977). Production of neutralising antibody is an  im portant factor in 
controlling initial spread of the virus and thus a determ inant for eventual 
host viral load. Longterm antibody titres to EBV VCA can be used as an 
indirect indicator of viral load (Henle & Henle, 1979).
The persistently infected host maintains antibody titres to EBV antigens 
throughout life; antibody titres are maintained by reactivation events which 
occur naturally in the infected host (reviewed by Lee, 1994). Reactivation 
results in transient expression of the immunogenic lytic phase gene 
products, triggering a recurrent wave of IgG production to EA, VCA and the 
major viral envelope glycoprotein gp350/220 (Thorley-Lawson & Geilinger, 
1980, van Grunsven et a l , 1993). Serum IgG specific for EBNA-1 can also 
be detected lifelong in healthy virus carriers (Lee, 1994).
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1.7 .2  Cellular immune response to  EBV
In an  attem pt to understand how the virus evades CTL recognition in the 
latent state, extensive studies have been performed to determine which 
MHC class I alleles present which viral epitopes. It has been found that 
peptides from all the latent proteins, with the exception of EBNA-1, are 
presented by a t least one HLA class I allele (Khanna et a l , 1992; 
R.J.M urray et a l , 1992). Several epitopes with structures compatible with 
presentation on class I molecules have been shown to be recognised by 
CTLs. A selection of HLA-A and -B alleles and the epitopes of EBV latent 
proteins which they are known to present is shown in Table I.v.
Distinct peptides from the same EBV latent protein can be presented by 
multiple HLA alleles. This is due to differences in the architecture of the 
peptide binding grooves of different HLA alleles, dem onstrated by studies 
using recombinant vaccinia virus expressing EBV latent genes (R.J.Murray 
et ah, 1990; 1992; Khanna et a l , 1991; 1992). Individual alleles may also 
present several epitopes from the same protein or from different proteins. 
For each subclass of MHC I molecule there are peptides which bind most 
stably into the grooves of the specific MHC molecules and therefore persist 
longer in the MHC complex a t the cell surface, thus generating the 
strongest response. These are referred to as immunodominant epitopes. 
For example, in the case of HLA-A 11 there are multiple peptides of the 
EBNA-3b protein presented, including a 9-mer and a 10-mer. There is a 
detectable CTL response to both of these peptides, however the 9-mer is 
immunodominant over the 10-mer. It was found tha t the 9-mer bound 
m uch more stably into the Al 1 peptide binding groove than  did the larger 
peptide (Gavioli e t a l ,  1993; 1995).
Some examples of immunodominant epitopes and MHC I alleles are shown 
in Table I.vi.
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Table I.v Presentation of epitopes o f EBV latent proteins by HLA 
class I alleles
protein alleles presenting epitopes
EBNA-1 none known
EBNA-2 A2, B7, B18
EBNA-3a A2, A24, B8 , B27, B40, B51
EBNA-3b A ll
EBNA-3C A2, Al 1, A24, B7, B8 , B27, B44
LMP-1 B24, B40, B51
LMP-2 A2
Khanna e t a l , 1992; Moss etal, 1992; R.J.Murray e t a l , 1992; Kurilla, 1993.
Table I.vi HLA class I immunodominant EBV epitopes
HLA class I allele latent protein presented immunodominant epitope
A ll EBNA-3b aa 416-424
B35 EBNA-3a aa 458-466
De Campos-Lima e t a l , 1993; Lee etal., 1993; Lee etaL, 1995.
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EBNA-1 has been repeatedly shown to be a poor target for the immune 
response (Rickinson et a l, 1992; Masucci & Emberg, 1994). The lack of 
recognition of any peptides from the EBNA-1 protein is of obvious value to 
the virus as EBNA-1 m ust be expressed in every infected cell in order to 
m aintain the viral episome. This is of particular importance when 
considering the pathogenesis of EBV-associated BL where EBNA-1 is the 
only viral protein expressed in the tum our cells.
It has recently been shown that the large glycine-alanine internal repeat 
region of the EBNA-1 protein, to which no clear functional properties have 
previously been attributed, is crucial to the inhibition of antigen processing 
and the absence of peptide epitopes of EBNA-1 from MHC class I restricted 
presentation (Levitskaya et a l, 1995). There is still little known about the 
possibility of a MHC class H-restricted CTL response to EBNA-1, although a 
recent study has identified an HLA-DR1 -restricted epitope recognised by 
CD4+ CTLs (Khanna et a l, 1995). In this study, however, it was noted tha t 
these CTLs were not capable of lysing target cells endogenously expressing 
the antigen.
1.7.3 Immune evasion by EBV in healthy populations
The phenomenon of viral escape m utants, generated by in vivo selection 
pressures from the host immune response acting on spontaneous viral 
m utations, has been acknowledged for some time. As discussed in section 
1.6.4, viruses such as HIV and influenza virus evolve rapidly in order to 
survive in the face of a specific host response. Herpesviruses in general 
tend not to be associated with this rapid viral evolution; there are many 
types of herpesvirus, which infect a huge and diverse range of creatures, 
and as a virus family they are well conserved. This would indicate th a t in 
m ost cases an  evolutionary balance has been reached, and therefore tha t 
the selection pressures acting on the viruses are less strong than  in the 
case of a relatively new host-virus relationship such as tha t of hum ans and 
HIV. There is, however, evidence for selection pressures in relation to EBV.
Studies have been carried out within an isolated population in Papua New 
Guinea which has an unusually high frequency of the HLA-A 11 allele (de 
Campos-Lima et aL, 1993; 1994). On investigation of the EBV seropositive 
individuals in this population it was found that, in all of the six cases
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studied, the immunodominant epitope presented on A l l ,  representing 
a a 4 16-424 of EBNA-3b, was mutated. The m utations were found in 
positions which rendered the epitope unable to bind into the A ll groove, 
th u s abolishing presentation of the epitope and therefore the 
immunodominant CTL response normally seen in A ll-positive individuals. 
It was postulated that this was a result of the selection pressure on the 
virus in this population, which had resulted in the virus evolving and thus 
evading the immunodominant immune response.
A second study was carried out looking at populations in parts of Africa 
which had high frequencies of the B35.01 allele (Lee et a l,  1995). The 
immunodominant response in B35.01-positive individuals occurs against 
the epitope of EBNA-3a representing aa458-466. When the epitope was 
investigated in this cohort it was found to be m utated in approximately 50% 
of Gambian and Kenyan isolates. Of the three types of m utations observed, 
one had no effect on CTL recognition while the other two gave 100-1000 fold 
weaker recognition. None of the observed m utations totally abolished the 
CTL response to this epitope.
In summary, in Papua New Guinea where A ll has an  allele frequency of up 
to 50%, the target epitope was mutated in 100% of cases studied and this 
m utation abolished CTL recognition of the peptide. In the African cohort, 
where B35.01 has an allele frequency of 30%, the target epitope was 
m utated in only 50% of cases and mutations did not completely abolish 
CTL recognition. These results may reflect the effect of different selection 
pressures acting on the virus within different populations. The selection 
pressure driving the occurrence of escape m utants in target epitopes may 
be greater in a population where the frequency of the presenting allele is 
higher. Another factor influencing the selection pressure may be the 
strength of the immune response to the epitope presented by the allele in 
question. In support of the latter possibility, it is known tha t the CTL 
response to aa4 16-424 of EBNA-3b presented by Al 1 is a stronger response 
than  tha t generated by aa458-466 of EBNA-3a presented by B35.01.
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1.7.4 Immune response to  EBV in disease
1.7.4.1 Immune response to  EBV in Burkitt's lymphoma
BL cells in culture, immediately following their isolation from fresh tum our 
material, display a Lat I pattern of EBV latent gene expression (section 
1.4.6). Additionally, there is no detectable expression of adhesion 
molecules such as LFA-3 and ICAM-1. If cultured continually, over time 
some BL-derived cell lines will drift through intermediate expression 
patterns, e.g. Lat n, and eventually acquire a Lat m  phenotype, with full 
expression of viral latent proteins and markers of cellular activation 
(Rooney et aLy 1986; Rowe et oL, 1987; 1992). This suggests th a t the 
primary BL cells have the potential for Lat in  expression, and th a t the 
absence of expression by BL cells in vivo is due to an  intact host immune 
response to EBV. However, EBV-associated BL occurs in geographical 
locales where malaria is holoendemic (Epstein & Achong, 1979). It has 
been shown that during certain types of malaria, T-cell control of latent 
EBV infection is diminished or lost (Moss et a l , 1983; Whittle et a l,  1984). 
This implies that there could be a role for transient immune suppression in 
the early stages of tum our development.
One of the features of the pathogenesis of BL is the ability of EBV-infected 
B-cells to evade detection by the immune response after acquisition of the 
malignant phenotype (section 1.4.7.2). Several mechanisms have been 
suggested for this evasion, all of which may play some contributory role to 
the overall pathogenesis of the disease. The ability of the EBV-positive 
tum our cells to express only EBNA-1 is thought to play a large part in the 
survival of these cells. As discussed in section 1.7.2, EBNA-1 is not 
presented by MHC class I molecules at the cell surface and can th u s  not be 
detected by host CTL surveillance.
Another such mechanism which has been dem onstrated involves 
downregulation of MHC class I expression at the surface of infected cells. 
Selective downregulation of HLA class I alleles occurs in various types of 
tum our, driven by the immunoselective process in vivo (Pandolfi et aL, 
1991; Moller & Hammerling, 1992; Browning et a l y 1993). This has been 
dem onstrated in the case of BL for the HLA-A 11 allele (Andersson et a l y 
1991; Gavioli et aLy 1992). The mechanism by which this downregulation 
occurs is thought to involve lack of cellular transcription factors and the 
occurrence of genetic abnormalities (Imreh et aLy 1995); the role played by 
EBV in these events is unclear.
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A second mechanism of immune evasion which has been reported is the 
induction of high levels of expression of IL-10 in BL cell lines by EBV 
(Magrath, 1990; Matsuda et a l, 1994). IL-10 has been shown to have a 
wide variety of stimulatory effects on B-cells. Of greater relevance in the 
context of BL, it has been found to suppress the function of helper T-cells 
(Fiorentino e ta l ,  1989) and down-regulate HLA class I expression (Matsuda 
e t a l , 1994). EBV is known to encode a homologue of IL-10 (v-IL-10) which 
shares a t least some of the biological properties of the hum an form (Moore 
e t a l , 1990). Unlike its cellular counterpart, it does not enhance MHC n 
expression, however it does inhibit IFN-7 production by helper T-cells. This 
indirectly inhibits the induction of MHC antigen production. Expression of 
v-IL-10 may occur a t some stage in the development of BL.
Downregulation of the cell surface adhesion molecules LFA-3 and ICAM-1 
h as also been demonstrated in primary BL cells in vitro (Gregory et a l , 
1988). This feature of BL cells could inhibit their detection by host CTLs 
due to the lack of necessary cellular interactions. It is not known whether 
EBV contributes to this effect; it has been shown tha t expression of LMP-1 
induces these molecules and LMP-1 is not expressed in BL tum our cells.
1.7.4.2 Immune response to  EBV in nasopharyngeal carcinoma
Tumour cells of NPC contain clonal EBV genomes and express a Lat n  
phenotype, which includes expression of EBNA-1 and LMP-1 and -2 (Brooks 
et a l , 1992). Although much is known about the pathogenesis of EBV in B- 
cell disease, it has been more difficult to study epithelial tum ours such  as 
NPC, as the tum our cells do not grow out in vitro and only rarely has there 
been successful transplantation into nude mice (Busson et a l, 1988; Li et 
a l, 1992).
The EBV LMPs are potentially good targets for the cellular immune 
response. Their expression on NPC cells suggests tha t there is no 
recognition of these antigens by CTLs in vivo in NPC patients. It has been 
dem onstrated tha t NPC patients do mount cell-mediated imm une responses 
to EBV antigens in vitro, although these may be slightly weaker than  those 
of healthy controls (Chan e ta l ,  1979).
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One of the striking features of NPC is the occurrence of unusually high 
antibody titres to EBV VCA and EA (Henle & Henle, 1976). In particular, 
raised IgA titres to these antigens are unique to NPC and precede the onset 
of disease by several years, suggesting that reactivation of EBV to 
productive replication occurs before development of the tumour.
1.7.4.3 Immune response to  EBV in Hodgkin's disease
As discussed in section 1.7.1, there are raised antibody titres to EBV in 
most cases of HD, both EBV-associated and non-EBV-associated. There 
are also raised titres to other herpesviruses e.g. HHV-6  (section 1.5.2). One 
possibility was that this merely reflected the immunosuppressive nature of 
HD, which was enabling increased viral reactivation and replication to 
occur. The fact that the raised titres to EBV and HHV-6  do not occur in the 
same individuals (Clark et aL, m anuscript in preparation) suggests tha t 
there is not ju s t a general increase in herpesvirus load. There is not a clear 
relationship between EBV sta tus of the tum our and serological titres. 
However, recent findings from our group suggest that EBV-associated cases 
as a group have higher VCA titres compared to non-EBV-associated cases.
There is a threefold higher risk of developing HD in people with a history of 
IM (Munoz et a l, 1978). It is possible that an  increased viral load results 
either as a consequence of a high infectious dose at primary infection, or as 
a result of a poor immune response to the virus. This would lead to an 
increased likelihood of reactivation events occurring and therefore increase 
the chance of an  RS cell precursor becoming infected with the virus. It 
m ust be emphasised that there is no direct evidence available to date tha t 
past history of IM predisposes to HD which is EBV-associated.
There is evidence to suggest that cellular immune defects precede the 
development of HD (Del Giacco et al> 1985; Merk et a l , 1990). We 
investigated this hypothesis by studying the overall cell-mediated immune 
response to EBV in HD. These experiments are described in chapter three 
of this thesis.
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RS cells in HD have a Lat n  pattern of EBV gene expression, comprising 
expression of EBNA-1 and the LMPs (Pallesen et a l, 1991; Deacon et a l , 
1993; Grasser et a l f 1994), as in NPC (section 1.7.4.2). A genetic co-factor 
has been described in relation to NPC (De The, 1982) and it may be that 
th is is also true for HD. The HLA genes are a good starting point for the 
investigation of this hypothesis as they have a major influence on immune 
handling of infectious diseases and neoplastic outgrowths in vivo. 
Experiments carried out to assess the involvement of HLA class I in  HD are 
described in chapter four of this thesis.
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Chapter 2 
General Materials & Methods
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2.1 CELL BIOLOGY
The following sections outline materials and methods frequently employed 
during the cell biology aspect of these studies. Sources of commonly used 
reagents and consumables are listed in Table Il.i and routinely used culture 
media are listed in Table Il.ii. Origins of cell lines used throughout the 
work of this thesis are detailed in Table Il.iii; sources of these cell lines are 
listed in Appendix A. Supplier details are given in Appendix B.
All clinical samples, cell lines, peripheral blood mononuclear cells (PBMCs) 
and viral preparations were handled in a Class II microbiological safety 
cabinet. All cell cultures were maintained a t 37°C with 5% CO2 during 
these studies unless otherwise stated. During routine procedures it was 
often necessary to change the density at which cells were resuspended; this 
was achieved by centrifugation followed by resuspension a t an  appropriate 
density. Cells were centrifuged at 400g for ten m inutes unless otherwise 
stated.
2.1.1 Collection o f blood samples and separation o f PBMCs
2.1.1.1 Collection of blood samples
Samples of peripheral and umbilical cord blood were received diluted 1:2 in 
travel medium (Table Il.ii).
2 .1 .1 .2  Separation of PBMCs from whole blood using a Ficoll-paque 
gradient
Peripheral blood samples were diluted a further 1:2 in wash medium (Table
Il.ii), containing preservative-free heparin a t 30U/ml, before being layered 
onto a Ficoll-paque gradient at room temperature. In order to obtain the 
necessary g-force at the interface, 30ml of diluted blood were layered onto 
15ml of Ficoll-paque in a 50ml centrifuge tube and the gradient centrifuged 
a t 1500g for 20 minutes a t room temperature. The interface band was 
removed using a Pastette® (Alpha Labs) and the cells washed twice in wash 
medium to remove any remaining Ficoll. PBMCs obtained in this way were 
counted as described in section 2.1.1.4.
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Table Il.i Sources o f com m only used m aterials
material source
RPMI 1640 medium Life Technologies
Hank’s balanced salt solution Life Technologies
Foetal bovine serum Life Technologies
Penicillin/streptomycin Life Technologies
Gentamicin Life Technologies
Fungizone® Life Technologies
Hepes buffer Life Technologies
Tissue culture grade distilled water Life Technologies
Ficoll-paque Pharmacia Biotech
Cyclosporin A Sandoz Pharmaceuticals
Preservative-free heparin Leo Laboratories
DMSO Sigma Chemical Company
TPA Sigma Chemical Company
Other chemicals Sigma Chemical Company
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Table Il.i Sources o f com m only used m aterials (continued)
material source
Plasticware
tissue culture flasks, 50cm2 or 250cm2 Costar (UK) Ltd.
tissue culture flasks, 750cm2 Nunclon
96-well microtitre plates Nunc
sterile pipettes, 5ml, 10ml or 25ml Costar (UK) Ltd.
polypropylene tubes, 15ml or 50ml Greiner Labortechnik
ciyostorage tubes, 1 .8 ml Nunc
ultra-clear ultracentrifuge tubes, 35ml Beckman Instrum ents
12 x 75mm sterile tubes Coulter Electronics Ltd.
screw-cap microfuge tubes Alpha Laboratories Ltd.
Pastettes® Alpha Laboratories Ltd.
Rainin pipette tips Anachem
54
Table Il.ii Media and reagents used in cell culture
solution constituents concentration
complete medium RPMI 1640 medium 
foetal bovine serum 
L-glutamine 
penicillin/streptomycin
1 0 %
2mM
400IU/ml; 400m g/m l
travel medium RPMI 1640 medium 
foetal bovine serum 
L-glutamine 
penicillin/streptomycin 
gentamicin 
fungizone 
Hepes buffer 
preservative-free heparin
2 0 %
2mM
400IU/ml; 400m g/m l
150pg/m l
2.5MCG
25mM
30U /m l
wash medium Hank’s balanced salt solution 
foetal bovine serum 
penicillin/streptomycin
2 %
400IU/ml; 400m g/m l
freezing medium foetal bovine serum 
DMSO
92%
8 %
cyclosporin A stock solution, dissolved in 
analytical grade absolute alcohol 1 m g/m l
working solution, diluted in 
complete medium 5ng/m l
TPA stock solution, dissolved in 
DMSO
2 0 0 |xg/ml
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Table Il.iii Commonly used cell lines
cell line description
B95-8 EBV infected marmoset B-cell line
HB82 Mouse hybridoma line secreting BB7.2 antibody
Jijoye EBV-infected hum an Burkitt’s lymphoma-derived B-cell line
J-Jh an T-cell line derived from acute T-cell leukaemia (clone of Jurkat)
Raji Human Burkitt’s lymphoma line - infected with defective EBV
VES EBV-infected B-lymphoblastoid cell line
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2.1 .1 .3  Separation of umbilical cord blood mononuclear cells (CBMCs) 
using a Ficoll-paque gradient
The umbilical cord blood samples used for these studies were diluted 1:3 in 
wash medium containing preservative-free heparin at 30U /m l before being 
layered onto a Ficoll-paque gradient. The subsequent procedure was as 
outlined in section 2.1.1.2 for the separation of PBMCs.
2 .1 .1 .4  Cell counting
PBMCs and CBMCs were fixed in two volumes of 2% acetic acid with a trace 
of crystal violet. This fixative was chosen because it causes lysis of any 
contaminating erythrocytes and so a true mononuclear cell count is 
obtained. The cells were fixed for five minutes before being counted in a 
Neubauer haemocytometer.
Following defrosting cells from liquid nitrogen, or for the purpose of 
counting cell lines in culture, trypan blue staining was used to estimate 
percentage viability. The cell suspensions were stained for five m inutes in a 
0.2% solution of trypan blue in saline (Sigma Chemical Company) before 
being counted as described above. Non-viable cells take up the stain  due to 
altered permeability of the cell membrane, thus appearing blue when 
examined (Fig.2.1).
2.1 .1 .5  Freezing of cells
Cell pellets were chilled to 4°C and resuspended in 1ml aliquots containing 
up to l x l 0 7 cells in freezing medium (Table Il.ii). The aliquots were placed 
in a Nalgene Cryo 1°C freezing container® at -80°C overnight. The 
containers were filled with isopropyl alcohol which allows the cells to cool 
slowly (approximately l°C/m inute) thus ensuring a good percentage 
recovery on defrosting. Following freezing, cells were stored in liquid 
nitrogen.
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Fig.2.1 PBMCs stained  with trypan blue
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Cells are  p ictured  against the graticule of a haem ocytom eter. 
Viable cells appear bright and refractile, w hereas dead cells 
which have taken  up  the sta in  appear dark  blue (x400).
58
2 .1 .2  Preparation o f EBV viral stocks and infection o f PBMCs
2.1.2.1 Preparation o f concentrated EBV stocks
The B95-8 cell line, which is productively infected by EBV, was cultured in 
complete medium a t 35°C and expanded by splitting 1:2 twice weekly with 
total medium replacement. When the culture reached 240ml in a 750cm3 
flask the medium was replaced and the culture left for four days without 
further attention.
The culture supernatant containing the virus particles was then clarified by 
centrifugation a t 500g for ten minutes to remove cells. The supernatant 
was filtered using a 0.45pm bottle filter (Costar UK Ltd.), on ice, and 
ultracentrifuged a t 21,500rpm for 2.5 hours in a prechilled SW28 Beckman 
rotor a t 4°C. The supernatant was discarded and the virus pellets placed 
on ice and resuspended in a total volume of 1.5ml cold complete medium 
for one hour, to allow complete resuspension of the virus particles to take 
place. The viral suspension was aliquotted into 6  x 250pl aliquots in screw- 
capped microfuge tubes and the aliquots stored a t -80°C until use.
2 .1 .2 .2  Titration of EBV stocks on CBMCs
For this assay 8 x l0 6 CBMCs, recovered from a Ficoll-paque gradient, were 
split into eight sterile 12cm x 75mm tissue culture tubes (Table Il.i) and the 
cells pelleted. Viral stock was thawed a t 37°C and ten-fold serial dilutions 
performed, on ice, from neat virus down to a 10-6 dilution. Seven of the cell 
pellets were resuspended in each of the serial viral dilutions and the 
remaining pellet resuspended in complete medium for use as an  uninfected 
control. The tubes were incubated at 37°C with 5% CO2 for one hour. 
After incubation, 2ml of wash medium were added to each tube and the 
cells pelleted. Cell pellets were resuspended in 1ml of complete medium 
containing 20% FBS and plated into a 96-well microtitre plate as  four 
replicate wells of 200[d. Cultures were fed weekly by 50% medium 
replacement, and transformation was assessed (Fig.2.2) after 3-4 weeks.
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Transformation appears as numerous refractile clumps of cells, with 
cytoplasmic projections visible on the outer cells of each clump (Fig.2.2). 
Transformed cells display the characteristic "hand-mirror" shape associated 
with EBV-infected lymphoblastoid cells and this is most easily visualised in 
the smaller clumps.
The result of the titration was scored as follows: the dilution a t which
transformation was evident in 50% of the wells was taken as the inverse of 
the viral titre.
2.1 .2 .3  EBV infection of PBMCs
PBMCs were counted and pelleted in a sterile 75mm x 12mm tissue culture 
tube (Table Il.i). The cell pellet, containing a minimum of 2x l0 5 cells, was 
resuspended in 250^1 EBV stock (thawed at 37°C) and the volume made up 
to 500|d with complete medium. The cell suspension was incubated for one 
hour a t 37°C with 5% CO2 .
After this time the cells were washed and resuspended a t a density of 3x106 
cells/m l in complete medium containing cyclosporin A (CsA) a t a 
concentration of O.lpg/ml. The cells were plated into 96-well microtitre 
plates in 200pl/well a t a density of 3x l06 cells/ml, and the surrounding 
wells filled with 200^1  sterile distilled water to m aintain humidity across the 
plate. The plate was incubated at 37°C with 5% CO2 and fed weekly by 
50% medium replacement.
Evidence of transformation could usually be seen 1-2 weeks following 
infection, as described above (section 2.1.2.2) for CBMCs. In some cases 
transformation was not evident until 6 -8  weeks after infection, and in these 
circum stances it was assumed that the B95-8 virus infection had failed to 
transform  the cells and a spontaneous transformation event, involving 
latent virus present in the PBMCs, had taken place.
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Fig.2.2 Appearance of EBV-transformed B-cells in vitro
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2 .1 .3  M iscellaneous cell biology procedures
2.1.3.1 Cytospins
Cells were pelleted a t 400g for five minutes and resuspended a t a density of 
lx l0 6 cells/ml; 100|d of this suspension were used for each cytospin, 
resulting in l x l 0 5 cells per spot. Cytospins were centrifuged a t 400g for 
ten m inutes in a Shandon Cytospin II using APES-coated slides (section 
2.2.7.1). Cytospins were air dried and fixed in either ice-cold acetone or 
m ethanol for 20 minutes and stored at -20°C for up to 8 weeks.
2.1 .3 .2  Preparation of cell lysates for PCR
Cell pellets containing 2x105 cells were defrosted from storage a t -80°C. 
Pellets were resuspended in 50^1 non-ionic detergent lysis buffer (Table II.v] 
containing proteinase K (Sigma Chemical Company) a t a concentration of 
60pg/ml. The cell suspensions were incubated at 56°C for one hour to lyse 
the cells and allow digestion of proteins and then steamed a t 95°C for ten 
m inutes to inactivate the protease.
2 .1 .3 .3  Mycoplasma screening
MRC-5 cells were seeded into slide flasks (Nunclon) and cultured in 
complete medium at 37°C with 5% C 02 until the cells were ju s t sub­
confluent. At this time 500jxL of supernatant from the test culture were 
added to the slide flask and incubated for three days. A negative control 
consisting of culture medium only was included in each assay. Following 
incubation, the slides containing the monolayers were snapped off the 
flasks and the cells fixed in a 3:1 solution of methanol and glacial acetic 
acid. Cells were fixed for ten minutes and immersed for a  further ten 
m inutes in a 1:20,000 dilution of Hoescht 33258 stain in HBSS without 
phenol red. Slides were washed for 2x five m inutes in distilled water. 
Slides were mounted while wet.
Slides were viewed using a  UV light microscope. The presence of 
mycoplasma is seen as strings of fluorescent dots distributed around the 
nucleus in a uniform manner. It is essential to bear in mind the EBV 
sta tu s of the samples to be screened as EBV can mimic the effect of 
mycoplasma using this technique.
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2 .2  MOLECULAR BIOLOGY
This section details routinely used materials and methods involved in the 
molecular biological investigations carried out for this thesis. Commonly 
used equipment, consumables and chemicals are listed in Table Il.iv and 
stock solutions and buffers are detailed in Table II.v. All chemicals used 
were of analytical quality. Deionised water from a MilliQ water filtration 
system (Millipore UK Ltd.) was used in all procedures with the exception of 
PCR and resuspension of high molecular weight DNA. For these 
manipulations either sterile ultra-pure deionised water, obtained from a 
reverse osmosis filtration system (Millipore UK Ltd.), or sterile nuclease-free 
water supplied by Pharmacia Biotech were used. A list of suppliers is 
detailed in Appendix B.
2.2.1 Extraction and manipulation o f high molecular weight DNA
2.2.1.1 Extraction of DNA from cell pellets
Cell pellets were digested in TNE buffer containing 0.5% sodium dodecyl 
sulphate (SDS) and Proteinase K a t a concentration of 0.1 mg/m l. Five 
millilitres of buffer were used for a pellet of lx l0 7 cells; the suspensions 
were incubated at 37°C overnight with continual shaking. The resulting 
lysates were allowed to cool to room temperature before performing organic 
solvent extractions for removal of protein. All subsequent steps were 
performed a t room temperature unless otherwise stated.
An equal volume of phenol equilibrated with Tris pH 8.0 (Rathbum 
Chemicals Ltd.) was added to the lysate in a 15ml polypropylene tube and 
mixed thoroughly, but gently, by inversion. The mixture was centrifuged at 
3000rpm for ten minutes in a benchtop Beckman GPR centrifuge to 
separate the aqueous and organic phases. The aqueous phase was 
removed and transferred to a fresh tube. This step was carried out using a 
wide bore Pastette® (Alpha Laboratories Ltd.) to prevent shearing of the high 
molecular weight (HMW) DNA.
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Table Il.iv Sources o f routinely used equipment, consumables and
chemicals
material/ item source
Apparatus for PAGE Bio-Rad Laboratories
Apparatus for agarose gel electrophoresis BRL (Life technologies)
Plasticware
Falcon tubes 15ml or 50ml 
screw cap microfuge tubes 
Petri dishes 
Falcon 2059 tubes 
pipette tips
Greiner Labortechnik 
Alpha Laboratories Ltd. 
Fisons Ltd.
A. & J . Beveridge Ltd. 
Costar UK Ltd./Anachem
Polaroid Film type 57 Genetic Research 
Instrum entation Ltd.
Molecular biology grade chemicals Sigma Chemical 
Company/BDH (Merck Ltd.)
Restriction enzymes Life Technologies
Easigel 37.5:1 acrylamide mix Scotlab
Sterile nuclease-free water Pharmacia Biotech
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Table II.v Stock solutions and buffers
solution constituents
TBE buffer 90mM Tris 
90mM boric acid 
2.25mM EDTA 
adjusted to pH 8.0
TAE buffer 40mM Tris
20mM sodium acetate 
20mM sodium chloride 
2mM EDTA 
adjusted to pH 8.0
TBS buffer 0.15M sodium chloride 
0.05M Tris 
adjusted to pH 7.6
TNE buffer 0.1M sodium chloride 
lOmM Tris 
ImM EDTA 
adjusted to pH 8.0
Alkali buffer 0.5M sodium hydroxide 
1.5M sodium chloride 
adjusted to pH 12.0
Neutralising buffer 0.5M Tris pH 8.0
3M sodium chloride
3.3% concentrated hydrochloric acid
30% acrylamide stock 29% acrylamide
1% N,N-methylene bisacrylamide
lOx gel loading buffer 0.42% bromophenol blue 
0.42% xylene cyanol 
50% glycerol
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Table II.v Stock solutions and buffers (continued)
solution constituents
SSC (lx) 0.15M sodium chloride 
0 .015M sodium citrate
D enhardt’s solution (lOOx) 2% FicoU
2% BSA (fraction V) 
2% polyvinylpyrolidine
Hybridisation buffer 50mM Tris pH 7.4 
lOmM EDTA 
6x SSC
5x Denhardt’s solution 
10% dextran sulphate 
0.1% SDS
lx  kinase buffer 50mM Tris pH 7.5 
ImM EDTA pH 8.0 
lOmM magnesium chloride 
5mM DTT 
ImM spermidine
lx  PCR buffer lOmM Tris pH 8.2 
50mM potassium chloride 
0 .01% gelatine
Non-ionic lysis buffer lx  PCR buffer 
0.45% Tween20 
0.45% NP40
AP substrate 0.1M Tris pH 8.2
200pg/m l naphthol-AS B1 phosphate 
0.5% DMF 
5mM levamisole
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The phenol extraction was repeated twice and then a final extraction 
performed using chloroform as the organic solvent. Following the 
chloroform extraction and subsequent centrifugation, the aqueous phase 
was pipetted into 15ml of 98% ethanol in a 50ml centrifuge tube in order to 
recover the HMW DNA. The solution was swirled gently until the DNA 
precipitate became visible; this was then spooled out using a sealed 
Pastette® (Alpha Laboratories Ltd.). The pellet was washed in 70% ethanol 
and air dried before being dissolved in sterile nuclease-free water.
2 .2 .1 .2  Quantitation of HMW DNA and oligonucleotides
The am ount of nucleic acid present in a solution was determined using a 
spectrophotometer. An optical density (OD) reading a t a wavelength of 
260nm  was used to calculate the concentration of the DNA solution, based 
on the fact tha t 50pg/ml of double-stranded DNA has an  OD reading of 1.0 
a t a wavelength of 260nm (Sambrook et a l , 1989). For oligonucleotides, a 
33pg/m l solution gives the same reading at 260nm. The purity of the DNA 
solution was determined by calculating the ratio of the OD reading at 
260nm  to that a t 280nm. For a pure solution of double stranded DNA a 
ratio of 1.6 - 1.8 should be obtained. If the ratio is less than  th is value it 
suggests that there is contamination of the DNA solution with protein, or 
there was insufficient removal of organic solvent following extraction.
2 .2 .2  Polymerase Chain Reaction
Amplification of a target DNA sequence using specific primer sets was 
achieved by use of the polymerase chain reaction (PCR), essentially as 
described by Saiki et a l (1985).
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2.2.2.1 Standard PCR reaction conditions
Standard PCR reactions were performed in a final reaction volume of 50pl. 
Present within each reaction were the following constituents:
DNA a t 660ng/reaction (equivalent of lx l0 5 cells)
Deoxynucleoside triphosphates (dATP, dCTP, dGTP, dTTP/dUTP) at 
200pM
lx  PCR buffer (Table II.v)
Amplitaq® DNA polymerase, one unit
Magnesium chloride at previously optimised concentration (section 
2.2.2 .2)
Primers a t previously optimised concentration (section 2.2.2.2).
All reaction components were supplied by Applied Biosystems Ltd. and 
primers were synthesised by Cruachem.
Some PCR reactions were carried out using cell lysates which had been 
digested in buffer containing non-ionic detergent and protease (section
2.1.3.2). In this situation, lx l0 5 cell equivalents were added to the reaction 
in a 25|_il volume.
2.2 .2 .2  Optimisation of PCR reactions
Primers were quantified using a spectrophotometer as described for 
oligonucleotides in section 2.2.1.2, and the optimum concentration for 
amplification was titrated in a standard PCR reaction as follows. Serial 
two-fold dilutions of primer were performed to yield a range of final 
concentrations from 4pM - 0.25|aM. Working primer concentration was 
chosen for optimal sensitivity and specificity.
Magnesium chloride concentration was also optimised for certain PCR 
reactions. Magnesium chloride was included in standard PCR reactions at 
final concentrations of 0.5mM - 2.5mM. As for primer concentration, 
optimal magnesium concentration was chosen as giving the most sensitive 
and specific result.
68
In order to avoid any cross contamination of PCR reactions, a designated 
"PCR-clean" area was used for aliquotting reagents and setting up 
reactions. A gown, gloves, mob cap and face m ask were worn and a 
separate set of PCR-clean pipettes was used with plugged or positive 
displacement tips. Samples and negative controls were handled separately 
from positive controls. Oligonucleotides for other applications were 
synthesised within the department, whereas PCR primers were synthesised 
externally to ensure that they were "PCR-clean”. Substitution of dUTP for 
dTTP in the PCR reaction allowed for use of the enzyme uracil DNA 
glycosylase where contamination from PCR product was suspected. It was 
not necessary to use this measure for any of the PCR reactions detailed in 
the work of this thesis.
2.2 .3  Electrophoretic analysis o f PCR products
2.2.3.1 Polyacrylamide gel electrophoresis for size-separation o f small 
DNA molecules
Polyacrylamide gel electrophoresis (PAGE) was used in the separation and 
purification of DNA fragments of less than 0.5kb e.g. PCR products. 
Acrylamide solutions were made up from stock solutions (Table II.v) to a 
final concentration of 8% in TBE buffer and polymerised by the addition of 
0.66% (w/v) ammonium persulphate and 0.12% TEMED. The gels were 
poured for use with the Mini-Protean II electrophoresis system (Bio-Rad 
Laboratories). DNA samples diluted 5:1 in loading buffer were loaded onto 
the gel and electrophoresed by applying 120V for 1-2 hours using TBE as 
the running buffer. Four hundred nanograms of the DNA fragment size 
m arker OX 174 RF DNA digested with the restriction enzyme Haelll (Life 
Technologies) were run  alongside each batch of DNA samples on the same 
gel.
Polyacrylamide gels were stained in a solution of ethidium bromide a t a 
concentration of 0.5pg/ml in TBE for ten minutes, and then destained for a 
further ten m inutes in deionised water before being visualised using a UV 
trans-illuminator.
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2 .2 .3 .2  Agarose gel electrophoresis
Different weights of agarose were dissolved in TBE buffer, by boiling the 
solution, to give gels of various percentages of agarose depending on the 
application. The agarose solution was cooled and the gels poured and 
allowed to solidify at room temperature before being chilled to 4°C for 30 
m inutes prior to use.
2.2 .3 .3  Purification of PCR products from agarose gels
A preparative gel of 2% Nusieve agarose (Flowgen Instrum ents Ltd.) 
containing ethidium bromide at a concentration of 0.5pg/m l was used to 
electrophorese the desired fragment. The gel was prepared and run  using 
TAE as buffer, as fragments prepared using TAE performed better in 
subsequent enzymatic reactions than  those prepared using TBE. The gel 
was visualised under long-wavelength UV light and the band containing the 
fragment of interest cut out of the gel using a scalpel. The excised piece of 
gel was incubated in 0.5M NaCl, 50mM MOPS pH 7.0 for 20 m inutes at 
70°C to melt the agarose and release the DNA into solution.
Following incubation the DNA was further purified by passage through an 
equilibrated Qiagen T20 tip, washing and eluting the fragment as per the 
m anufacturers instructions. DNA was recovered by ethanol precipitation.
2 .2 .4  Electroblotting and hybridisation using radioactivelv-labelled 
probes
The solutions used in these procedures are specified in Table II.v.
2.2.4.1 Electroblotting of PCR products
Electroblotting was used to transfer PCR products from polyacrylamide gels 
onto nylon membrane for further analysis. Polyacrylamide gels were 
electrophoresed as described in section 2.2.3.1 and then the gels placed in 
alkali buffer for eight minutes to denature the DNA. Gels were placed in 
neutralising buffer for eight m inutes and briefly equilibrated in lx  TAE 
transfer buffer prior to blotting. Nylon membranes (Hybond-N, Amersham 
International PLC) were soaked in transfer buffer and placed onto the gels
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in the blotting cassettes. The cassettes were placed in the Mini-Protean II 
electroblotting system (Bio-Rad Laboratories) and blotting was achieved by 
applying 15V across the apparatus for one hour. Following electroblotting, 
the DNA was irreversibly bound to the membrane by crosslinking with a UV 
light source a t 120j/cm2 for 0.8 minutes (UV Stratalinker 1800, 
Stratagene). Blots were stored dry until required.
2 .2 .4 .2  Five prime end-labelling of oligonucleotide probes
Oligonucleotides for use as probes were synthesised within the departm ent 
onto commercially available columns (Applied Biosystems Ltd.). The 
oligonucleotides were recovered from the column by elution in 2ml aqueous 
ammonia solution. The oligonucleotide solutions were incubated a t 55°C 
overnight to remove the ammonium groups, dried down in a Speed-Vac 
SC 100 (Savant Instrum ents Inc.), and resuspended in 100|d sterile 
nuclease-free water.
Five prime end-labelling was performed in a lOOpl reaction volume 
containing 70pmoles of oligonucleotide and 70pmoles of 32P-yATP (300 
Ci/mM) (ICN Biomedicals Ltd.). Twenty units of T4 polynucleotide kinase 
were used to catalyse the end-labelling reaction in the presence of lx  kinase 
buffer (Table II.v) and the reaction was incubated at 37°C for one hour. 
After incubation, unincorporated nucleotides were removed by passage 
down a Sephadex G50 gel filtration column. This was achieved using 
commercially available NICK columns (Pharmacia Biotech) and following the 
m anufacturers instructions.
2.2 .4 .3  Hybridisation with oligonucleotide probes
PCR products were transferred from polyacrylamide gels onto nylon 
membrane as described in section 2.2.4.1. The specificity of the PCR 
products was determined by hybridisation to radioactively-labelled 
oligonucleotide probes.
DNA blots (section 2.2.4.1) were soaked briefly in a solution of 3x SSC, 
0.1% SDS prior to the hybridisation procedure. Membranes were placed 
into 50ml centrifuge tubes with the bound DNA facing inwards. Pre­
incubation with 2.5ml hybridisation buffer (Table II.v) was carried out for 1- 
2 hours in the presence of 250mg/ml Gene-bloc (I.G.I. Ltd.) to block any
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non-specific binding of the probe. Incubation was carried out a t 37°C on a 
roller mixer. After the prehybridisation step, lx l0 6 cpm /m l of probe were 
added to the pre-hybridisation buffer, and the reaction incubated overnight 
at 37°C on a roller mixer. Formamide was added to the hybridisation buffer 
a t a  percentage which ensured hybridisation was carried out a t 5°C below 
the Tm for the oligonucleotide probe used, in accordance with the 
recommendations made by Sambrook etaL  (1989).
Following hybridisation the membranes were briefly washed twice a t room 
tem perature in a solution of 6x SSC, 0.1% SDS to remove excess probe. 
The blots were then subjected to two washes, for 30 m inutes each wash, in 
the same composition buffer equilibrated to 60°C. Following washing, 
m embranes were dried briefly and wrapped in Saran wrap (Scotlab) before 
being exposed to autoradiographic film (Hyperfilm, Amersham International 
PLC) a t -80°C using an intensifying screen. Exposure times varied 
according to the individual experiment.
2.2 .5  Cloning and sequencing o f PCR products
Compositions of bacterial culture media used are given in Table Il.vi.
2.2.5.1 Cloning o f PCR products
In situations where PCR products were to be subsequently cloned, PCR 
reactions were performed in the presence of a dNTP mix containing dTTP in 
preference to dUTP (see section 2.2.2.1 for standard PCR reaction 
conditions). It had been shown previously that PCR products containing 
dUTPs could not be cloned efficiently (A.Philbey, personal communication). 
In cases where nucleotide sequencing of cloned PCR products was to be 
performed, the use of UlTma™ DNA polymerase (Applied Biosystems Ltd.) 
was preferred over the standard Amplitaq®. This was to utilise the 5’ proof­
reading activity of the UlTma™ enzyme which allows more faithful 
amplification of the target sequence.
Cloning of PCR fragments was achieved using the commercially available 
pCR-script™ cloning kit (Stratagene). This cloning protocol utilises a blunt 
end cloning technique, suitable for these PCR products, as the UlTma™ 
DNA polymerase generates fragments with no 3' polyadenosine overhangs 
(cf. Amplitaq®). The vector included in the kit is based on the pBluescript
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(SK+) plasmid and contains the ampicillin resistance gene for antibiotic 
selection. The (5-galactosidase gene is also present in the plasmid, and 
insertion of sequences into the vector a t the Sifi restriction site causes 
disruption of this gene. When expressed, the [5-gal gene encodes a protein 
which can metabolise the chromogenic substance X-gal, in the presence of 
IPTG, to give a blue pigmentation to the colony. Disruption of the (5-gal 
gene abolishes expression of the protein and colonies remain white. The 
use of the (5-gal gene in a plasmid therefore facilitates blue/w hite colony 
selection for presence of the inserted fragment.
Table II. vi Bacterial media
medium constituents
Luria-Bertani (LB) medium 170mM sodium chloride 
1% bactotryptone 
0.5% bacto-yeast extract 
adjusted to pH 7.0
L-Agar as for LB medium 
1.5% agar
SOC medium 2% bactotryptone 
0.5% yeast extract 
lOmM sodium chloride 
2.5mM potassium chloride 
lOmM magnesium chloride 
lOmM magnesium sulphate 
20mM glucose 
adjusted to pH 7.0
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Following the m anufacturers specifications, ligation reactions were 
performed in a final volume of 10|xL. Reactions contained lOng of cloning 
vector, 0.5mM rATP, lx  ligation buffer, 5U Sifi restriction enzyme, 4U T4 
DNA ligase and 4(ol of a tenfold dilution of PCR product. The reaction was 
incubated a t room temperature for one hour and then heat inactivation of 
the enzymes was carried out by heating to 65°C for ten minutes.
The ligation reaction was transformed into Epicurian Coli XL 1-Blue MRF 
supercompetent cells (Stratagene) according to the m anufacturers protocol. 
Bacterial cells were thawed on ice, the ligation reaction added and then 
incubated for 30 minutes in the presence of 25mM p-mercaptoethanol. 
After incubation the cells were heat-shocked for 45 seconds a t 42°C and 
placed on ice for two minutes. Following transformation, the bacteria were 
incubated in SOC medium for one hour a t 37°C in an  orbital shaker to 
allow the cells to recover.
LB agar plates containing ampicillin a t lOOpg/ml were poured, allowed to 
solidify, and then dried a t 37°C for 15-20 minutes. Plates were spread with 
100|xl X-gal (20mg/ml stock solution in dimethyl formamide) and 8[d IPTG 
(0.5M stock solution) to facilitate blue/white colony selection. As X-gal is 
dissolved in DMF, which is toxic, plates were treated with X-gal and IPTG at 
least 30 m inutes prior to use to allow the DMF to absorb into the agar. The 
transformed bacteria were spread onto the prepared plates in lOOjfi, 150pl 
and 200pl volumes and the plates incubated a t 37°C overnight. White and 
pale blue single colonies were chosen for further analysis, which is 
described in sections 2.2.5.2 - 2.2.5.5.
2 .2 .5 .2  Small scale preparation of plasmid DNA
The chosen colonies were inoculated into 3ml cultures of LB-broth 
containing 100|jg/ml ampicillin and grown overnight in an  orbital shaker at 
37°C. A volume of 1.5-2ml of each bacterial suspension was aspirated and 
the cells pelleted in a MSE microfuge at 13,000rpm for 30 seconds. 
Plasmid preparations were then performed using commercially available 
purification columns (Wizard Minipreps, Promega UK Ltd.), as follows.
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The bacterial pellets were resuspended in cell resuspension buffer and 
subjected to sequential alkaline lysis and neutralisation using solutions 
provided within the kit. Bulk protein contaminants were removed from the 
solution by centrifugation in a microfuge at 13,000rpm for ten minutes. 
The clarified DNA suspensions were mixed with purification resin and 
passed through the Wizard purification columns under vacuum. The 
columns were washed twice and centrifuged briefly to dry the resin. Fifty 
microlitres of sterile nuclease-free water were added to each column and 
these were then centrifuged to elute the DNA.
2 .2 .5 .3  Restriction endonuclease digestion of plasmids
Purified plasmid DNA was quantitated using a spectrophotometer (section
2.2.1.2) and 200ng of DNA were digested using Psfl and Ssfl restriction 
enzymes. Five units of each enzyme were added to a 20pl reaction volume 
with lx  reaction buffer containing lOmM magnesium chloride and 50mM 
Tris pH 8.0 (REact® 1 buffer, Life Technologies). Incubation a t 37°C for two 
hours allowed sufficient digestion of the plasmid to take place. Ten 
microlitres of the digest were electrophoresed on an 8% polyacrylamide gel 
alongside 0.4pg of OX 174 RF DNA digested with Haelll (Life Technologies), 
which was used as a size standard to facilitate estimation of DNA fragment 
size. The electrophoresis results confirmed the presence or absence of the 
inserted sequence.
2 .2 .5 .4  Frozen bacterial stocks
Frozen bacterial stocks were prepared from cultures containing the desired 
plasmid construct.
Bacterial cultures were streaked onto L-agar plates containing ampicillin at 
a concentration of lOOpg/ml and incubated a t 37°C overnight. The 
following day, single colonies were picked and grown overnight in 2ml 
cultures of LB medium. Glycerol was then added to the cultures to 20% 
final concentration and the stocks stored as 1ml aliquots a t -80°C. In this 
form the bacteria containing the cloned sequence can be stored indefinitely.
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2.2 .5 .5  Nucleotide sequencing
Solutions used in the procedures described below are detailed in Table Il.vii.
Preparation of plasmid DNA on a small scale gave sufficient m aterial to 
perform nucleotide sequencing. DNA was prepared for sequencing utilising 
reagents from the Sequitherm™ Long-Read™ cycle sequencing kit for Li-Cor 
sequencers (Epicentre Technologies) (Wilson e t a i , 1994).
Five hundred nanograms of each plasmid were used in a cycle sequencing 
reaction using universal primers M13Rev/IRD41 and M13Fwd(-29)/IRD41 
(Li-Cor) which were complementary to vector sequences. The clones were 
sequenced using a Li-Cor DNA 4000 automatic sequencer which detects 
infra-red emissions; primers were labelled with infra-red dye which is 
extremely sensitive to light, therefore primers were handled in the dark. 
The sequencing reactions utilised a chain termination method, therefore 
four reactions were carried out per sample, one containing each 
dideoxynucleotide mix.
Five units of Sequitherm™ DNA polymerase were used in a reaction 
containing lx  reaction buffer, nucleotides, primer a t 0.1-0.2pm ol/pl and 
DNA template. Following an initial denaturation a t 95°C for five m inutes, 
thirty amplification cycles of 95°C for 30 seconds, 60°C for 30 seconds and 
70°C for 60 seconds were performed before addition of termination mixes 
(Epicentre Technologies) for each nucleotide. Immediately prior to running 
the samples on the sequencing gel, stop solution/loading buffer (Epicentre 
Technologies) was added to each reaction. Samples were denatured by 
boiling a t 95°C for five minutes to separate the synthesised fragments from 
the template DNA before being loaded onto the gel.
A 6% polyacrylamide sequencing gel was poured between glass plates 
designed to give a 20cm x 36cm gel, and allowed to polymerise for two 
hours. The gel was pre-electrophoresed at 1000V for one hour prior to 
loading the samples. Gel electrophoresis was carried out at 1000V for 6-8 
hours during which time the sequence data were collected automatically 
onto an  optical disk. The image was analysed a t a later date.
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Table Il.vii Solutions for nucleotide sequencing
solution constituents
lOx reaction buffer 500mM Tris pH 9.3 
25mM magnesium chloride
Stop solution/loading buffer 95% formamide 
20mM EDTA 
0.05% bromophenol blue 
0.05% xylene cyanol
Li-Cor Long-Read™ sequencing gel 5% bis-acrylamide 
1% acrylamide 
8M urea
0.05% ammonium persulphate 
0.05% TEMED
Running buffer 130mM Tris pH 8.5 @ 50°C 
40mM boric acid 
2.5mM EDTA
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Table Il.viii Solutions used in Western blot analysis
solution constituents
Sample lysis buffer 50mM Tris pH 8.0 
0.15M sodium chloride 
0.1% SDS
0.5% Sodium deoxycholate 
1% NP40
2x sample loading buffer 
(reducing)
12.5mM Tris pH 8.8 
40% glycerol 
4% SDS
10% (3-mercaptoethanol 
0.04% bromophenol blue
Protein resolving gel 15% Easigel 37.5:1 acrylamide mix 
0.375mM Tris pH 8.8 
0.1% SDS
0.1% ammonium persulphate 
0.04% TEMED
Protein stacking gel 5% Easigel 37.5:1 acrylamide mix 
125mM Tris pH 6.8 
0.1% SDS
0.1% ammonium persulphate 
0.1% TEMED
SDS-PAGE running buffer 25mM Tris pH 8.3 
250mM glycine 
0.1% SDS
Semi-dry transfer buffer 48mM Tris 
39mM glycine 
0.01% SDS 
20% methanol
Marvel blotting buffer 3-5% Marvel 
0.5% Tween 20 
TBS pH 7.6
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2 .2 .6  Western blotting
Details of stock solutions, buffers and gel compositions are presented in 
Table ILviii.
2.2.6.1 Preparation of cell lysates for Western blotting
Cells were washed twice in lx  PBS and pelleted prior to lysis. The pellets 
were resuspended in an appropriate lysis buffer a t a concentration of 
1.3x10® cells/ml. Protease inhibitors were included in th is buffer, for 
example lOOpg/ml PMSF, lOpg/ml aprotonin and lOpg/ml leupeptin. The 
cell suspensions were vortexed and incubated on ice for 15 m inutes. The 
lysates were then centrifuged to remove debris and the supernatants 
harvested. Protein suspensions obtained in this way were mixed with an 
equal volume of sample loading buffer and snap frozen in liquid nitrogen 
before being stored a t -80°C until use.
2 .2 .6 .2  SDS-PAGE for protein separation
Proteins were separated using 15% denaturing polyacrylamide gels with a 
5% polyacrylamide stacking gel. The resolving gels were poured between 
glass plates designed for the Bio-Rad Mini-Protean II system which resulted 
in gels sized 10cm x 6cm x 0.1cm with a 10cm x 1cm x 0.1cm stacking gel. 
Sample lysates (section 2.2.6.1) were thawed and then boiled for five 
m inutes to ensure the proteins were denatured. Samples were then loaded 
onto the stacking gel a t lx l0 6 cell equivalents per lane. Electrophoresis 
was carried out by initially applying 150V for 15 m inutes to allow the 
proteins to stack; after this step the voltage was increased to 200V for 45 
m inutes.
2 .2 .6 .3  Western blotting
The SDS-PAGE resolving gels were soaked in transfer buffer for ten m inutes 
prior to blotting. The membranes (Immobilon P; Millipore UK Ltd.) were 
placed in 100% methanol before being soaked in transfer buffer alongside 
the gels. The membranes and gels were aligned and loaded into a Semidry 
Transblotter (Bio-Rad Laboratories) between two sheets of extra thick filter 
paper (Bio-Rad Laboratories) soaked in transfer buffer. Blotting was 
achieved by applying 15V across the apparatus for 40 minutes.
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After blotting, the membranes were equilibrated briefly in TBS pH 7.6 before 
being placed in a solution of 5% Marvel buffer (Table ILviii) for 30 minutes. 
This ensured blocking of non-specific binding sites. All incubations were 
carried out a t room temperature on an orbital shaker. Following blocking, 
the buffer was removed from the blots and primary monoclonal antibody 
added at a concentration of lpg/m l in 3% Marvel buffer. All subsequent 
steps were performed in this buffer. The blots were incubated with the 
antibody for two hours, after which time the solution was removed and the 
m embranes washed three times in excess volumes of Marvel buffer for ten 
m inutes each wash. The blots were then incubated for 90 m inutes with 
secondary antibody, conjugated to horseradish peroxidase (Amersham 
International PLC), diluted 1:3000 in Marvel buffer. The mem branes were 
subjected to three washes of ten minutes in TBS pH 7.6, 0.5% Tween20. 
Omission of Marvel was necessary in the final washes as the milk proteins 
contain biotin which interferes with the detection process.
The blots were developed using the Amersham ECL Western blotting protein 
detection reagents. The ECL system is based on the emission of 
chemiluminescence from the combined detection reagents. The horseradish 
peroxidase, conjugated to the secondary antibody, oxidises an  enzyme 
present within the ECL detection kit reagents. This then catalyses a 
reaction involving luminol and a phenolic enhancer compound under 
alkaline conditions. The result is luminol in the excited state; the reaction 
peaks after 5-20 minutes and the 428nm wavelength emissions generated 
can be detected by short exposure to blue-light-sensitive autoradiographic 
film. Hyperfilm-ECL (Amersham International PLC) was used for this 
procedure and exposure times of 30 seconds, two m inutes and five m inutes 
were used.
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2.2 .7  Immunohistochemical assays
2.2.7.1 Coaling slides with APES
Microscope slides were coated with APES to enable greater adherence of cell 
preparations and tissue sections. This was important for use in the 
immunohistochemical procedures detailed below, as the slides were 
subjected to lengthy incubations and numerous washes.
Glass microscope slides were soaked overnight in 10% Decon (Fisons Ltd.) 
a t room temperature. They were then washed in running tap  water and 
rinsed in distilled water to remove any traces of Decon. Slides were dried 
overnight a t 60°C. Once cool the slides were immersed in a 2% v/v  solution 
of APES (Sigma Chemical Company) in acetone for five seconds, rinsed 
briefly in acetone alone and then washed with distilled water (Maddox & 
Jenkins, 1987). The slides were dried overnight a t 37°C and stored at room 
tem perature until use.
2 .2 .7 .2  Dewaxing paraffin-embedded tissue sections
Paraffin-embedded sections of biopsy tissue 3-5pm thick were mounted on 
APES-coated microscope slides (section 2.2.7.1). The sections were 
dewaxed for a minimum of ten minutes in two changes of a xylene 
substitu te e.g. Citroclear (National Diagnostics), and then rehydrated in an 
ethanol gradient as follows. The slides were placed in 100% ethanol for two 
m inutes, 70% ethanol for two minutes and methylated spirit for a further 
two m inutes before being rinsed in clean water. They were then immersed 
in Lugel’s iodine for two minutes to remove any traces of mercuric fixatives, 
placed in clearing solution (5% w/v sodium thiosulphate) to remove 
iodine/m ercury complexes, and then rinsed in distilled water. The sections 
were equilibrated in TBS pH 7.6 for five m inutes prior to 
immunohistochemical analysis.
2 .2 .7 .3  Preparation of samples
Paraffin-embedded tissue sections were dewaxed as described in section
2.2.7.2 and equilibrated in TBS pH 7.6. Cell cytospins which had been 
stored a t -20°C were allowed to reach room temperature before being 
equilibrated in TBS pH 7.6 for a minimum of ten minutes.
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2 .2 .7 .4  Avidin-biotin complex (ABC) im munohistochemistry
Cytospin preparations used in this procedure were fixed in ice-cold acetone 
for a t least 15 minutes and air dried. Paraffin sections were pretreated as 
described in section 2.2.7.2. At no time during the described procedure 
were the sections allowed to dry out as this produced staining artefacts. All 
steps were performed at room temperature unless otherwise stated.
The slides were immersed in TBS pH 7.6 containing 0.1% BSA (TBS buffer) 
for ten m inutes and then microwaved for ten m inutes in 0 .01M tri-sodium 
citrate buffer a t pH 6.0 to unm ask antigens. The slides were rinsed briefly 
in distilled water and returned to TBS buffer for five minutes. The sections 
were incubated with a solution of heat-inactivated normal rabbit serum 
(SAPU), diluted to 20% in TBS buffer, for 30 minutes, which served to block 
any non-specific binding of antibody.
The blocking buffer was removed and primary antibody was added to the 
sections at an  appropriate dilution in TBS buffer and incubated overnight 
a t 4°C. After incubation, sections were washed for 2 x 5 m inutes in TBS 
buffer and the secondary antibody added to the slides a t a dilution of 1:200 
in TBS buffer. The secondary antibody used was biotinylated rabbit anti­
mouse immunoglobulins (Dako Ltd.). The sections were incubated with the 
antibody for 30 minutes and then washed for 2 x 5  m inutes in TBS pH 7.6. 
ABC-alkaline phosphatase (AP) complex (Dako Ltd.) was added to the 
sections a t a dilution of 1:50 in TBS pH 7.6 and incubated for 30 minutes. 
The ABC-AP suspension was prepared 30 m inutes prior to use to enable 
complex formation to take place. Following incubation the sections were 
washed in TBS pH 7.6 for 2 x 5 minutes. Fast red TR salt (Sigma Chemical 
Company), the substrate for the reaction, was diluted in AP substrate buffer 
(Table II.v) to 1 m g/m l and this was filtered through W hatman No.l filter 
paper (Fisons Ltd.) and incubated with the slides for 20 minutes.
The sections were rinsed briefly in water and counterstained in Mayer’s 
haematoxylin before being mounted using an  aqueous m ountant 
(Aquamount, BDH (Merck Ltd.)).
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2 .2 .7 .5  Alkaline phosphatase anti-alkaline phosphatase (APAAP)
immunohistochemistry
The procedure used was essentially the same as that described in section
2.2.7.4 until the addition of the secondary antibody. For the APAAP 
method the secondary antibody is a bridging antibody and the antibody 
used was biotinylated rabbit anti-mouse immunoglobulins (Dako Ltd.). 
This was added to the slides a t a dilution of 1:25 in TBS buffer and 
incubated for 30 minutes. The sections were then washed in two changes 
of TBS pH 7.6 for ten minutes. APAAP complex a t a 1:50 dilution in TBS 
pH 7.6 was incubated with the sections for a further 30 m inutes, and the 
slides washed in TBS for ten minutes. The secondary antibody and APAAP 
incubations were repeated, with washes, for 15 m inutes each before 
staining with Fast red TR salt and mounting as described in section 2.2.7.4.
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Chapter 3
Use of the in vitro regression assay to  investigate 
EBV-specific cell-mediated immune responses 
in Hodgkin's disease
84
3.1 Introduction
EBV is a  common pathogen with over 90% of the population seroconverting 
in the first decade of life. The immune response to EBV has two main 
components. The first, or primary, response is mounted a t the time of 
initial infection with the virus, and is important in containing the virus and 
limiting its spread. This response plays a part in determining the eventual 
viral load of EBV that is carried throughout life. The second component is 
the memory immune response. This is important in m aintaining the host- 
virus equilibrium and it acts to control the extent of virus reactivation 
events tha t result in the production of extracellular infectious virus. CTLs 
function in both the primary and memory immune responses.
Neutralising antibodies are generated against viral antigens, including EA 
and VCA, as part of the primary immune response to EBV (De The, 1982). 
This antibody response plays a major role in the control of initial virus 
spread. Presence of neutralising antibodies is therefore a  factor in the 
determination of the eventual persistent viral load in peripheral blood and 
lymphoid tissue. Longterm antibody titres to EBV VCA can be used as an 
indirect indicator of viral load (Henle & Henle, 1979).
Initial virus load can be an important determinant of the outcome of a 
persistent viral infection. For example with HTLV-1 infection high antibody 
titres to the virus correlate with a high viral load, and are associated with 
conditions resulting from immune mediation of infection e.g. tropical 
spastic paraperesis (Bangham, 1993; Bangham et a l, 1996).
CTLs, particularly of the memory immune response, are known to be a 
major influence in the control of viral infections (Nowak & Bangham, 1996). 
In the case of HTLV-1 there is usually a vigorous CTL response to the virus 
in seropositive people; however, patients with a low CTL response develop 
the highest viral load (Bangham et aL, 1996). For EBV, it has been shown 
tha t there are virus-specific CTLs which respond to peptide epitopes of viral 
latent and lytic proteins presented by MHC class I molecules (reviewed by 
Kurilla, 1993). Removal of CTL immune surveillance can result in 
reactivation events occurring unchecked, and to the frequent development 
of EBV-driven lymphoproliferative disease. When im m unosuppression is 
removed, regression of such disease states usually occurs (Starzl et aL, 
1984). It can thus be concluded that CTL control of EBV infection is vital to 
the establishment of a lifelong virus-host relationship.
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Raised antibody titres to EBV in HD patients were reported in several 
studies in the 1970s, initiating the theory that there was an association 
between the virus and the disease (Levine etaL, 1971; Henle & Henle, 1973; 
Evans et a l, 1978). Since then a subgroup of HD cases which are 
associated with EBV has been identified using molecular biology techniques 
(section 1.5.1). It is now clear, however, that raised antibody titres to EBV 
antigens occur in both EBV-associated and non-EBV-associated cases of 
HD. Serology does not provide an indication of EBV sta tus of RS cells, but 
as a group EBV-associated HD cases display higher titres to VCA than  non­
associated cases (D.Clark, unpublished results). These findings provide 
indirect evidence tha t HD patients, particularly those with EBV-associated 
disease, have a high EBV viral load prior to disease onset. It can therefore 
be postulated that high EBV viral load may be a risk factor for the 
development of HD.
Increased viral load is likely to be accompanied by an increased num ber of 
EBV-infected cells. This would increase the chance of an  RS cell precursor 
becoming infected with EBV, both directly and by increasing the num bers 
of reactivation events occurring. The existence of larger num bers of 
infected RS cell precursors would increase the chances of one of these 
acquiring other m utations necessary for tum our development. As little is 
known about the exact role played by the virus in EBV-associated HD, 
either of these possible consequences of high viral load may contribute to 
the pathology of these cases.
RS cells in approximately 40% of HD cases carry EBV genomes and express 
a restricted subset of viral gene products, namely EBNA-1 and the LMPs 
(Pallesen et a l, 1991; Deacon et a l, 1993; Grasser et a l , 1994), which is 
referred to as a type II pattern of latency or Lat II (section 1.4.6). The LMPs 
are immunogenic proteins and several peptide epitopes of these proteins 
have been shown to elicit an HLA class I-restricted response (Khanna et a l , 
1992; R.J.Murray etaL, 1992). This raises important questions with regard 
to EBV-associated HD, where the RS cells have been shown to express 
LMP-1 on their surface. LMP-2 expression has been dem onstrated at the 
mRNA level, and is presumed to be expressed as protein; this has not been 
confirmed as there are no good monoclonal antibodies to LMP-2 available at 
the present time. The expression of these viral proteins suggests that RS 
cells should be a target for lysis by class I-restricted CTLs. However the RS 
cells persist, suggesting that an underlying impairment of cell-mediated 
immunity to EBV might be present in people who develop EBV-associated 
HD.
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Abnormalities of T-cell mediated immune function have been reported in 
HD patients (reviewed by Slivnick etaL, 1990). These abnormalities include 
reduced CTL proliferation in response to soluble antigen (Levy et aL, 1974; 
Holm et aL, 1976), lymphocytopoenia (Matchett et aL, 1973), distorted 
ratios of T-cell subpopulations (Gupta, 1980) and increased susceptibility to 
certain types of infection (Casazza etaL, 1966). These defects can persist in 
HD patients who have entered remission (Fisher, 1982). In non-Hodgkin’s 
lymphomas (NHL), secondary immuno-suppression is a  common feature. 
However in NHL, abnormalities of cell-mediated immunity occur mostly in 
advanced disease states, whereas in HD these abnormalities occur early in 
disease development (Kumar & Penny, 1982). There are also documented 
cases of defective CTL function occurring in first order relatives of HD 
sufferers (Del Giacco et aL, 1985; Merk et aL, 1990). These separate lines of 
evidence support the suggestion tha t immune dysfunction precedes onset of 
disease rather than  being secondary to tum our development.
In summary, the CTL immune response to EBV is a major component of 
both the primary and memory response. Decreased efficiency of the 
’’primary’’ CTLs may result in high viral load, which in tu rn  may predispose 
to the onset of EBV-associated HD. The memory immune response, namely 
CTLs, should provide immunity to EBV-related tum our development 
throughout life regardless of viral load. Reactivation events are normally 
recognised and contained. Latently infected B-cells expressing 
immunogenic viral antigens should also be recognised and eliminated. 
Defects in the CTL arm of the memory immune response may therefore also 
be a  critical determining factor in the development of EBV-associated 
malignancies including EBV-associated HD.
The experiments described in this chapter investigated whether a  general 
defect in EBV-specific cell-mediated immunity is a feature of HD. The 
method used to investigate this was an in vitro technique which m easures 
the ability of memory CTLs in the peripheral blood to regress the outgrowth 
of EBV-transformed B-cells (Moss et aL, 1978). The original study 
describing the assay used it to investigate long-term T-cell-mediated 
immunity to EBV in healthy individuals. Since then it has been 
implemented in a number of studies, including investigations into 
alterations of the virus-host balance in post-transplant patients and in IM 
patients receiving antiviral therapy (Yao etaL, 1985; 1989a).
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The assay, termed in vitro regression (IVR) assay, was developed to allow 
quantitative comparisons of cell-mediated immunity to EBV between 
individuals. PBMCs from test donors are obtained and, in order to 
stim ulate EBV-specific T-cell responses, PBMCs are infected with EBV 
using high concentrations of B95-8 viral stock in vitro. The strength of any 
EBV-specific CTL response can then be measured by recording the ability of 
the test donor’s T-cells to recognise and lyse EBV-transformed B-cell 
outgrowths within the cultures. This results in “regression” of the 
transformed outgrowths. Following infection with EBV, PBMCs are 
cultured a t a series of twofold dilutions of cell number. Regression is 
strictly cell concentration-dependent, and is most readily observed a t high 
cell concentrations. Thus the "strength" of regression of an  individual, 
representing the effectiveness of EBV-specific CTLs, can be assayed and 
expressed as the minimum initial cell concentration required for 50% of 
replicate cultures to show regression (Moss et a l , 1983). This is an 
endpoint value which can be used for comparisons between individuals 
(section 3.3.2).
In 1981, IVR assays were performed on the peripheral blood of 54 patients 
with NPC (Chan & Chew, 1981). All patients and controls (n=38) included 
in the study were EBV seropositive. It was found tha t there was no, or only 
partial, regression of EBV-transformed B-cells in NPC patients, whereas in 
controls there was complete regression in most cases. It was concluded 
from this study that there was a marked deficiency in the generation of 
EBV-specific CTLs in vitro, and it was postulated tha t this could be a  factor 
in the persistence of tum our cells in NPC patients.
This study is of particular relevance to the work of this chapter, as there are 
several similarities between NPC and HD. The pattern of viral latent gene 
expression is the same for NPC tum our cells and RS cells of HD; both 
express a Lat II phenotype. There is a large cellular infiltrate present in 
NPC tum ours as with HD lesions. As described above, impairment of cell- 
mediated immunity to EBV is implicated in the pathogenesis of NPC and is 
suspected in HD. Both diseases display varying degrees of familial 
clustering, and a proportion of cases are HLA-associated (Chan et a l , 1983; 
Lu et a l , 1990; Burt et a l , 1994); some epidemiological studies suggest a 
similar association for this disease (Amiel, 1967; Bodmer et a l, 1989).
In these experiments we investigated the possibility of decreased strength of 
regression occurring in HD patients relative to healthy control individuals.
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3.2 Materials & methods
3.2.1 Case selection
Peripheral blood samples were collected from HD patients in the West of 
Scotland and Northern Region of England. At the time of setting up the 
assays, EBV sta tus of HD cases was not known. Pretreatm ent cases were 
chosen exclusively for this study to nullify any effects of treatm ent on the 
possible outcome of the investigation. Age and sex matched healthy 
controls were collected, where possible, and assayed alongside cases. 
Seropositive and seronegative control samples were also included in 
experiments. In total, results were obtained from 13 HD cases and nine 
controls.
3.2 .2  Sample preparation
Samples of peripheral blood were received as described in section 2.1.1.1. 
PBMCs were isolated from these samples using a Ficoll-paque density 
gradient as outlined in section 2.1.1.2. In some cases PBMCs were stored 
frozen in liquid nitrogen (section 2.1.1.5) prior to the IVR assay.
3.2 .3  Determination of EBV status
Sections of paraffin-embedded lymph node biopsies, mounted on APES- 
coated slides (section 2.2.7.1), were used for EBER in situ  hybridisation 
analysis. Sections were hybridised with a biotinylated oligonucleotide probe 
specific for the EBV EBER-1 RNA, which is abundantly transcribed in cells 
latently infected with EBV (Weiss et aL, 1991; Armstrong et a l , 1992). In 
later experiments EBER RNA expression was examined using commercially 
prepared FITC-conjugated EBER oligonucleotide probes (Dako Ltd.). The 
hybridisation signal was detected using an alkaline phosphatase conjugated 
antibody system utilising nitroblue tetrazolium as chromogenic substrate. 
A known positive sample was included in each assay and a biotinylated 
nonsense oligonucleotide probe was used as a negative control. EBER in 
situ  hybridisation was carried out by Alison Armstrong and Diane Gray.
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3 .2 .4  EBV serology
Antibody titres to EBV VCA and EA were determined using indirect 
immunofluorescence assays (IFA). The primary aim of this aspect of the 
study was to determine whether individuals were EBV seropositive. All sera 
were initially screened at a dilution of 1:10. Positive sera were diluted two­
fold further until an  end titre was reached, defined as the reciprocal of the 
serum  dilution a t which specific fluorescence was last observed. VCA IFA 
utilised B95-8 cells as a source of antigen, according to the method first 
described by Henle & Henle (1966). Diffuse and restricted components of 
EBV EA were assayed in an IFA based on that of Long et a l  (1974), either 
utilising Raji cells, treated with 5-iododeoxyuridine, as  antigen, or using 
commercially available slides (Gull Laboratories Inc.). EBV serology was 
performed by Diane Gray.
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3.3  In vitro  regression assay
The principle of this assay is based on the ability of EBV-specific CTLs to 
regress the outgrowth of EBV-transformed autologous B-cells in primary 
lymphocyte cultures. Mononuclear cells from peripheral blood are infected 
with EBV to facilitate outgrowth of virus-transformed B-cell foci. Cells at 
six hours post infection are illustrated in Fig.3. la . The appearance of 
transformed B-cell clumps, seen 7-10 days post infection, is shown in 
Fig.3. lb . The transformed B-cells express a Lat III phenotype and are 
recognised by CTLs in the culture which are specific for EBV latent 
antigens. CTL lysis of EBV-infected B-cells occurs, and is seen in the 
cultures as regression of the clumps of transformed cells; the clumps 
appear to disintegrate. Eventually complete regression of B-cell outgrowths 
can be seen (Fig. 3.1c). In the absence of an EBV-specific CTL response, or 
in the presence of cyclosporin A (CsA) which inhibits T-cell function, 
regression is not seen and large LCL-like clumps of latently-infected, 
transform ed cells can be seen (Fig.3. Id). The end result of the assay is 
scored a t four weeks post infection.
The IVR assay is carried out in a 96-well microtitre plate (Fig 3.2). The 
assay lanes consist of 6 replicate wells of 6x l05, 3 x l0 5, 1.5x10s , 7 .5xl04, 
3.8x104, and 1.9xl04 cells per well. The controls for the assay include two 
replicate wells of uninfected cells a t each cell concentration and two 
replicate wells of infected cells in the presence of CsA a t a concentration of 
0.1^g/m l. The uninfected control lanes are necessary to exclude the 
possibility tha t spontaneous transformation has occurred. The CsA control 
is included as an  indicator of the transformation efficiency of the viral 
stock. Replicates of any cell concentration are scored only if the cells in the 
CsA control wells are transformed and those in the uninfected control wells 
are dead.
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Fig.3.1 Appearance of cells during the  IVR assay
a. cells a t six h o u rs  post infection
b. tran sfo rm ed  outgrow ths of cells after 7-10 days
c. regression  of EBV-transform ed B-cell c lum ps seen after 2-3 weeks
d. LCL-like grow th of non-regressed B-cells seen after 3-4 weeks
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Fig.3.2 Layout of th e  IVR assay
oooooooooooo cells/w elloooooooooooo 6 x l0 5oooooooooooo 3 x l0 5oooooooooooo 1.5x10 soooooooooooo 7.5x104oooooooooooo 3 .8 x l0 4oooooooooooo 1.9x104oooooooooooo
( ^ )  u n in fe c te d  c o n tro l w ells 
( ^ )  a s s a y  w ells 
CsA c o n tro l w ells
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3.3.1 Protocol for setting up the IVR assay
PBMCs used in this assay were either freshly isolated or thawed from 
storage in liquid nitrogen (section 2.1.1.5). The cells to be infected with 
EBV were resuspended in 300|il of concentrated viral stock (thawed at 
37°C) and the volume made up to 600^1 with complete medium. The cells 
for the uninfected control were resuspended in 600|ol of complete medium 
alone. Cell suspensions were incubated a t 37°C with 5% C 02 for one hour 
with occasional agitation to ensure tha t the cells remained in suspension.
Following incubation the cells were washed, resuspended a t 6x106 cells/m l 
and serial doubling dilutions performed. At th is point the cells for the CsA 
control lanes were aliquotted into wells of the microtitre plate and CsA was 
added. Cells were plated out in 200^1 of medium, which was made up to a 
total of 300^1 per well with complete medium.
In cases where there were too few cells to set up a complete assay, the 
assay was scaled down within certain limits. The initial step was usually to 
use 3 x l0 5 cells per well (cf. 6x l05) as the highest cell concentration. Where 
necessary the assay was further limited by including only one lane of each 
control and reducing the number of replicate assay wells a t each dilution 
from six down to four or two. The latter reduction was necessary in only 
one case, the seronegative control.
3.3 .2  Scoring the IVR assay
Scoring the assay lanes involves recording the occurrence of transformation 
or regression for each of the wells. A formula (Appendix C) is used to give a 
value for the minimum initial cell num ber required to give a 50% incidence 
of regression (Reed & Meunch, 1938). This value can then be compared 
among individuals assayed.
The normal range of strengths of regression for healthy carriers is defined 
as minimum initial cell concentrations of 0.4x105 - 6 x l0 5 cells/well 
(Rickinson et a t ,  1981; Yao et a t ,  1985). Within this range, regression at 
the higher cell concentrations, 3x l05 - 6 x l0 5 is accepted as being a t the 
weaker end of normal (Yao et a l, 1985).
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3,4  Development of the assay
It is essential that a very high transformation efficiency is attained in order 
to be able to score the result of this assay. Difficulties were encountered 
due to sub-optimal transformation and to cell death occurring in the second 
week of the assay. Extensive optimisation experiments were therefore 
performed, using control PBMCs from healthy donors, prior to running the 
assay on HD samples. The optimisation experiments described were 
carried out contemporaneously.
3.4.1 Preparation of concentrated B95-8 EBV stocks
Originally the virus used was prepared as described in "Lymphocytes - A 
Practical Approach”, Chapter Seven (Walls & Crawford, 1987). The EBV 
stocks consisted of neat tissue culture supernatant harvested from TPA- 
stimulated B95-8 cells five days post-stimulation. TPA stimulation was 
performed as it increases the quantity of infectious virus available in the 
supernatant as a consequence of lytic replication. Use of this viral stock 
resulted in inefficient transformation and the assay could not be scored.
Initially virus was prepared from B95-8 stock cell lines stored within the 
department. Due to the inefficiency of transformation described above, a 
new stock of B95-8 cells was obtained from Dr. Q-Y. Yao a t the CRC 
Laboratories, Birmingham University Medical School. These cells had 
different growth characteristics from our original stock, growing in larger 
clumps and to greater density. The new batch of cells was grown as 
described above and the supernatant harvested and titrated on CBMCs 
(section 2.1.2.2). The transformation efficiency of this virus was too low to 
give an  accurate titre. However, in all subsequent optimisations these B95- 
8 cells were used in place of the original batch of cells.
Following these observations, the TPA-stimulated B95-8 supernatant 
containing the viral particles was harvested, as described above, and 
concentrated 100-fold by ultracentrifugation (section 2.1.2.1). The viral 
stocks were titrated using CBMCs as each new batch was prepared (section 
2 . 1.2 .2 ).
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The efficiency of transformation improved greatly following the use of 
concentrated virus and at one week post-infection all the infected assay 
wells showed evidence of outgrowth of transformed B-cells, i.e. clumps of 
cells were present in all the infected wells and absent from the uninfected 
controls. However, these clumps did not increase in size or num ber and, 
after 2-3 weeks, cells within the clumps became dark and granular in 
appearance, and eventually no viable clumps remained.
Cells in the uninfected wells also died during the course of the assay, but 
the appearance of these cells was different from that of the infected cells. 
Some cells clumped after initial plating out (depending on the donor) and 
some remained as single cells. Cell death occurred a t around 3-4 weeks 
with disintegration of cells and appearance of transparent debris and cell 
ghosts.
Due to the above observations, it was hypothesised tha t the viral 
preparation m ust in some way be causing the cell death seen in the infected 
wells. Consequently the viral harvest method was again scrutinised. It is 
known that TPA, which was present in the B95-8 tissue culture 
supernatant a t 20ng/ml, is toxic to cells at high concentration. It was 
originally thought that as TPA is a  small molecule it would not be 
concentrated on centrifugation along with the virus. It is also known that 
TPA associates with cell membranes, and as an extrapolation of this it was 
suggested that the TPA was associating with the envelope of the virus 
particles and being concentrated along with the virus during 
ultracentrifugation. Thus it was proposed that a toxic concentration of TPA 
was present in the viral preparations.
To test this possibility, viral suspensions were harvested from unstim ulated 
B95-8 culture supernatant and concentrated as described in section 
2.1.2.1. Cultures were grown at 35°C as this is known to increase virus 
production from the cells.
Assays were set up using all the optimisations described above and using 
the viral stock prepared without the use of TPA. The results were 
noticeably different from the previous assays. One week post-infection the 
infected wells contained numerous small clumps of transformed B-cells. 
The cells within the clumps were bright and refractile and cytoplasmic 
protrusions could be seen at the surface of the clumps. The clumps 
increased in size and number up to the two week point and still appeared 
healthy in the assay wells.
96
3.4 .2  Presence of contaminating organisms
Experiments were carried out to determine whether bacteria or mycoplasma 
were present, as these organisms could have an effect on the survival of 
long-term cultures.
MRC-5 cells were seeded into slide flasks and allowed to reach confluence. 
At this stage 1ml of medium taken from the assay wells and CsA control 
wells a t one, two and four week time-points was inoculated onto the 
monolayers. Bacterial contamination can cause disruption of the 
monolayer and peeling off of the cells; mycoplasma in the fibroblasts can be 
visualised using Hoescht staining (section 2.1.3.3).
The cultures were negative for mycoplasma at all times and were clear of 
bacteria a t all except the four week time point. It was concluded th a t the 
death of the cultures could not be attributed to the presence of either 
organism.
3.4 .3  General culture conditions
The culture conditions used in the assay were scrutinised for ways to 
prolong cell viability and promote transformation. Several param eters were 
investigated during the course of these optimisations.
3.4.3.1 Effect o f humidity
It was noted that after two weeks in culture the volume of medium in the 
outermost wells of the microtitre plate had decreased. In order to minimise 
this the outside empty wells were filled with complete medium to maintain 
humidity across the plate. This was indeed found to decrease the loss of 
volume in the outside wells. In addition to this, cells were plated out in 
300|al of medium per well in place of the initial 200|ol. The individual and 
combined effects of these changes did maintain a more even humidity 
throughout the duration of the assay.
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3.4 .3 .2  Effect o f pH
The pH of the cultures, as indicated by phenol red dye present in the RPMI 
1640 medium, was noted to be high from early in the assay through to the 
end point a t four weeks. In order to investigate the effect of addition of 
HEPES buffer (Table Il.i), an experiment was set up in duplicate using 
PBMCs from a single donor. Presence of HEPES maintained the culture at 
a lower pH, however, this modification did not alter the overall success of 
the assay and was subsequently omitted.
3.4 .3 .3  Effect o f CO2  concentration
Following improvements in the production of viral stocks, concern was 
again directed a t the high pH of the culture medium. Concentration of C 02 
was maintained a t 5% throughout the development of the assay using a 
Heraeus incubator which operated with high humidity. Scrutinisation of 
the incubator led to the discovery that the instrum ent had been wrongly 
calibrated. Although it was reading 5% C 02 it was actually running at 
approximately 3.5% C02. Following rectification of the fault, assays were 
sustainable for the four week period required for scoring.
3.4 .4  Conclusions
In retrospect the assay was initially failing for several reasons. The most 
critical factors overall being the presence of TPA from the virus preparation 
step and the high pH of the culture medium. When both these factors were 
identified and rectified the assay had a much greater frequency of success; 
however other factors also affected the performance of the assay although to 
a lesser degree.
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3.5 Results
3.5.1 Serology and EBV status
Serology was performed for all 23 individuals in the study and the results 
are given in Table Ill.i. All individuals included in the study were EBV 
seropositive, with the exception of two seronegative individuals included as 
controls. These results are part of a larger HD data set which shows raised 
EBV titres in cases of EBV-associated HD as a group, as compared to non­
associated cases.
EBV sta tus of the 13 HD cases, as determined by EBV-EBER in situ 
hybridisation analysis, is also given in Table ELL An example of a positive 
result, showing dark staining localised to the nuclei of RS cells, is shown in 
Fig.3.3.
3 .5 .2  Results o f IVR assays
The end results of the IVR assays fall into three main categories as follows. 
First, there were those which did not show regression a t all, with 
transformation persisting in all wells for the duration of the assay. An 
example of this group of cases is shown in Fig.3.4a. At the end of the four 
weeks, cells in the uninfected control wells were dead. Cells in the CsA 
control wells were transformed and LCL-like outgrowths could be clearly 
seen in all the wells. In the assay wells, transformation was also seen in all 
the wells. Eight cases, including two cases of EBV-associated HD and five 
controls, came into this category. As expected, neither of the seronegative 
controls showed regression.
Secondly, there were cases in which varying degrees of incomplete 
regression occurred. Assays for five HD cases, one of which was EBV- 
associated, and four controls behaved in this way. An example of partial 
regression is shown in Fig.3.4b.
Thirdly, the occurrence of complete regression was seen. The uninfected 
control wells and the CsA control wells were as described for “non- 
regressers”. Complete regression was seen in the assay wells. One assay, 
which was subsequently used as a positive control, came into this category. 
The appearance of this assay a t the four week time point is shown in 
Fig.3.4c.
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Table m .i Serology results and EBV status for cases and controls
HD cases:
patient no. EBV status VCA titre EA titre
3200 EBV+ 2560 40
3248 -ve 12(80 160
3249 -ve 5120 160
3250 -ve 1280 160
3251 -ve 1280 40
3277 EBV+ 2560 320
3292 -ve 2560 80
3543 ND* seropositive
3619 -ve seropositive
3763 -ve 80 0
3790 -ve 5120 1280
3886 EBV+ 5120 40
3888 -ve 20480 40
*ND = not done
seropositive = tested at 1:10 dilution, no further titration performed
controls:
patient no. VCA titre EA titre
3213 2560 10
3258 2560 0
3260 40 0
3261 10240 80
3272 640 20
3788 2560 80
3893 seropositive
3894 seropositive
neg. 1 seronegative
neg. 2 seronegative
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Fig.3.3 EBER in situ  hybridisation of EBV+ case
/
*
*
T
< •  *
A ppearance of a positive result of EBER in situ hybridisation, 
show ing dark  sta in ing  localised to the nuclei of RS cells (x200)
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Fig.3.4 D iagram m atic represen tations of IVR assays
uninfected control assay CsA control
a.
b.
c.
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6 x l 0 5
3 x l0 5
1.5xl05
7 .5 x l0 4
3 .8 x l0 4
1 .9x l04
£ )  transform ed ( ^ )  regressed or
102 non-transfo rm ed
A summ ary of the values for minimum cell concentration required for 50% 
incidence of regression, scored at four weeks post infection, is given in 
Table Ill.ii. The microtitre plate scores for regression and transformation of 
each well, plus calculations of the 50% endpoints for each assay, are given 
in Appendix C.
Five of thirteen HD cases showed regression within the normal range, 
defined as minimum initial concentrations of 0.4x105 - 6x105 cells/well 
(Rickinson etaL , 1981; Yao etaL, 1985b) (section 3.3.2), compared to five of 
eight controls. With such a small study it is not possible to assess the 
significance of the observed difference. One of three EBV-associated HD 
cases displayed regression, compared to four of ten non-EBV-associated 
cases. Minimum initial cell number for 50% regression for the EBV- 
associated case was 3.3x105, which is a t the weaker end of the normal 
range (Yao etaL , 1985b). The non-EBV-associated HD cases which showed 
regression were all at the stronger end of the normal range, with values of 
1 -I.9x l05.
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Table Ill.ii Results o f IVR assays
HD cases:
patient no. sex/age EBV status regression 50% endpoint
3248 F38 -ve part 1.1x10s
3250 F65 -ve part l .lx lO 5
3277 M59 EBV+ part 3 .3x l05
3292 M24 -ve part lx lO 5
3888 F33 -ve part 1.9xl05
3200 F61 EBV+ none
3249 F68 -ve none
3251 F36 -ve none
3543 M20 none
3619 M35 -ve none
3763 M28 -ve none
3790 F65 -ve none
3886 F20 EBV+ none
controls:
patient no. sexfage regression 50% endpoint
3213 M46 total <0.2xl05
3258 F26 part 1.2x l05
3788 M30 part 1.5x10s
3893 F33 part 0 .9x l05
3894 F26 part 0 .9x l05
3260 M21 none
3261 M40 none
3272 M37 none
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3.6 Discussion
The aim of this study was to assess the strength of EBV-specific CTL 
responses in HD patients, comparing EBV-associated and non-associated 
cases, relative to healthy individuals. Five of thirteen HD cases and five of 
eight controls showed regression within the normal range. One EBV- 
associated HD case displayed regression representative of a CTL response 
a t the weaker end of normal.
Individuals displaying regression within the normal range occurred in both 
the healthy controls and the HD cases. The mean value for minimum initial 
cell num ber giving 50% regression was 1.7xl05 for HD cases and 0 .8x l05 
for controls. Among the HD cases, regression was seen in one out of the 
three EBV-associated cases, refuting the null hypothesis tha t people who 
develop EBV-associated HD do not have EBV-specific memory CTLs. 
However, the minimum initial cell concentration for 50% regression in this 
individual was 3.3x105 cells/well, which is at the weaker end of the range 
for normal responses, while the rest of the HD cases were in the range 1- 
1 .9xl05. Thus the possibility remains tha t there are diminished CTL 
responses in these cases, relative to other HD cases and to healthy controls. 
The issue cannot be concluded with certainty from this study due to the 
small num ber of cases included, particularly EBV-associated cases.
One of the unexpected results of this study was the relatively high 
proportion (38%) of controls which showed no regression. The reasons for 
this are unclear, as the individuals in question were found to be EBV 
seropositive. As no batch of assays performed at any time was without at 
least one sample showing regression, there was no reason to doubt the 
technical aspects of the assays. In the original study by Moss et a l  (1978), 
18 healthy seropositive donors were examined for regression using IVR. All 
of these showed regression within the normal range, with two of the donors 
being at the weaker end of the range (50% endpoint = 4 x l0 5 cells/well). A 
further study from this group looked at 22 healthy EBV-positive donors. 
Variable degrees of regression were seen within the normal range, with two 
donors exhibiting only weak regression (Moss et a l, 1981). However, in a 
study of NPC patients performed by Chan & Chew (1981), 20 of 38 healthy 
controls did not exhibit any regression within the limits of their assay. 
There is no obvious explanation for these differences but it is harder to 
draw conclusions from a study in which a high proportion of individuals are 
"non-regressers".
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The results of this study negate the suggestion that individuals with EBV- 
associated HD lack EBV-specific CTLs, but leave open the possibility that 
these persons have diminished CTL responses to EBV. These data 
emphasise the need for further investigations into EBV-specific CTL 
response in HD patients. It is obvious from the results tha t it would be 
necessary to analyse samples from a much larger num ber of HD cases by 
this method before the significance of potential differences between EBV- 
associated and non-associated cases could be assessed. However, use of 
the IVR assay has confirmed that EBV-specific CTLs do exist in the 
peripheral blood of some cases of EBV-associated HD, an issue which had 
not been addressed at the start of this work. For future investigation, 
analysis of specific responses to peptides of individual EBV proteins may 
prove more fruitful. It is possible that the CTLs are specific for peptides of 
the immunogenic EBNA-3 family of proteins. Such CTLs, although able to 
regress LCL-like outgrowths in the IVR which are probably expressing a Lat 
III phenotype including the EBNA-3s, would not be effective against EBV- 
positive RS cells in vivo which express Lat II, i.e. no EBNA-3 antigens.
This study provides potential evidence of diminished responses to EBV 
occurring in EBV-associated cases of HD. During the course of the work of 
this thesis, Dolcetti et a l  (1995) published a study which looked a t T-cells 
isolated from the lymph node of a single case of non-EBV-associated HD. 
EBV-specific CTL responses to LMP-2 and, to a lesser extent, EBNA-3c, 
were observed. The investigators conclude that the inherent immuno­
suppression associated with HD does not include diminished memory CTL 
responses. They also suggest that their findings lend weight to the theory 
tha t EBV-associated and non-associated disease are characterised by 
distinct pathogenic mechanisms.
A second related study went on to examine the CTL responses within the 
lymph node environment in greater detail (Frisan et a l, 1995). This type of 
study is critical in determining whether the responses in peripheral blood 
reflect those in the lymph node. Frisan et a l  investigated samples of T-cells 
isolated from both blood and lymph node from cases of EBV-associated and 
non-associated cases of HD. EBV-specific CTLs were found in the lymph 
nodes of EBV-negative cases but were not detectable in nodes from EBV- 
positive cases of HD. One of these EBV-positive cases was subjected to 
investigation of a paired sample of blood and lymph node, and this did have 
detectable CTLs to EBV present in the peripheral blood even though they 
were absent from the lymph node CTLs. These data, although preliminary,
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support the suggestion that EBV-specific CTL responses may be different 
between the two groups of HD cases, and that diminished responses in 
EBV-associated cases may be an important factor in disease pathogenesis. 
There may be cytokine-mediated suppression of EBV-specific cytotoxicity in 
the lymph node environment.
Other defects in the effector arm of the immune response in HD remain to 
be investigated. Absolute num bers of CD8+ CTLs may be reduced in HD. 
The decreased ratio of CD8+/CD4+ T-cells in the reactive cellular infiltrate 
in HD is well documented (Poppema & Visser, 1995), and may be a feature 
of the immunosuppression associated with HD. Alternatively it may be a 
result of local cytokine production within HD lesions, perhaps even by the 
RS cells themselves, which selects against the emigration of CD8+ cells into 
the node.
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Chapter 4
Determination of HLA-A2 antigen status in 
Hodgkin's disease patients and analysis of an 
HLA-A2-restricted epitope of LMP-2
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4.1 Introduction
There is now very good evidence for an association between EBV and a 
proportion of HD cases. In these cases, viral genomes can be detected in 
the RS cell population and the clonality of these genomes can be 
dem onstrated (Jarrett et a l, 1991). There is a Lat n  pattern of expression 
of viral gene products (Pallesen et a l , 1991; Deacon et a l , 1993; Grasser et 
a l,  1994), including EBNA-1 and the latent membrane proteins LMP-1 and 
LMP-2a and -2b.
A high level of LMP-1 protein expression has been dem onstrated in RS cells 
(Pallesen e ta l ,  1991; P.Murray e ta l ,  1992; Armstrong e t a l , 1992). LMP-2 
expression has been demonstrated at the mRNA level bu t has not yet been 
confirmed at the protein level, due to the lack of availability of suitable 
antibodies to the protein. The LMP-2s are presumed to be expressed as 
protein alongside LMP-1 and, as the two colocalise in patches a t the cell 
membrane (Longnecker & Kieff, 1990), it would be realistic to assum e that 
the level of protein expression of LMP-2 is comparable to tha t of LMP-1. 
The LMPs are potentially immunogenic proteins and CTL responses have 
been demonstrated to peptides of LMP-1 and LMP-2 (Khanna et a t,  1991; 
1992; R.J.Murray et oL, 1988; 1992; Lee et a l , 1993). Therefore it may be 
postulated that presentation of epitopes of these viral proteins in an 
appropriate HLA class I background may protect against EBV-associated 
forms of HD.
It is clear that RS cells are not successfully eliminated by the CTL response. 
There are several possible explanations for this. First, EBV-associated HD 
may occur only in individuals expressing HLA class I alleles which, by 
virtue of the architecture of their antigen binding site, are unable to present 
peptides from the LMPs. Secondly, epitopes eliciting immunodominant CTL 
responses may have undergone mutation in individuals with HD. Thirdly, 
HLA class I proteins may not be expressed on the surface of RS cells. 
Finally, effector responses may be impaired. In these experiments we tested 
the first two of the hypotheses listed above.
HLA-A2 antigen-positive individuals were the focus of this study, as the 
HLA-A2 molecule is known to present at least one epitope of the LMP-2 
proteins and generate a CTL response (R.J.Murray et a l, 1992; Lee et a l, 
1993). Presentation of this target epitope of LMP-2a occurs in conjunction
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with the HLA-A*0201 allele of the A2 family. Possession of the HLA-A2 
allele, specifically allele A*0201, may therefore convey a decreased risk of 
developing EBV-associated HD. To test this hypothesis we studied the 
frequency of occurrence of the HLA-A2 antigen in EBV-associated and non­
associated cases of HD, and compared this to the frequency in the general 
population. Selected cases which were HLA-A2-positive were investigated 
further to determine which alleles of HLA-A2 were present.
The possibility of viral escape from CTL surveillance through m utations in 
target CTL epitopes in vivo has been previously described, particularly in 
the case of genetically unstable viruses, for example with HIV infection of 
hum ans (Phillips et aLf 1991). There is also an animal model illustrating 
this phenomenon in the case of lymphocytic choriomeningitis virus (Pircher 
et a l,  1990). It is less well documented for the genetically stable DNA 
viruses with long histories of host-virus coexistence, however, there are 
reports of viral escape m utants of EBV occurring in more geographically 
isolated, healthy populations (de Campos Lima e ta l ,  1993; 1994).
In th is study we looked at the possibility of viral escape m utants, 
possessing a novel sequence of the LMP-2 epitope, occurring in cases of 
EBV-associated HD arising in an HLA-A2 antigen-positive individual. The 
epitope which was investigated represents amino acids 426-434 of the LMP- 
2a protein (Lee e t a l , 1993).
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4.2  Materials & methods
4.2.1 Case and sample selection
Overall, 410 samples from 313 individuals, including 205 HD cases, were 
investigated. Samples from 149 individuals were collected as part of a case- 
control study investigating lymphoid malignancy occurring in young adults 
aged 15-24 years in England and Wales. Peripheral blood samples were 
collected from all individuals in this study, and paraffin-embedded biopsy 
material was obtained from cases. In order to increase the age range of HD 
cases included, peripheral blood and biopsy samples were collected from 
164 cases of lymphoid disease occurring in Scotland and the Northern 
Region of England. The age distribution of cases and controls is given in 
Fig.4.1. All cases included were part of population-based studies, thus 
eliminating potential selection bias. Peripheral blood samples were 
collected from 15 additional healthy individuals to augment the num bers of 
controls in the study. HLA-A2 status was determined using PBMCs, LCLs 
or biopsy material. EBV status was determined using paraffin-embedded 
biopsy material.
4 .2 .2  Sample preparation
PBMCs were separated from whole blood using a Ficoll-paque density 
gradient (section 2.1.1.2). LCLs were established where possible by 
infection of PBMCs with EBV from the B95-8 cell line, as described in 
section 2.1.2.3. Cell suspensions were obtained from biopsy samples by 
m anual disruption of the tissue; in some cases frozen biopsy tissue was 
used as described below.
Cell lysates of PBMC pellets were prepared as described in section 2.1.3.2. 
DNA was extracted from LCL pellets using proteinase K digestion and 
organic solvent extraction (section 2.2.1.1). DNA was similarly extracted 
from fresh or frozen biopsy tissue following initial maceration using a 
stom acher (Seward Medical Ltd.). DNA was extracted from formalin-fixed, 
paraffin-embedded tissue sections by digestion in buffer containing lOmM 
Tris pH 7.4,, lOOmM sodium chloride, 25mM EDTA, 0.5% SDS and 
200pg/m l proteinase K for 16 hours a t 37°C (Shimizu & Bum s, 1995), 
followed by organic solvent extraction (section 2.2.1.1) and isopropanol 
precipitation (Shimizu & Bum s, 1995). All DNA samples were resuspended 
in nuclease-free water (Pharmacia Biotech).
i l l
F ig .4 .1 Age d istribu tion  of cases and controls
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4 .2 .3  Determination of EBV status
Paraffin-embedded lymph node biopsy sections mounted on APES-coated 
slides were used for EBER in situ hybridisation analysis, as described in 
section 3.2.3. EBER in situ hybridisation was carried out by Alison 
Armstrong and Diane Gray.
4 .2 .4  Determination of HLA-A2 antigen status
Three approaches were used to determine HLA-A2 antigen sta tu s of cases 
and controls. First, flow cytometric analysis was used in cases where viable 
cells or LCLs were available. Secondly, in order to increase the num ber of 
cases which could be included in the study, we attem pted to develop an 
immunohistochemical assay to identify the HLA-A2 antigen in formalin- 
fixed, paraffin-embedded tissue sections, as discussed in section 4.2.4.2. 
Finally, a PCR strategy was introduced to determine HLA-A2 sta tu s using 
DNA samples and cell lysates prepared from non-viable PBMC pellets.
4.2.4.1 Flow cytometric determination of HLA-A2 status
Flow cytometry was carried out on a total of 163 samples from 158 
individuals. Sample types used for this analysis included PBMCs obtained 
from whole blood (n=19), single cell suspensions from disrupted lymph 
nodes (n=58) and EBV-immortalised LCLs (n=ll). In later experiments 
whole blood preparations were also used (n=75).
The primary antibody was the BB7.2 monoclonal antibody to HLA-A2, 
which was in the form of tissue culture supernatant from the hybridoma 
cell line HB82 (Table Il.iii). BB7.2 recognises HLA-A2 and a low frequency 
variant of HLA-A28 (Parham & Brodsky, 1981). It is an  IgG2b class 
antibody which recognises its substrate via a bivalent interaction (Parham 
& Brodsky, 1981). An isotype-matched murine monoclonal antibody was 
used as a negative control in all experiments.
The positive control cells utilised in these experiments were from the VES 
LCL which is homozygous for HLA-A2. The negative control cells used were 
from the Jijoye cell line which is HLA-A2 negative. Both VES and HB82 
were kindly provided by Dr. P. Chandler.
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Approximately 2x106 cells were assayed per sample. All steps were carried 
out a t room temperature unless otherwise stated. Cells were washed twice 
in lx  PBS containing 0.01% BSA and 0.1% azide (PAB). In order to block 
any non-specific binding sites, cells were incubated with a solution of 20% 
normal rabbit serum (SAPU) in PBS for 30 minutes. Following a washing 
step, cells were split into equal aliquots and incubated with 40|fl of either 
BB7.2 or the control primary antibody for 30 minutes. Following washing 
in PAB, cells were resuspended in 1 OjlxI undiluted goat-anti-mouse FITC- 
conjugated secondary antibody (Dako Ltd.) for 30 minutes. Finally, cells 
were washed twice in PAB and fixed in 1% paraformaldehyde.
For whole blood preparations, 200^1 of blood were used. Following 
incubation with secondary antibody, whole blood lysis was performed using 
the commercially available Immunolyse kit (Coulter Electronics Ltd.) 
following the manufacturers instructions. This resulted in lysis of red blood 
cells and therefore reduced non-specific background labelling. The cells 
were analysed using a Coulter EPICS Elite flow cytometer. EPICS analysis 
of lymph node cell suspensions was carried out by Linda Andrew.
4 .2 .4 .2  Immunohistochemical determination of HLA-A2 status
Flow cytometry was used exclusively on samples from which viable material 
was available. In order to increase the number of cases which could be 
included in the study, we explored the use of an  immunohistochemical 
assay to determine HLA-A2 antigen status. The assay utilised the BB7.2 
monoclonal antibody used for flow cytometric analysis. This antibody had 
been shown to work on cytospins and frozen tissue sections (Poppema & 
Visser, 1994a) but no data were available regarding its use on paraffin- 
embedded material. The advent of microwave techniques for unmasking 
antigens has enabled many antibodies previously only used on frozen tissue 
or cytospins to be used on formalin-fixed, paraffin-embedded material.
The assay was initially optimised using sections of paraffin-embedded cell 
pellets of HLA-A2-positive and -negative control cell lines. The basic 
immunohistochemical techniques used are described in section 2.2.7. 
Optimisations included comparisons of ABC and APAAP staining methods, 
variation of antibody incubation times and temperature, and addition of 
extra blocking agents such as 0.1% BSA to wash buffers. Once the assay 
was optimised on controls it was tested on clinical samples. Unfortunately 
a satisfactory signal to noise ratio could not be obtained on these samples, 
and no further optimisation was attempted.
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4 .2 .4 .3  Analysis o f HLA-A2 antigen status by PCR
A PCR assay was introduced and used to analyse DNA samples (n=27) and 
cell lysates (n=198). Each PCR sample was assayed alongside a mock 
lysate which was handled with the sample from the time of sample 
preparation. Positive controls for each batch of samples included DNA and 
cell lysates from the JY and VES cell lines; JY is an  LCL which is 
homozygous for HLA-A*0201. Negative controls for each experiment 
consisted of DNA and cell lysates from the Jijoye cell line.
PCR primers specific for exons two and three of the HLA-A2 gene were used 
to amplify a 813bp fragment (Krausa et aL, 1995). The primer sequences 
are detailed in Table IV.i. The reaction conditions were as described in 
section 2.2.2.1. The optimal concentrations of magnesium chloride and 
primers included in the reaction were 1.5mM and 0.5pM respectively, as 
determined by titration (section 2.2.2.2J. The PCR buffer used was as 
detailed in Table II.v; this was different from that used by Krausa et a l  
(1995). A set of internal control primers, also at 0.5^iM, were included in 
the reaction to verify the presence of amplifiable DNA. These were specific 
for a 330bp fragment of the fern gene (Krausa et a l, 1993) and the primer 
sequences are detailed in Table IV.i.
Thermal cycling was performed as described by Krausa et a l  (1995), using 
a Gene Amp® PCR system 9600 (Applied Biosystems Ltd.). Cycling 
param eters were as  follows:
Initial denaturation at 
Five cycles of
Twenty five cycles of
Final polymerisation at 
Soak at
95°C for 7 minutes; 
95°C for 1 minutes, 
65°C for 1 minutes, 
72°C for 2 minutes; 
95°C for 1 minutes, 
55°C for 1 minutes, 
72°C for 2 minutes; 
72°C for 7 minutes; 
4°C indefinitely
The 65°C reannealing temperature for the first five cycles was used to 
reduce non-specific priming (Krausa e t a l , 1995).
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Table IV.i Primer specifications
primer nucleotide sequence 5'-3' length
HLA-A2 5' primer CCT CGT CCC CAG GOT CT 17
HLA-A2 3' primer TGG CCC CTG GTA CCC GT 17
fom 5' primer CGA TAT TCC TCA GGT ACT 18
fcm  3' primer CAA CTT TCA GCA GCT TAC 18
subtyping primers
3 GAC GGG GAG ACA CGG AAA 18
22 CAC TCC ATG AGG TAT TTC TA 20
26 GAC GGG GAG ACA CGG AAT 18
27 CAC TCC ATG AGG TAT TTC TT 20
55 AAG GCC CAC TCA CAG ATT G 19
N CCC CAC GTC GCA GCC AA 17
Q CTC CAG GTA GGC TCT CAA 18
R CTC CAG GTA GGC TCT CTG 18
AE TCC GCC TCA TGG GCC GT 17
AF ACG TCG CAG CCA TAC ATC A 19
AK ACT GGT GGT ACC CGC GC 17
BJ CCG ACC CCA CGT CGC AGG CAC 21
BL CTC TCT GCT GCT CCG CCT 18
*0201/9 from genomic:
29 CAG CTC AGA CCA CCA AGC A 19
AL TGG AAG GTT CCA TCC CCT T 19
LMP-2a 5f primer GTA TCT ATT TGT TAC TCC TG 20
LMP-2a 3’ primer AGC GTG TTA GAC ATC ACC GT 20
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Table IV.ii HLA-A2 subtyping: primer combinations and allele 
specificities
primers
used
alleles identified size o f  
product
reaction
22, Q *0201, *0204, *0207, *0209, *0211 715 a
22, AK *0202 579 b
22, AE *0203 694 c
22, AF *0204 540 d
3, AK *0202, *0205, *0214 409 e
27, AK *0205, *0208, *0214 579 f
22, BJ *0207 549 g
26, AK *0208 408 h
27, Q *0206, *0210, *0214 715 i
27, N *0210 546 j
55, Q *0211 522 k
22, R *0212, *0213 705 1
22, BL *0203, *0213 695 m
29, AL *0209 907 209
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PCR products were analysed using 8 % polyacrylamide gels (section 2.2.3.1) 
which were subjected to electrophoresis a t 120V for two hours. Gels were 
initially visualised using ethidium bromide staining and UV light. 
Subsequently, in order to confirm specificity and increase sensitivity, 
Southern hybridisation was also carried out. PCR products were 
transferred onto nylon membrane by electroblotting (section 2.2.4.1) and 
hybridised to a 30-mer internal 32P-labelled oligonucleotide probe (section 
2.2.4.3) specific for exon two of the HLA-A2 gene.
4.2 .5  Subtyping of the HLA-A2 locus by PCR
Nested PCR "subtyping" analysis was carried out on selected cases, which 
were identified in the HLA-A2-specific PCR (section 4.2.4.3J, to determine 
the alleles of HLA-A2 which were present. The subtyping protocol was 
essentially as described by Krausa et a l  (1995). Control DNAs for alleles 
A*0201-*0212 were obtained from Dr. Trevor Jones, UK Transplant Support 
Service Authority, Bristol. The A*0201 control DNA was from the JY cell 
line which is homozygous for HLA-A*0201.
Following first round amplification of the 813bp fragment (section 4.2.4.3), 
nested PCR analysis was performed on 14 cases of EBV-associated HD 
which were HLA-A2-positive. Thirteen sets of primer combinations (a-m) 
were used to identify alleles A*0201-*0213. To distinguish A*0201 and 
*0209, PCR from genomic DNA (reaction 209, Table IV.i) was necessary. 
Primer sequences are detailed in Table IV.i. Allele specificities of primer 
combinations are detailed in Table IV.ii. DNA from the first round PCR was 
diluted 1 /1 0 0 0  before inclusion in the nested reaction.
Cycling conditions for the subtyping reaction, as described by Krausa et a l  
(1995), were as follows:
Initial denaturation at 
Five cycles of
Ten cycles of
Final polymerisation at 
Soak at
95°C for 5 minutes; 
95°C for 1 minutes, 
65°C for 1 minutes, 
72°C for 2 minutes; 
95°C for 1 minutes, 
55°C for 1 minutes, 
72°C for 2 minutes; 
72°C for 7 minutes; 
4°C indefinitely.
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4.2 .6  Amplification of LMP-2 epitope
Cases for this analysis were selected for EBV positivity of RS cells by EBER 
in situ  hybridisation. PCR analysis was performed on DNA extracted from 
tum our material. Initially DNA was extracted from frozen tissue, however 
in some instances this could not be obtained and DNA was therefore 
extracted from paraffin-embedded tissue sections (section 4.2.2).
DNA extracted from the Raji cell line, which is infected by EBV, was used as 
a positive control. DNA prepared from the J-Jh an  cell line, which is EBV- 
negative, was included as a negative control. As described for the HLA-A2 
PCR, each assay contained a positive and negative control for EBV and, in 
addition, each sample included in the experiment had an  individual 
negative control.
PCR was used to amplify a 248bp fragment of the LMP-2 gene containing 
the CTL epitope sequence representing codons 426-434 of LMP-2a. The 
primers used for this amplification are detailed in Table IV.i. UlTma™ DNA 
polymerase (Applied Biosystems Ltd.) was used as the thermostable 
polymerase since it has proof-reading ability, i.e. it incorporates 3’-5’ 
exonuclease activity. In order to facilitate more accurate amplification, 
lower nucleotide concentrations were used than  in the standard PCR 
reaction, and the nucleotide mix contained dTTPs, in place of the standard 
dUTPs, to facilitate subsequent cloning of PCR products. Primer and 
magnesium concentrations were optimised by titration (section 2 .2 .2 .2 ). 
The reaction conditions were as follows.
DNA, 500ng 
dNTPs (dTTP), 40pM 
lx  UlTma™ reaction buffer 
UlTma™ enzyme, 3 units 
Magnesium chloride, 0.5mM 
Primers, lpM each.
The PCR was performed as a hot start reaction using Ampliwax® beads 
(Applied Biosystems Ltd.), as per the UlTma™ specification sheet, with the 
DNA and enzyme in the upper reaction mix and the other reagents below 
the wax bead. This prevented truncation of the primers, due to the
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exonuclease activity of UlTma™, occurring prior to the sta rt of the reaction. 
Hot sta rt also increases specificity of amplification by eliminating non­
specific annealing of primers to sample DNA at low tem peratures. The 
Ampliwax® beads were melted over the lower reaction mix by heating to 
80°C for 10 minutes. The final reaction volume was 100^1.
The PCR cycling conditions were as follows.
Initial denaturation a t 95°C for 5 minutes;
Forty cycles of 95°C for 1 minute,
55°C for 1 minute,
72°C for 2 minutes;
Final polymerisation at 72°C for 7 minutes;
Soak at 4°C indefinitely.
4.2 .7  Nucleotide sequencing of PCR products
Products of the LMP-2 PCR were subjected to electrophoresis using 8 % 
PAGE (section 2.2.3.1) to confirm that a fragment of the correct size had 
been amplified. Fragments were sequenced either directly from the PCR 
reaction mix or following cloning into pBluescript vector using the pCR- 
Script™ cloning kit (Stratagene) as described in section 2.2.5.1. In the case 
of cloned products, nucleotide sequencing was performed on 3-4 
independent clones from each case studied, to ensure tha t the sequence 
obtained was representative of the main population present. Sequencing
was performed on both strands to minimise artefactual errors. Initially,
nucleotide sequencing of clones was performed using a Li-Cor DNA 4000 
autom ated sequencer (section 2.2.5.5). Latterly, direct nucleotide 
sequencing of PCR products was carried out using an ABI Prism™ 310 
autom ated sequencer (Applied Biosystems Ltd.) as described below. 
Occasional clones were sequenced commercially by Alta Bioscience, 
Birmingham University. Sequences obtained were analysed and compared 
within and between individual samples.
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4.2.7.1 Nucleotide sequencing using the ABI Prism™ 310
Direct nucleotide sequencing of PCR products was performed as per the 
chain termination method, utilising fluorescent dye-labelled 
dideoxynucleotides. Fragments were purified from PCR reactions using the 
High Pure PCR Product Purification Kit (Boehringer Mannheim UK Ltd.), 
following the manufacturers instructions. Sequencing reactions were 
performed using the ABI Prism™ Dye Terminator Cycle Sequencing Ready 
Reaction Kit (Applied Biosystems Ltd.), as per the m anufacturers 
instructions, using a Thermal Cycler TCI (Applied Biosystems Ltd.).
4 .2 .8  Statistical analysis
For the HLA-A2 analyses, individuals were grouped into several different 
categories. For examination of the HLA-A2 frequency in control groups 
(non-HD), these were classified as lymphoid malignancy, other disease 
controls, and healthy controls. For HLA-A2 analysis of HD cases, these 
were analysed as a whole group or following separation into ’’classical” HD 
and HDLP. Where age distribution of cases is analysed, the age groups 1- 
14 year, 15-24 year, 25-49 year, 50-64 year, and over 65 year are used.
The analysis of the association between HLA-A2 and HD was performed 
both with and without adjustment for the effect of age. For these analyses, 
HD cases were considered first as a whole group, and secondly as EBV- 
associated (EBV+) and non EBV-associated (EBV-) cases. These groups of 
HD cases were compared to all controls, all sick controls, and all controls 
except lymphoid malignancy. The data were also investigated for 
association between HD subtypes and HLA-A2 positivity.
Statistical analyses were performed by Dr. Freda Alexander. Logistic 
regression was applied using the statistical package EGRET. Odds ratios 
and 95% confidence intervals are given.
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4.3  Results
The study included 313 individuals, comprising 205 HD cases, 78 other 
lymphoid disorders and 30 healthy controls. The age distribution of 
individuals included in each case or control group [section 4.2.8) is 
illustrated in Fig.4.1.
4.3.1 EBV-association
EBER in situ  hybridisation was performed on samples from 140 cases, of 
which 132 were HD. Thirty-five of these were positive and 97 were negative 
for EBER expression. Overall, 27% of HD cases were EBV-associated. 
Sixty percent of HD cases in the 0-14 year age group, and 60% of cases over 
50 years, were EBV-associated. Although the majority of cases analysed 
were in the 15-24 year age group, this group displayed only 16% EBV- 
association, which is consistent with previous findings from our group. To 
summarise, EBV-associated cases were under-represented compared to the 
expected num ber for a  non-selected group of HD cases. Age distribution 
and EBV sta tus of HD cases are given in Table IV.iii.
Table IV.iii Age distribution and EBV-positivity o f HD cases
age group total cases EBV+ (%) EBV- (%) cases excluded*
1-14 year 10 6 67% 3 33% 1
15-24 year 94 15 19% 65 81% 14
25-49 year 36 2 9% 21 91% 13
50-64 year 23 8 57% 6 43% 9
>65 year 11 4 67% 2 33% 5
*Cases excluded from the analysis were those for which EBV status was not available.
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4 .3 .2  HLA-A2
Overall, HLA-A2 sta tus was available for 276 of 313 individuals. Flow 
cytometry results were available for 158 individuals. Fig.4.2 illustrates 
histograms obtained from flow cytometric analysis of HLA-A2-negative and - 
positive samples.
PCR results were available for 187 individuals. A result was only scored if 
the 330bp product of the fcm PCR was visible on ethidium bromide-stained 
gels. Fig.4.3 shows an ethidium bromide-stained polyacrylamide gel of 
HLA-A2 PCR products.
Both flow cytometry and PCR results were available for the same individual 
in 6 8  cases. Of the persons for whom a result was obtained using both 
assays, only one was discrepant between the two assays, giving a 98.5% 
correlation. The discrepant case, patient 3090, was A2-negative by flow 
cytometric analysis but weakly positive by Southern hybridisation following 
PCR analysis. The fcm band was strong when visualised with ethidium 
bromide. It is probable that the band observed on Southern hybridisation 
was artefactual, and any results for patient 3090 have been omitted from 
the analyses.
Of the individuals in this study, 122 of 276 (44%) were HLA-A2-positive, 
which is consistent with the findings of earlier studies and is not 
significantly different from the expected population frequency of HLA-A2 
(Imanishi et a l ,  1992). HLA-A2-positivity was less than  expected for 
healthy individuals and disease controls (on exclusion of lymphoid 
malignancy). This may reflect the small num bers of individuals in these 
two groups. The analysis of HLA-A2 status and HD is illustrated in Table 
IV.iv. In the unadjusted analysis, there were significant differences between 
frequencies of HLA-A2 in HD cases and controls. These were 49% for HD 
cases and 35% for all controls, giving a p-value of 0.025. The difference is 
not statistically significant following adjustm ent for age.
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Fig.4.2 Flow cytom etric analysis of HLA-A2
a. HLA-A2-negative sample
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Fig.4.3 PCR analysis
( J ) x l 2  3 4 5 6  7 8 9  10 11
813bp (HLA-A2) 
330bp (p2 m)
Lane: <j)x, size m arker: 1, pos control; 2, neg control;
4 ,6 ,8 ,10, w ater controls; 3,5, HLA-A2-neg sam ples; 
7,9,11, HLA-A2-pos sam ples
125
Table IV. iv HLA-A2 and HD
Status HLA-A2 +ve Total number % positivity
all HD cases 8 6 176 49%
classical HD cases 79 162 49%
all controls 35 1 0 0 35%
lymphoid malignancy 24 53 40%
other disease controls 5 2 0 25%
healthy controls 6 27 2 2 %
Table IV.v HLA-A2 and EBV status
Status HLA-A2 +ve Total number % positivity
all HD cases 8 6 176 49%
all EBV-associated HD 14 35 40%
non EBV-associated HD 52 97 54%
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4 .3 .3  HLA-A2 and EBV-association
Fourteen of thirty-five (40%) EBV-associated HD cases were HLA-A2- 
positive, compared to 52 of 97 (54%) of non-EBV-associated cases. 
Unadjusted analysis of the relationship between EBV sta tus and HLA-A2 
antigen positivity is given in Table IV.v. Statistical analysis (section 4.2.8) 
of this relationship, adjusted for age, is detailed in Table IV.vi. Although 
fewer of the EBV-associated cases were HLA-A2-positive, the differences 
observed did not approach statistical significance.
4 .3 .4  HLA-A2 subtyping
Nested subtyping analysis of the HLA-A2 locus was performed for 14 cases 
of EBV-associated HD which were HLA-A2-positive by PCR. Thirteen cases 
typed as HLA-A*0201. One case, patient 2151, typed as HLA-A*0205. 
Results were obtained for reaction 209 (Table IV.ii), which distinguishes 
allele A*0201 from A*0209, in six of the thirteen A*0201 -positive cases, with 
these cases typing as A*0201. However, A*0209 is known to be an 
extremely rare allele in many world populations including Caucasians 
(M.Browning, personal communication). The results obtained for an 
A*0201-positive case, and for the A*0205-positive case, are shown in 
Fig.4.4 alongside the results for JY, the A*0201-positive control (results of 
reaction 209 not shown).
4 .3 .5  Analysis o f LMP-2 epitope
The nucleotide sequence of a fragment containing the epitope corresponding 
to amino acids 426-434 of LMP-2a was determined for seven cases of EBV- 
associated, HLA-A2-positive HD and four HLA-A2-negative cases. The 
epitope present in cells of the Raji cell line was included in this analysis to 
exclude the possibility of contamination from the PCR positive control. An 
example of the results of amplification of an LMP-2 fragment, shown on 8 % 
PAGE stained with ethidium bromide, is illustrated in Fig.4.5.
In all of the non-HLA-A2 cases the LMP-2 epitope was conserved. In six of 
the seven HLA-A2-positive cases studied, the epitope was also conserved. A 
representative electropherogram from one of these cases is shown in 
Fig.4.6. In the remaining case, patient 3070, there was a single base-pair 
change A->T in codon 432. This translates as an  amino acid replacement of 
threonine by a serine residue.
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Table IV.vi HLA-A2 status by case/control group
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Fig.4 .4  Subtyping of HLA-A2 alleles by PCR
a.
715bp —►
b. (J)x a b e  d h 1 m
330bp
C, ( J j x a b c d  e f g h i  j k  l m
579bp
409bp 330bp
a. JY positive control
b. HLA-A*0201-positive sample
c. HLA-A*0205-positive sample
(primer sets a-m detailed in Table IV.ii)
330bp
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Fig.4 .5  8% PAGE showing products of LMP-2 fragm ent am plification
(|)X
Lane: §x, size marker
1 neg. control (J-Jhan DNA)
2 pos. control (Raji DNA)
3 blank lane
4 sample 845
5 water control
248bp
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Fig.4.6 The nucleotide sequence of the 248bp PCR fragment is given above 
the electropherogram trace. The epitope sequence lies within the arrows.
Fig.4.6 Electropherogram  of LMP-2 epitope nucleotide sequencing
A A T A C G A C  T C A C T T A N T G  N G G C G  AA7 T G  G G T  A C C G  G  G C  C C C C C  C T C G A G G T  C G A C  G G T  A T C G A T  A A
3 C T T G A  T A T C G A A T T C C T  G C A  G C  C  C  G G G G G A  T C C  G C  C C A  G C G T  G T T A G A C A T C A C C  G T  C A G C  C
A C A C *  G C Q C C G G C T A C C A  T G Q T G A G C A G G C C A C C Q A Q G C A C A T A A A A A C T  O G A C C G T A T G T T C
T A T T T C C A C T G C C C C A T T C G G T C A G G A T A G T A A G A A T G A A G A G T A T G C C A G C G A C A A T C A G T A T
200 210 220 230 240 250
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4 .4  Discussion
In this study we investigated the frequency of occurrence of the HLA-A2 
antigen among 313 individuals, including 205 cases of HD. Results were 
obtained for 276 individuals, of which 176 were HD cases. No significant 
differences were noted between HD cases and control groups, or between 
EBV-associated and non-EBV-associated cases of HD. The data from this 
study therefore argue against the hypothesis that individuals possessing 
the HLA-A2 antigen are under-represented among cases of EBV-associated 
HD. These results confirm the findings of a previous study reported by 
Poppema & Visser (1994a), in which the relationship between HLA-A2 
sta tu s and HD was investigated in 72 cases. Substantially larger num bers 
of cases and controls were included in our study, enabling u s to confidently 
corroborate and extend their findings.
In the 1994 study, HLA-A2 status was determined by antibody staining of 
frozen sections of tum our biopsy material. In our study we extended the 
analysis to determine which alleles of the A2 family were present. This 
question has biological relevance since it is known that the CTL epitope 
representing aa426-434 of EBV LMP-2a is restricted through HLA-A*0201. 
Ten of the eleven cases of EBV-associated HD which were subtyped a t the 
HLA-A2 locus were found to be A*0201; this allele accounts for 96% of the 
HLA-A2 alleles in Caucasian populations (Krausa et a t,  1995). The 
remaining case was a young adult Caucasian male, who subtyped as 
A*0205-positive, an allele more common among African populations 
(Krausa et a l f 1995). The findings of this analysis suggest tha t the rare 
alleles of HLA-A2 do not account for the HLA-A2-positive cases of EBV- 
associated HD.
Seven cases of EBV-associated HD, which were found to be HLA-A*0201- 
positive, were investigated for the presence of viral escape m utants. A 
248bp fragment encompassing the coding sequence of the LMP-2a CTL 
epitope aa426-434 was amplified and the nucleotide sequence determined. 
In all bu t one of these cases the epitope sequence was perfectly conserved 
with respect to the sequence of the B95-8 viral isolate, as were the epitope 
sequences of the non-HLA-A2 controls. In one case there was a one base 
pair change, an  A-»T substitution at the beginning of codon 432. This 
results in a threonine to serine change at position 7 of the peptide epitope. 
As both serine and threonine have uncharged, polar side chains of 
approximately the same size, and position 7 is not one of the anchor
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residues, it is assum ed that this will not interfere with the presentation or 
recognition of the epitope. We conclude from this study tha t the existence 
of viral escape m utants a t this site is unlikely to be a contributory factor to 
the pathogenesis of EBV-associated HD. Conservation of this epitope of 
LMP-2 is clinically relevant as it may be used as a possible target for 
immunotherapy.
In th is study we have shown tha t possession of the HLA-A2 allele, 
specifically A*0201, does not protect against development of EBV- 
associated HD. We have further shown that viral variants, m utated a t a 
key epitope involved in EBV-specific CTL recognition, are not an  im portant 
feature of the pathogenesis of EBV-associated HD. Other possible 
m echanism s by which RS cells may survive in the face of the host CTL 
surveillance have still to be investigated. Some of these are considered 
below.
There are known to be three CTL epitopes of the LMP-2 protein, however the 
existence of viral variants with m utations a t these sites has yet to be 
reported. The absence of good monoclonal antibodies to LMP-2 has 
thwarted efforts to demonstrate the expression of this protein in RS cells. It 
therefore remains possible that there is a post-transcriptional block in the 
expression of LMP-2.
LMP-1 is also a  potentially immunogenic protein, although responses in vivo 
are rarely immunodominant (Murray et al> 1988; Khanna et a t, 1992). 
Deletion m utants of LMP-1 exist which have decreased immunogenicity in 
some systems (Khanna et oL, 1992; Trivedi et aL, 1994). It has been 
reported tha t such deleted forms of the protein may lack CTL target 
epitopes and could therefore contribute to immune evasion (Knecht et a l , 
1993). However, a more recent study suggests tha t the existence of 
accompanying effector cell defects is a necessary criterion for the survival of 
RS cells expressing such m utant LMP-1 proteins (Santon et a l , 1995). The 
latter study investigated the presence of deleted forms of LMP-1 in HD 
occurring in both immunocompetent individuals and patients with HIV- 
related immune suppression. LMP-1 deletion m utants were found more 
frequently in HIV-associated HD than  other HD cases, suggesting tha t these 
m utan ts only persist where immune surveillance is diminished. It seems 
unlikely, given these observations, tha t LMP-1 variants contribute 
significantly to the immunopathology of HD.
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Another possible mechanism for immune escape is the lack of adequate 
presentation of viral antigens at the surface of infected RS cells. It is known 
tha t the class I-associated peptide transporter molecules, TAP-1 and TAP-2, 
are expressed in RS cells (Oudejans et a l, 1996; L.S.Young, personal 
communication). This suggests that the auxiliary machinery for processing 
and presentation of peptides is intact. There is controversy, however, 
regarding the ability of class I molecules to reach the RS cell surface. 
Poppema & Visser (1994b) reported that there was down-regulation of HLA 
class I expression on the surface of RS cells, however a more recent study 
found increased HLA class I expression on EBV-positive, as compared to 
EBV-negative, RS cells (Oudejans et a l, 1996). It would seem unlikely 
therefore, that this is an important mechanism of immune escape in EBV- 
associated HD.
Due to the nature of RS cells and the lack of in vitro systems for the study 
of HD, it is more difficult to investigate events which are im portant to 
disease development and progression within the lymph node environment. 
There may be local cytokine-mediated suppression of effector cells in the 
immediate vicinity of the RS cell, or defects in the effector cells themselves; 
the latter possibility is discussed in chapter 3 of this thesis. Future studies 
of CTL responses to EBV proteins in blood and lymph node should help 
resolve this issue.
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Chapter 5
Generation and characterisation of 
B-lymphoblastoid cell lines
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5.1 Introduction
LCLs provide a useful renewable viable resource for the future investigation 
of many aspects of the patient from which they were derived. Throughout 
the duration of the work described in this thesis, a  large num ber of LCLs, 
primarily from HD patients, were established. This chapter describes the 
generation and characterisation of these LCLs.
One of the aims of creating such a resource was to enable a pilot study into 
genetic instability in HD to be performed. The possibility th a t abnormal 
karyotype may be an  important feature of HD pathogenesis has been 
suggested for over 30 years (Spriggs & Boddington, 1962). Since then it has 
not been extensively studied. Investigations into chromosome banding 
patterns observed in RS cells of HD report a wide range of cytogenetic 
features (Teerenhovi et a l ,  1988). Chromosomal aberrations have been 
identified in approximately 50% of primary HD cases studied (Banks et a l , 
1991; Schouten e ta l ,  1989; Tilly e ta l ,  1991) but no consistent cytogenetic 
m arkers have been described.
The em phasis of other studies has not been to look for consistent 
karyotypic markers, but to investigate the separate phenomenon of 
generalised chromosomal instability as a predisposing factor for 
development of HD (Barrios et a t, 1988; Fonatsch et a l, 1989; Kapp et a l, 
1993). The first two studies examined LCLs and PBMCs from HD patients 
for abnormalities, rather than attempting to look in RS cells. Twice as 
many aberrations were observed in PBMCs from untreated HD patients 
compared to PBMCs from healthy individuals (Barrios et a l,  1988). LCLs 
from HD patients were reported to be more susceptible to drug-induced 
gross chromosomal m utation than were LCLs derived from healthy donors 
(Fonatsch et a l, 1989). The 1993 study observed a high frequency of 
karyotypic abnormalities in LCLs arising from HD material serially 
transplanted into SCID mice (Kapp et a l, 1993). These may have arisen 
from RS cells or bystander B-cells with inherent cytogenetic instability.
In light of these data, six LCLs from HD patients were used in this small 
pilot study to investigate the occurrence of random chromosomal 
abnormalities, aiming to assess whether inherent genomic instability, 
rather than  particular cytogenetic markers, is indeed a feature of 
individuals who go on to develop HD.
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5.2 Materials & methods
In most instances, LCLs were established by EBV-infection of PBMCs. 
Occasionally LCLs arose spontaneously from cultures of cells obtained from 
lymph node biopsies during work being undertaken concurrently in the 
unit. Some of these were included in the eventual bank of HD LCLs.
5.2.1 Generation o f LCLs
PBMCs were separated using a Ficoll-paque gradient (section 2.1.1.3) and 
infected with concentrated B95-8 EBV stock (section 2.1.2.1 - 2.1.2.3). 
Cells were seeded a t a  density of 2 x l0 6/well in 96-well microtitre plates and 
initially treated with Cyclosporin A a t a concentration of 0 .lug /m l to 
suppress CTL function. Cultures were fed weekly by 50% medium 
replacement. Evidence of transformation was routinely seen a t 10-14 days 
post infection. Occasionally transformation was not evident until 6 -8  weeks 
post infection, and in these cases it was assum ed that the B95-8 virus 
infection had failed and a spontaneous transformation event, involving 
latent virus present in the donor PBMCs, had occurred.
After the first signs of transformation were seen, cells continued to be fed 
weekly by 50% medium replacement for a further 2-3 weeks or until growth 
was exponential; the cultures were then expanded up to 250ml in six 
250cm3 tissue culture flasks by splitting 1:2 twice weekly. Viable stocks 
were stored in liquid nitrogen (section 2.1.1.5) and cells were grown up and 
used for further analysis as described below.
5.2 .2  Characterisation o f LCLs
Putative LCLs were characterised for three main reasons. First, to 
determine whether they were indeed a  B-cell line. Secondly, to confirm the 
presence of EBV and determine whether they expressed viral latent 
antigens. It was desirable to know if the virus was B95-8 or originated from 
the patient's latent virus reservoir. Thirdly, LCLs were investigated to 
confirm their individuality, i.e. that they were indeed derived from the 
patient's PBMCs.
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Fixed cells were taken and phenotyped using flow cytometry. Cell lysates 
were prepared and used in Western blot EBNA-2 typing to establish the 
identity of the virus present. LCLs were examined immunohistochemically 
to determine viral antigen expression. Forensic typing was performed on 
DNA extracted from LCL pellets.
5.2.2.1 Phenotyping of LCLs by flow cytometry
A panel of FITC-conjugated antibodies was used to phenotype putative LCLs 
(Table V.i). The method used was essentially as described in section 
4.2.4.1, except that this was a direct labelling technique. Flow cytometric 
analysis was carried out using an EPICS Elite (Coulter Electronics Ltd.).
Table V.i Antibodies used in flow cytometry
antibody to expression pattern
CD2 all T-cells
CD23 activated cells, e.g. EBV-infected
CD45 haemopoeitic cells
CD14 myeloid cells - monocytes
CD19 all B-cells
CD30 activated cells, LCLs
EMA epithelial cells
CD15 granulocytes, activated cells
%/k B-cells (express one or other)
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5.2 .2 .2  EBNA-2 typing by Western blot analysis
The basic method used is as described in section 2.2.6. Several 
optimisations were made, which included the following: nuclear enrichment 
lysis was performed, using lysis buffer (Table Il.viii) containing only 0.1% 
Triton X as detergent, which disrupted the plasma membrane only, allowing 
the nuclei to be purified by pelleting at 13,000rpm in an MSE microfuge for 
10 m inutes a t 4°C. The pellet of nuclei was then subjected to lysis in 
standard buffer (Table Il.viii). Western blots were performed using a  B95-8 
cell lysate as a control. Lysates prepared from an  uninfected J -Jh an  cell 
line and a mouse fibroblast line were included as negative controls.
A second modification consisted of the addition of 20% heat-inactivated 
normal sheep serum (SAPU) to all Marvel buffer, prior to incubation with 
secondary antibody. The secondary antibody used in this procedure was 
raised in sheep, therefore this blocked any non-specific binding sites 
present on the membrane and reduced background signal.
5.2 .2 .3  Immunohistochemical Analysis
Immunohistochemical analysis was carried out on cytospins of the putative 
LCLs to investigate expression of EBV antigens. Cytospins of each LCL 
were prepared (section 2.1.3.1) and stained for EBNA-2 and LMP-1 using 
APAAP and ABC staining methods respectively (section 2.2.7). For EBNA-2 
staining, PE2 primary antibody was used and for detection of LMP-1, CS1-4 
was the antibody of choice. Antibody to rotavirus antigens was used as a 
negative control antibody. Cytospins of a previously characterised LCL (not 
described here) were included in each assay as a positive control, and 
cytospins prepared from the uninfected J-Jh an  cell line were used alongside 
these as a negative control.
5 .2 .2 .4  D1S80 forensic typing of LCLs
At certain time points in this study, large num bers of LCL cultures were 
being generated and handled concurrently. It was necessary to confirm 
individuality of LCLs before further analyses were carried out.
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The hum an genome contains a large number of repetitive DNA sequences, 
arranged as tandem repeat units, which are known as variable num ber of 
tandem  repeats, or VNTRs (Nakamura et a l , 1987; 1988). Individuals 
possess different num bers of repeat units, therefore VNTRs are classed as 
"length,, polymorphisms rather than  sequence polymorphisms. The VNTR 
m arker D1S80 contains a variable num ber of 16bp repeat units (Kasai et 
a l , 1990) and can occur as over 400 different genotypes.
Using the commercially available D1S80 forensic typing kit (Applied 
Biosystems Ltd.) it was possible to distinguish LCLs arising from different 
individuals. The kit utilised a PCR strategy which exploited the allelic 
patterns unique to each individual, with a population-based discrimination 
power of 95-98%.
For D1S80 analysis, l x l 0 7 cells were pelleted, washed twice in sterile PBS, 
and pelleted at 500g for 10 minutes. Pellets were stored a t -80°C and 
subsequently defrosted, protease digested and the DNA recovered using 
organic solvent extraction (section 2 .2 .1 .1).
PCR reactions were set up as described in the m anufacturers instructions. 
The reaction mix contained reaction buffer, deoxynucleoside triphosphates 
and Amplitaq® DNA polymerase. Magnesium chloride was added to a final 
concentration of l.OmM. Twentyfive nanograms of sample DNA were added 
to the reaction mix. Positive control DNA, with a known allelic pattern, was 
included in the kit and run alongside each batch of samples. Water was 
also included as a negative control. The PCR reaction was performed using 
a GeneAmp® PCR system 9600 machine (Applied Biosystems Ltd.) with 
thermocycling parameters as follows: Initial denaturation a t 95°C for 5
minutes; thirty cycles of 95°C for 15s, 6 6 °C for 15s, 72°C for 40s; final 
polymerisation at 72°C for 10 minutes. Reaction products were analysed 
by 8 % PAGE (section 2.2.3.1).
5.2 .3  Karyotypic analysis
LCLs established from HD patients were sent in culture to Prof. Loma 
Secker-Walker, Royal Free Hospital, London, where they were examined for 
the presence of karyotypic abnormalities. A sample of 10-20 m etaphases 
from each LCL was subjected to cytogenetic analysis.
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5.3 Results
Thirty LCLs were generated during the course of this work, from both HD 
patients and healthy individuals. The first 12 established were extensively 
characterised and the results are detailed below.
5.3.1 Characterisation o f LCLs
LCLs phenotyped included lines which had been in culture for only five 
weeks and those which had been cultured for more than  six m onths. All 
LCLs analysed were polyclonal populations of B-cell origin as dem onstrated 
by flow cytometry; the longer the LCL had been in culture the larger the 
main clonal population. CD23, CD30 and CD45 were expressed by all 
LCLs.
Of the 12 LCLs which were analysed by EBNA-2 typing, seven appeared to 
contain B95-8 virus. The remaining five contained an  EBNA-2 species 
which had a  slightly different electrophoretic mobility to the B95-8 protein, 
most of which were smaller.
Immunohistochemistry was successfully performed on eight LCLs, all of 
which were LMP-1 positive. In six cases EBNA-2 expression was clearly 
demonstrable. In the remaining two cases the staining was faint and 
uninterpretable.
Forensic typing by PCR revealed tha t all LCLs were indeed unique lines 
derived from separate individuals (see Fig.5.1).
5.3 .2  Karyotypic analysis
Six LCLs established from HD patients were analysed. Three of these were 
karyotypically normal in all m etaphases examined. Results for the 
remaining three LCLs are described in Table V.ii.
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Fig. 5.1 8% PAGE showing resu lts of forensic typing PCR analysis
Lane: <J>x, size marker;
1, pos control;
2, water control; 
selection of LCLs
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Table V.ii Cytogenetic results
LCL no. cells results analysis
2459 10 46,XY; add (22) (ql3) extra material on ch r .2 2
- not of chr .2 2  origin
- not balanced translocation
2686 (2 0 ) 18 46,XY; normal
1 45,XY; missing chr.2 random chromosome loss;
1 45,XY; missing chr.13 no chromosome breakage
2802 (2 0 ) 10  
10
46,XY; normal 
46,XY; der(6 ) t(5;6)
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5 .4  C onclusions
Thirty LCLs were stored during the course of this work. They will provide a 
useful resource for future genetic analyses and will also be available for 
further immunological studies of CTL responses in HD.
A subset of these LCLs were karyotyped in order to investigate whether 
genetic instability is a feature of HD as previously suggested. Three of the 
six lines had abnormalities and therefore the results were somewhat 
inconclusive. The findings do suggest tha t this may be a worthwhile area 
for further research. Future studies, however, m ust involve larger case 
num bers alongside LCLs from a comparable num ber of healthy control 
individuals, and allow for comparisons of passage number.
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Chapter 6
General D iscussion
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One of the most notable advances in the study of HD in the past 25 years 
has been to link the disease to a viral agent, specifically to associate a 
subset of HD cases with the herpesvirus EBV. This answered several 
questions relating to the aetiology of these disease cases, bu t posed many 
others. Although the bank of evidence supporting the association is now 
large and widely accepted, the exact role played by the virus in EBV- 
associated HD is still not understood.
In the proportion of HD cases which are EBV-associated, around 40% in 
developed countries, latent virus is detectable in the tum our cells, the RS 
cells. These cells express viral latent antigens EBNA-1, LMP-1 and LMP-2 
(Pallesen et a l, 1991; Deacon et a l , 1993; Grasser et a l , 1994). The 
persistence of RS cells in HD lesions, without recognition or elimination by 
circulating CTLs, is an enigma in EBV-associated cases in which 
immunogenic viral membrane proteins are expressed. How do EBV-positive 
RS cells survive in the lymph node in the face of the CTL imm une response? 
Several theories concerning this issue were addressed during the course of 
the work for this thesis.
HLA class I-restricted CTL responses to peptides of the LMPs have been 
dem onstrated in vitro (R.J.Murray et a l , 1988; 1992; Khanna et a l , 1992; 
Lee et a l , 1993). Thus it was postulated that EBV-associated HD would not 
occur in individuals expressing HLA class I alleles which present epitopes 
from the LMPs. HLA-A2 was the allele investigated in our study, as it is 
known to present an epitope of LMP-2 and generate a CTL response (Lee et 
a l , 1993). The results of the study refuted the hypothesis tha t HLA-A2 
individuals would be under-represented among EBV-associated HD cases.
It is known tha t there are several alleles in the HLA-A2 family. A*0201 is 
the commonest in Caucasian populations in which it accounts for 96% of 
all HLA-A2 alleles (Krausa et a l , 1995). It is this allele tha t presents the 
CTL epitope representing aa426-434 of LMP-2a. We therefore went on to 
determine whether rarer alleles of the A2 family account for the observed 
HLA-A2 antigen-positivity seen in EBV-associated HD. This hypothesis was 
also refuted.
In light of recent reports of the occurrence of EBV viral escape m utants 
arising in more geographically isolated populations (De Campos-Lima et a l , 
1993; 1994), it was thought that such viral variants may contribute to the 
pathogenesis of EBV-associated HD. Cases of HLA-A2-positive, EBV-
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associated HD were investigated for the presence of m utations in LMP-2 
which would abolish CTL recognition of an A*0201-restricted epitope. No 
such m utations were found, although one conservative m utation was 
identified in one case from an  HLA-A*0205-positive individual. In 
conclusion, it is clear tha t there are other mechanisms by which RS cells of 
EBV-associated HD evade immune detection.
An alternative hypothesis was that of RS cells being unable to process 
an d /o r present viral antigens to circulating CTLs. However, the cellular 
mechanism for antigen processing has been found to be intact in these cells 
(Oudejans et a l ,  1996; L.S.Young, personal communication). The capacity 
of RS cells to present peptides of viral antigens at the cell surface remained 
controversial. In 1994 it was reported tha t class I molecules were absent 
from the surface of RS cells in some cases (Poppema & Visser, 1994b). 
Since then th is finding has been contradicted, with a  report of class I 
expression being present on RS cells of both EBV-associated and non­
associated HD (Oudejans e t a l ,  1996).
It has long been known that immune dysfunction accompanies the 
development of HD (Kadin, 1992), although there is still debate regarding 
how im portant th is is in disease development. We performed a  series of in 
vitro assays to examine the EBV-specific CTL responses in HD patients 
relative to healthy people, to determine whether a decrease in these CTL 
responses was a feature of HD. In addition, we compared EBV-associated 
and non-associated HD cases to establish whether decreased EBV-specific 
responses may predispose to EBV-associated HD, or whether all HD 
patients had decreased responses due to the immunosuppressive nature of 
the disease.
The results of our study found slightly lower levels of EBV-specific CTL 
responses in HD patients relative to healthy individuals. We also observed 
diminished responses in EBV-associated HD cases compared to non-EBV- 
associated HD, although the num bers of individuals included in the study 
were small, therefore the results are not statistically significant. We may 
suggest from our findings tha t reduced effectiveness of EBV-specific CTLs is 
a  feature of HD, and may be most marked in EBV-associated cases, 
suggesting this may be a significant factor in the pathogenesis of EBV- 
associated disease.
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The finding that EBV-specific CTL responses do exist in some cases of EBV- 
associated HD opens up several avenues for the treatm ent of EBV- 
associated disease. If the CTL responses present in these patients are 
directed to the LMPs, then potential immunotherapeutic approaches may be 
devised to boost these responses in an  attem pt to achieve effective CTL 
recognition and elimination of EBV-positive RS cells. This finding also 
raises the question, however, of why the existing CTL response is failing to 
do ju s t that. Adoptive transfer strategies may be an  effective approach for 
treatm ent of HD.
The results of the studies in chapter four of this thesis confirm tha t a t least 
one CTL epitope of LMP-2 is present and not m utated in HD patients, 
making this a potential target for immunotherapeutic intervention. Future 
studies will focus on investigation of the nature of other specific responses 
present in EBV-associated HD, both in peripheral blood and in the lymph 
node, which may shed light on other potential targets for adoptive 
immunotherapy.
One of the confounding features of the study of HD is the absence of 
suitable in vitro systems for the direct study of RS cells. It is probable that 
RS cells need to be present in a specific cellular microenvironment in order 
to survive, a t least in the early stages of disease development, and this may 
explain why RS cell lines are difficult to establish in culture. The necessary 
cellular environment may be provided by the large reactive cellular infiltrate 
present in HD lesions. There is no suitable system for investigating events 
which are important to disease onset and development within the lymph 
node itself. It has been suggested that there may be local suppression of 
CTL function within the lymph node environment, probably mediated by 
cytokine expression (Frisan e ta l ,  1995). There is also an observed increase 
in CD4+/CD8+ T-cell ratios in the reactive cellular infiltrate found in HD 
lesions (Poppema & Visser, 1995). This may be a reflection of the lack of 
CD8 + CTLs in these nodes. CD8 + CTLs which can be seen in HD nodes 
tend not to be in the immediate vicinity of the RS cells, rather the RS cells 
are rosetted by CD4+ T-lymphocytes. This may also be a function of a 
particular pattern of cytokine expression by RS cells. Until the RS cells can 
be successfully separated from the rest of the cellular infiltrate this 
question will be difficult to address.
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The role played by such factors in the pathogenesis of HD rem ains to be 
resolved. The main areas which remain to be clarified in future work 
include determination of the lineage of RS cells and their precursors. Use 
of cell culture systems, such as those utilising CD40 (O'Grady et aL, 1994), 
may facilitate future in vitro propagation of RS cells. Single cell studies and 
gene expression profiles may shed light on the cytokines expressed by RS 
cells and cells of the surrounding infiltrate.
In young adult HD cases, which have the strongest epidemiological evidence 
for an  infectious aetiology, an infectious agent has yet to be isolated. When 
and if this happens, it will shed considerable light on the pathogenesis of 
these cases, and will provide interesting comparisons with EBV-associated 
disease.
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Appendix A: Sources o f com m only used cell lines
cell line source
B95-8 Q.Y.Yao, CRC laboratories, University of Birmingham
HB82 P.Chandler, Clinical Research Centre, Northwick Park Hosp., London
Jijoye ATCC
J-Jh an M.Steele, Western General Hosp., Edinburgh
Raji ATCC
VES P.Chandler, Clinical Research Centre, Northwick Park Hosp., London
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Appendix B: List o f suppliers
supplier
A. & J. Beveridge Ltd.
Alpha Laboratories Ltd.
Amersham International PLC 
Anachem
Applied Biosystems Ltd.
BDH (Merck Ltd.)
Beckman Instrum ents (UK) Ltd. 
Bio-Rad Laboratories 
Boehringer Mannheim UK Ltd.
Costar UK Ltd.
Coulter Electronics Ltd.
Cruachem 
Dako Ltd.
Epicentre Technologies (Cambio Ltd. 
Fisons Ltd.
Flowgen Instrum ents Ltd.
Genetic Research Instrum entation Ltd 
Greiner Labortechnik Ltd.
Gull Laboratories Inc.
ICN Biomedicals Ltd.
I.G.I. Ltd
Leo Laboratories
Li-Cor
Life Technologies Ltd.
Millipore (UK) Ltd.
National Diagnostics 
Pharmacia Biotech 
Promega UK Ltd.
Qiagen Ltd.
R athbum  Chemicals Ltd.
Sandoz Pharmaceuticals 
SAPU
Sarstedt Ltd.
Savant Instrum ents Inc.
Scotlab
Seward Medical Ltd.
Shandon
Sigma Chemical Company 
Stratagene
location
Glasgow
Eastleigh, Hampshire 
Aylesbury, Buckinghamshire 
Luton, Bedfordshire 
Warrington, Cheshire 
Lutterworth, Leicestershire 
High Wycombe, Buckinghamshire 
Hemel Hempstead, Hertfordshire 
Lewes, East Sussex 
High Wycombe, Buckinghamshire 
Luton, Bedfordshire 
Bearsden, Glasgow 
High Wycombe, Buckinghamshire 
Cambridge
Loughborough, Leicestershire
Sittingboume, Kent
Felsted, Dunmow, Essex
Stonehouse, Gloucestershire
Salt Lake City, Utah, USA
High Wycombe, Buckinghamshire
Sunderland, Tyne & Wear
Princes Risborough, Buckinghamshire
Lincoln, NE, USA
Inchinnan, Renfrewshire
Watford, Hertfordshire
Atlanta, Georgia, USA
Knowhill, Milton Keynes
Chilworth, Southampton
Crawley, West Sussex
Walkerbum, Scotland
Camberley, Surrey
Carluke, Lanarkshire
Beaumont Leys, Leicestershire
Farmingdale, New York, USA
Coatbridge, Lanarkshire
London
Basingstoke, Hampshire 
Poole, Dorset 
Cambridge
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Appendix C: Calculation of 50% endpoints using the m ethod o f  
Reed & Meunch
This method of calculating 50% endpoints is used when there is a wide 
range of variations in titre and is designed to take advantage of results from 
all dilutions tested, rather than ju s t those around the endpoint. This is 
achieved by calculating the accumulated num ber of wells showing 
regression at and above each dilution and expressing this as a percentage. 
When using this method of calculation, the assumption is made th a t a well 
of culture displaying regression at a low cell concentration would also do so 
a t a  higher cell concentration.
The following formula is used for the initial calculation of the percentage of 
regression:
% regression at dilution N = total no. regressed wells up to and including N
total no. wells up to and including N
In practice the endpoint usually lies between two dilutions. To calculate 
the actual endpoint it is therefore necessary to determine the proportional 
distance (D) from the dilution below or above the 50% endpoint. This is 
achieved using the formula
D = 5 0 - Y 
X - Y
where X = % regression occurring a t the dilution above the 50% endpoint 
Y = % regression occurring a t the dilution below the 50% endpoint
Since cell dilutions are increasing on a logarithmic scale, the final value is 
calculated as follows:
log(endpoint) = logY + [log(dilution factor) x D]
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Tabulations used to  score IVR assays
*P.no. cell no. tftn'n regr'n total tfin'n toted regr'n % regr'n
3248 6 x 1 0 s 0 6 0 18 1 0 0
3x105 0 6 0 12 1 0 0
1.5x10s 1 5 1 6 8 6
7.5xl04 5 1 6 1 14
3.8xl04 6 0 12 0 0
1.9xl04 - - - - -
3250 6 x 1 0 s 0 4 0 1 2 1 0 0
3x10s 0 4 0 8 1 0 0
1.5x10s 1 3 1 4 80
7.5xl04 3 1 4 1 2 0
3.8x104 4 0 8 0 0
1.9xl04 - - - - -
3258 6 x 1 0 s _ _ _ _ _
3x10s 0 6 0 11 1 0 0
1.5x10s 2 4 2 5 71
7.5xl04 5 1 7 1 13
3.8x l04 6 0 13 0 0
1.9xl04 6 0 19 0 0
3277 6 x 1 0 s 1 5 1 9 90
3x10s 4 2 5 4 44
1.5x10s 4 2 9 2 18
7.5xl04 6 0 15 0 0
3 .8xl04 - - - - -
1.9xl04 - - - - -
3292 6 x 1 0 s _ _ _ _ _
3x10s 0 6 0 13 1 0 0
1.5x10s 0 6 0 7 1 0 0
7.5xl04 5 1 5 1 16
3 .8xl0 4 6 0 11 0 0
1.9xl04 6 0 17 0 0
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P. no. dilution tfm'n regr'n total tfm'n total regr'n % regr'n
3788 6x l0 5 0 6 0 18 100
3 x l0 5 0 6 0 12 100
1.5x10s 0 6 0 6 100
7.5xl04 6 0 6 0 0
3.8xl04 6 0 12 0 0
1.9x104 6 0 18 0 0
3888 6x l0 5 1 5 1 13 93
3 x l0 5 0 6 1 18 89
1.5x10s 4 2 5 2 29
7.5xl04 6 0 11 0 0
3.8x104 6 0 17 0 0
1.9xl04 6 0 23 0 0
3893 6x105 0 6 0 20 100
3 x l0 5 0 6 0 14 100
1.5xl05 1 5 1 8 89
7.5xl04 4 2 5 3 38
3.8x104 5 1 10 1 9
1.9xl04 6 0 16 0 0
3894 6x l0 5 0 6 0 20 100
3x105 0 6 0 14 100
1.5xl05 0 6 0 8 100
7.5xl04 4 2 4 2 33
3.8xl04 6 0 10 0 0
1.9xl04 6 0 16 0 0
*P.no., patient number; tfm'n, transformation; regr'n, regression
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